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Abstract 
The constant demand of oil-derived products in the market has pushed 
science to develop alternative ways to cope with this demand. Therefore the 
development of efficient cell factories as sustainable alternative is an 
expanding trend. These are envisioned as future workhorse manufacturers of 
pharmaceuticals, biofuels and biomaterials. The focus of this thesis is to 
develop new genome engineering methods to relieve one of the major 
bottlenecks in metabolic engineering, the strain design and optimization. 
The aim is to generate an engineering tool-box applicable to different model 
organisms, which can potentially be standardized in an automatable platform 
and, in the future be integrated with metabolic modeling tools. In 
particularly it describes the technologies developed in the three widely used 
organisms: E. coli, S. cerevisiae and CHO mammalian cells using the recent 
breakthrough CRISPR/ Cas9 system. These include CRMAGE, a MAGE 
improved recombineering platform using CRISPR negative selection, 
CrEdit, a system for multi-loci marker-free simultaneous gene and pathway 
integrations and CRISPy a platform to accelerate genome editing in CHO 
cells. 
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Danske resumé !
Det constant forøgede forbrug af fossile ressourcer til fået videnskaben til at 
fokusere på at udvikle alternative metoder til at fremstille de kemikalier, der 
er brug for i vores samfund. Fremstilling af biokemikalier ved hjælp af 
biologiske cellefabrikker er derfor et hastigt voksende forskningsområde. 
Disse cellefabrikker har mulighden for at producere fremtidens 
farmaceutiske stoffer, biomaterialer og brændstoffer fra genanvendelige 
ressourcer. Fokus i denne afhandling har været at udvikle nye metoder til at 
modificere genomer, sammen med design og optimering af 
produktionsorganismer. Målet har været at udvikle en sæt redskaber til 
modificering af genomer. Disse metoder har mulighed for at blive 
standardiseret i en automatisk platform, og som i fremtiden vil kunne blive 
fuldt integreret i de redskaber, som man bruger til metabolic engineering. I 
særdeleshed har fokus været på at udvikle teknologier til tre af de mest 
anvendte organismer, E. coli, S. cerevisiae samt de mammale CHO celler, 
ved at udnytte gennembruddet indenfor CRISPR/Cas9. De udviklede 
metoder inkluderer CRMAGE, som forbedrer effektiviteten af MAGE 
recombineering ved hjælp af CRISPR-baseret negativ selektion. CrEdit er et 
system til effektivt at integrere flere kassetter på genomet i S. cerevisiae 
uden brug af selektionsmarkører, mens CRISPy er en platform til at 
accelerere modifikation af genomer i CHO celler. 
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Chapter 1: Introduction and Thesis Overview 
 
1.1 Cell Factories And Metabolic Engineering Bottlenecks 
 
One cubic mile of oil (CMO) corresponds very closely to the world's current 
total annual consumption of crude oil. The world's total annual energy 
consumption from all energy sources is currently 3.0 CMO. By the middle 
of this century the world will need between 6 and 9 CMO of energy per year 
to provide for its citizens1. We are facing the necessity of producing the 
everyday-life oil derived goods in a cheap, fast and eco-compatible manner. 
For this reason in late 90´s, early 2000 the idea of engineering cell as 
sustainable alternative to produced chemicals and fuels has begun to grow 
and to gain importance in the scientific community. In a market of oil 
derived chemicals worth about US$ 5.5 Trilion in 2015, according to the 
New Report by Global Industry Analysts Inc., the potential of sustainable 
biotechnology is unlimited. Cell factories are envisioned as future workhorse 
manufacturers of pharmaceuticals, biofuels and biomaterials. Indeed the 
sources are infinitely renewable (cells replicate themselves) and the 
substrates can be adapted on demand by modifying the cell metabolism or 
by reconverting them into profitable substrates in microbial communities. 
Metabolic engineering is a multidisciplinary field where several disciplines 
such as genetic engineering, molecular biology, biochemistry, system 
biology, chemical engineering collaborate in order to convert cells into 
!!!!!!
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biocatalysts for a cost-effective production of chemicals2. Whilst this field is 
rapidly improving, there are still several issues that need to be addressed for 
a more competitive bio-based industry; such as the enhancement of the 
substrate spectrum with the focus on the efficient utilization of renewable 
feed-stocks, broaden out the product spectrum and hosts, improve genome 
editing and genetic tools to control cell behavior and maximize production3. 
This discipline was first introduced in the early 90’s by Bailey as subgroup 
of the engineering field concerning of “the improvement of cellular activities 
by manipulation of enzymatic, transport, and regulatory functions of the cell 
with the use of recombinant DNA technology”4. Currently one of the main 
bottlenecks to achieve an efficient, competitive and versatile cell factory is 
hindered by the limitations of conventional methods of strain design.  
In this scenario synthetic and molecular biology have the potential to 
provide tools for engineering cell factories in a more efficient and 
controllable way. Thus their improvement in the context of a more 
systematic approach with the advent of OMICS and computational modeling 
approaches will allow to expand the arrays of obtainable products and 
available hosts as well as achieve titers and yields more competitive for the 
global market. 
The focus of this thesis is to create a set of genetic engineering tools 
applicable as potentially high-through put, parts-standardized and 
automatable platform for virtually any organism, both prokaryotes and 
!Ph.D. Thesis, 31/08/2015                                                                                                                           3 
eukaryotes. In particularly, we developed genome editing methods using 
CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) 
technology in order to accelerate the strain construction. 
 
1.2 Thesis Outline 
This thesis is structured in seven chapters. The current one (Chapter 1) aims 
to introduce the field where this thesis has been focused on and the broad 
scope. The second chapter (Chapter 2) introduces the CRISPR system and 
describes the technology derived from it. Chapter three, four and five 
(Chapter 3; Chapter 4; Chapter 5) are organism-based genetic 
engineering monographs. They focus on the model organisms, E. coli, S. 
cerevisiae and CHO cells, respectively and the state of the art genetic 
engineering tools followed by the description of the CRISPR-based methods 
that have been developed during this project, and their contribution to the 
field. Finally chapter six (Chapter 6) discusses the future prospective and 
provides a final constructive conclusion of this thesis. Chapter 7 (Chapter 
7) collects all full lengths papers. 
 
!!!!!!
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Chapter 2: CRISPR revolution 
The advent of recombinant DNA technology in the late 70s opened a new 
era for biology. For the first time it became possible to manipulate DNA and 
reprogram the genetic code of potentially any organism. It enabled the direct 
study of DNA in the context of cell physiology by modulating or editing the 
function of its sequences in their endogenous context. It was possible to 
elucidate the functional organization of the genome at the system level and 
the casual genetic variations. The recent advance of genome editing and 
engineering techniques due the advent of CRISPR/Cas technology integrated 
with next generation sequencing and gene synthesis, and the merging of 
large datasets with modeling and novel bioinformatics tools, has opened new 
prospective for the design of industrially relevant strains for production of 
novel compounds.  
 
2.1 CRISPR history and phylogeny 
 
CRISPR is a bacterial immune mechanism used by many prokaryotes to 
protect themselves from foreign nucleic acids like viruses or plasmids. Most 
of the Archea (about 84%) and bacteria (about 48%) bear this system in their 
genome5. It appeared in literature for the first time in 1987 described as “five 
highly homologous sequences of 29 nucleotides arranged as direct repeats 
with 32 nucleotides as spacing”6, but it was only in 2002 that the name 
!!!!!!
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CRISPR (Clustered regularly interspaced short palindromic repeats) was 
coined for the first time7. Initially it was inferred by computational studies 
that this system might be a possible repair system due to the high homology 
of the genes associated with it to helicases and nucleases8, however later 
studies discovered that CRISPR spacers were homologous to fragments of 
mobile genetic elements (MGE) and thus they hypothesized for the first time 
that CRISPR system could instead be an adaptive immunity system9–11. 
However, it was not until in 2007 that Barrangou et al., described its 
function as system of acquired resistance to bacteriophages via integration of 
viral DNA fragments in the lactic acid bacterium Streptococcus 
thermophilus12. 
CRISRP/Cas systems are extremely heterogeneous in terms of the repeats13 
and cas gene sequences beside the architecture of the cas genes within the 
operons7,14,15. This is probably due to the rapid evolution they have 
undergone because of the strong selective pressure imposed by the foreign 
MGEs. On the basis of this phylogenetic diversity they, are grouped into 
three major CRISPR/Cas systems and several different subtypes16. These 
three main systems are defined on the basis of the three unique signature 
effector genes: Cas3 nuclease-helicase for type I, Cas9 nuclease for the type 
II and for the type III Cas10 that so far has an unknown function. The type II 
is phylogenetically and structurally distinct from Type I and III, which seem 
more related17. Indeed while Type I and type III CRISPR–Cas systems are 
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spread in various combinations among phylogenetically diverse bacteria and 
archaea, the type II systems (sometimes in combination with other CRISPR– 
Cas types) are restricted to only few species of bacteria. Different subtypes 
of CRISPR/Cas system are classified by the way the crRNA and Cas 
proteins form the crRNP complex (CRISPR ribonucleoprotein), which is the 
machinery required to target and cleave invading nucleic acid11. The 
cascade  (CRISPR-associated complex for antiviral defense) is the complex 
formed by the subtypes of type I (A to F) whereas in the type II (type II-A, 
type II-B and type II-C systems) the complexes are defined as Cas9. Type I 
and type III CRISPR/Cas systems are found in various combinations among 
phylogenetically diverse bacteria and archaea, whereas the type II systems, 
often in combination with other CRISPR/Cas types, have been found only in 
some bacterial species14,18. It has been speculated that the phylogenetic 
heterogeneity of the CRISPR/Cas system is the result of horizontal gene 
transfer15, consistently with the fact that it has been found also in several 
viral genomes and plasmids19–23. !  
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2.2 CRISPR mechanism of action 
 
The CRISPR/Cas surveillance system consists of three main stages: 
adaptation, expression and interference. Based on their function during 
the adaptive immune system, all Cas proteins can be grouped into four 
categories: (i) nucleases and/or recombinases, which are involved in the 
adaptation process; (ii) ribonucleases that process crRNA guides and (iii) the 
proteins that assemble with the RNA guides to form the crRNP complexes, 
which characterize the expression stage; and other nucleases (iiii) that are 
recruited to the complete crRNP complex to degrade the DNA or RNA in 
the final stage, in the interference24 (Fig 1). 
I. Adaptation: the adaptation represents the stage where the bacterium 
construct the “memory” of the virus or plasmids invaders by incorporating 
30 nucleotides of their DNA at the leader side of the CRISPR locus12,25,26. 
The spacer acquisition takes place at the leader end and they are arranged as 
a chronological record of previously encountered invader nucleic acids. 
Therefore the closest are the spacers to the leader the most recent is their 
acquisition12,27,28 (Fig. 1). The selection of the spacer is directed upon 
detection of a specific short nucleotide sequence known as PAM 
(Protospacer Adjacent Motif)29–31 followed by processing of the DNA 
substrates into spacer precursors of a defined size32. Each new acquisition has 
to be accompanied by the duplication of the leader end repeat in order to 
create a new spacer-repeat unit33 and the new spacer is integrated according 
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to the PAM orientation32,34. Occasionally a spacer derived form 
chromosomal DNA can be integrated but they are typically associated with 
toxicity35,36 unless the PAM is mutated or Cas protein are inactive33,35. This 
proves that CRISPR/Cas systems can distinguish invading DNA from the 
host chromosome. Some of the mechanisms to avoid autoimmunity have 
been partially elucidated but most of them remain still unclear. It seems that 
the host restriction and methylation system might be involved24. 
II. crRNA processing: during this stage the crRNAs are produced from a 
long single transcript of the CRISPR array followed by a maturation process 
catalyzed by endoribonucleases that cleave the precursor long pre-crRNA 
into the final short crRNAs (Fig. 1). The enzymes involved in this process 
can be either a subunit of a larger complex (e.g. Cascade) or operate as 
single enzymes37,38. The primary processing of the pre-crRNA in type I (with 
the exception of I-C system39) and type III is catalyzed by Cas6 which 
typically leaves a 5’ handle of 8 nucleotides a central spacer sequence and a 
longer 3’ handle37,40–42 that can either form a stem-loop secondary structure 
or undergo further processing, of which the mechanism of action and 
enzymes involved remain still unknown38,43,44 (Fig. 1). The type II system 
relies upon a completely different mechanism based on Cas9 endonuclease 
and the indigenous RNAase III. This will be further discussed in the 
following paragraphed (2.3 Type II system). 
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 III. Interference: during the interference the invading MGE (either double-
stranded DNA or single-stranded RNA) is recognized and degraded by the 
surveillance crRNP complex (Fig. 1). This is a stepwise process that 
involves first the recognition of the protospacer sequence by base pairing 
between the 7–8 nucleotide seed region of the spacer and the complementary 
crRNA accompanied by the discrimination of self versus non-self DNA45–49, 
followed by complete base pairing between spacer and protospacer that 
generates a strand displacement46,48 and an R-loop structure. This seems to 
trigger a conformational change in the in the crRNP surveillance complex 
which leads to the intrinsic nuclease activity of type II and type III-B 
systems or promotes the recruitment of a trans-acting nuclease in the type I 
and type III A40,50–52. 
In order to not be deleterious and trigger an autoimmune response, the 
CRISPR system has to be able to distinguish between “self” from “non‐
self”. In silico studies have elucidated that CRISPR surveillance system type 
I and type II rely on a specific motif of generally 2-5 nucleotides to 
discriminate the crRNA spacer on the host genome from the spacer 
precursor (proto-spacers) sequence of the invading DNA, which is the 
sequence complementary to the crRNA31. This particular motif is recognized 
as the Protospacer Adjacent Motif (PAM)29,30 and it is located at the 5’ end 
of the protospacer sense strand in the type I system, whereas it is at the 3’ 
end in the type II system29–31 (Fig. 1). The PAM has been demonstrated to 
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play a key role in the adaptation of type I49,53,54 and type II systems32,55–57, 
but it does not seem to be required in the type III system. Indeed while the 
first two systems have been shown to have a “non-self activation” strategy 
upon recognition of the PAM by the crRNP complex that triggers the 
interference by either recruiting a nuclease (like Cas3 in type I systems) or 
inducing the intrinsic crRNP nuclease activity (like in the case of Cas9 in 
type II systems)48,58,59. In the type III system this strategy is substituted by a 
PAM-independent mechanism of “self inactivation”. This response is 
mediated by the interaction between the 5’-handle of the crRNA bound to 
the crRNP complex, and the repeat sequence of the host CRISPR array.  The 
base paring of the repeat in the CRISPR array with the crRNA assembled to 
the crRNP complex activates the “self DNA” recognition thus preventing the 
interference most likely by blocking the recruitment of the endonuclease60.  
 
2.3 Type II CRISPR/Cas systems 
While the type I and type III systems share some overarching characteristics, 
like specific nuclease-mediated maturation of the crRNA and a multi-
subunit complex (e.g. cascade) that is recruited and guided by the mature 
crRNA to recognize (by sequence complementarity) and cleave the foreign 
nucleic acid, the type II system differs considerably in the mechanism of 
crRNA processing and interference. Indeed these two processes rely on three 
main components (i) a type II specific RNA, the trans-activating crRNA 
(tracrRNA), (ii) the crRNA, (iii) and a single nuclease Cas9 (formerly 
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Csn1). Cas9 is a large bi-lobe protein that contains two endonuclease 
domains (an HNH close to the N-terminal and an RuvC-like domain in the 
middle of the protein) and it is considered the major player in both the 
crRNA processing and the intereference12,25.  
II. crRNA processing: during pre-crRNA processing the tracrRNA (that 
contains 25 nucleotides complementary to the repeat sequences in pre-
crRNA) forms a RNA duplex with the pre-crRNA repeats, together they 
assemble in the Cas9-RNP complex that promotes the pre-crRNA 
processing (probably by binding and positioning the RNA molecule) 
mediated by the double-stranded (ds) RNA-specific ribonuclease RNase 
III18,56,61. After the first processing the tracrRNA:crRNA hybrid remains 
docked to Cas955,56 and undergoes to further maturation at the 5’-end, 
resulting in a final spacer length of 20 nucleotide61.  
III. Interference: the hybrid tracrRNA:crRNA with the processed spacer 
length, in a complex with cas9, forming the Cas9-RNP is the only 
component required for the interference25,55,56,61. The PAM-dependent (GG 
dinucleotide-containing) target recognition mediated by the base pairing 
between the spacer and the foreign DNA, triggers a conformational change 
that activates the nuclease domains responsible for the interference. Recent 
studies have unraveled the Cas9 structure (from type II-A and C) both alone 
and in complex with the sgRNA (a synthetic RNA result of a fusion between 
tracrRNA and crRNA56)62,63 and has made it possible to elucidate the 
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mechanism of interference in more detail. Cas9 contains two highly 
conserved lobes: an α-helical recognition lobe, which is primarily involved 
in coordinating the guide RNA, and the nuclease lobe, which is responsible 
for PAM recognition and subsequent cleavage of the target. When the 
sgRNA is loaded to form the Cas9-RNP complex, it causes a conformational 
change in the protein making it ready to bind the target. Subsequently Cas9-
RNP complex scans the DNA seeking for the PAM motif58 located close to 
the 3’ handle of the crRNA spacer region. After the PAM recognition and 
the subsequent target matching at 12 nucleotide seed sequence, the RuvC-
like domain displaces the target DNA strand56,62 and there is a formation of a 
R-loop structure that triggers the intrinsic nuclease activity in both HNH and 
RuvC domains of the nuclease lobe 62,63.  The HNH domain cleaves the 
DNA strand that interacts with the crRNA, while the RuvC-like domain cuts 
the displaced DNA strand. This results in a blunt double-stranded cut at a 
specific site, which is typically 3 nucleotides from the 3ʹ  end of the 
protospacer25,64. Mutations in the PAM and seed region prevent the 
interference65. 
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2.4 CRISPR Craze: from immunity system to genome engineering tool 
The remarkable ability of sequence-specific targeting and cleavage has made 
CRISPR/Cas an attractive system for genetic engineering. The 
understanding of the mechanism of action of the interference complex66 and 
the mechanistic insights58,61–63,67 has allowed scientists to reprogram CRISPR 
components, thereby opening a new revolutionary era of genetic 
engineering68. The Cas9 complex has been engineered as the “perfect tool” 
for genome editing by using synthetic sgRNA56 (which is a fusion between 
trascrRNA:crRNA) or reprogramming CRISPR arrays65 it has been possible 
to redirect this nuclease to induce DSB at almost any genomic locus. Mali et 
al., and Cong et al., have independently demonstrated for the first time in 
vivo that it was possible to program the type II CRISPR/Cas9 nucleases 
(from S. pyogenes) using short synthetic gRNAs to induce precise cleavage 
at endogenous genomic loci in human and mouse cells69,70, and shortly after 
Jiang et al., showed it in bacteria using Cas9 from S. pneumonie and 
engineered CRISPR array65. CRISPR-based genome editing technology 
relies on the cellular DNA repair system that is triggered upon DSB 
introduction by the targeted nucleases. There are two different pathways in 
mammalian cells, non-homologous end-joining (NHEJ) or homology-
directed (HDR) and each one of them gives different result when triggered 
by Cas9-generated DSB (Fig. 2A). The NHEJ is an error-prone repair 
system that involves direct ligation of the broken ends and can create indels 
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that result in frame-shift and consequent loss of function. For this reason, it 
is use for generating targeted gene knock outs (Fig. 2A). The HDR pathway 
instead uses homologous DNA sequences as templates for repair, and, by 
supplying an exogenous repair template, it can be exploited for precise 
genome editing or to insert exogenous DNA (Fig. 2A). The ability of Cas9 
DSB-mediated highly efficient targeting of multiple loci at the same time in 
a cheap and easy way, especially for mammalian cell, has revolutionized the 
genome editing field and it has been applied successfully to basically any 
organism or type of cells from human cells 69–73, mammalia cell lines74–77, 
mice78–81, Drosophila82–84, Zebrafish85–90, Xenopus91, C. elegans92, 
silkworm93, plants72,94–96 and non- human primates97 to bakery yeast98–104 and 
bacteria65,105–109. Despite the great efficiency and possibility of multiplexing, 
concern has been raised regarding its specificity mainly due to its potential 
therapeutic implications. Therefore several studies have been focused on 
investigating further this aspect, part of the studies actually found some off-
target effects but the results in different studies are incongruous (data ranges 
from 83% or 60% to less than 1%) so the whole-genome target specificity 
and the influence of chromatin structure on Cas9 acivity remain still 
controversial 58,110–118. One strategy that has been applied to limit the off 
target effect was to use a mutated version of Cas9 that instead of producing 
DSB, cuts only one strand (“nicks” the DNA) (Fig. 2B). This should 
promote the HDR or base excision repair system (BER) over the NHEJ and 
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thus ensure high-fidelity repair and minimizing off target effect70,119–121. The 
Cas9 nickase is derived either from the mutation of the aspartate residue 
(D10A) in the catalytic site of the RuvC domain70 or the histine (H840A) in 
HNH domain, depending on which strand is targeted56 (Fig. 2B). Moreover, 
scientists inspired by previous genome editing tools such as TALENS and 
Zinc Finger nuclease, have fused a catalytically inactive Cas9 (mutated at 
both sites, D10A and H840A) to a Fok1 nuclease domain in order to further 
narrow its specificity (Fig.2D). Indeed it relies on the specificity of two 
different targets122  instead of one since it is necessary that two Cas9 proteins 
are bound in close proximity to enable the interaction between the Fok1 
domains and thus activate the nuclease activity (Fig.2D). In this way the 
probability of having a-specific binding and cleavage is sensitively 
reduced122. 
Using CRISPR/ Cas9, it has been possible to perform in vivo genome-wide 
functional genomic studies in eukaryotes by using full genomic libraries of 
gRNAs in different mammalian cell lines (human, mice, ESC) to identify 
genes associated with specific phenotypes73,123–125 or to map tumor growth 
and metastasis126. Even though targeted gene knock out was already possible 
with other DNA binding nuclease (Zinc Finger and TALENs) 127,128 and 
RNA interference (RNAi) knockdown129 was already employed for rapid, 
inexpensive and high-throughput method for genome-wide studies, 
CRISPR/Cas9 based approach has outperformed them qualitatively. Indeed 
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it enables more efficient multiplexing knockouts (which is basically 
impossible to perform using other techniques) and to generate more reliable 
and consistent data than RNA interference (RNAi) which varies between 
experiments and laboratories and has more unpredictable off-target 
effects130, while providing only temporary inhibition of gene function129.  
The possibility of creating a DSB break virtually at any locus in genome has 
been exploited in bacteria as a negative selection system (Fig. 2A). For 
example Gomaa et al. have used the nuclease activity of Cas9 to program 
DSB-induce killing towards a specific sequence in the genome131. In this 
way they were able to selectively remove a population from a mixed culture. 
By using the same principle engineering techniques like λ red in E. coli has 
been improved and optimized (see Chapter 3). Moreover, Cas9 
programmable toxicity has been used to develop sequence specific 
antimicrobials, whose spectrum of activity is chosen directly by the 
sequence of the gRNA-guide132,133 or indirectly using lytic phages, by 
targeting the genes that confer resistance and thus enriching the antibiotic-
sensitive population134.  
The remarkable ability to redirect a DNA binding protein just using a short 
RNA guide has made CRISPR/Cas9 technology appealing as a scaffold for 
various other applications. For example catalytically inactive Cas9, dead 
Cas9 (dCas9 or cas9D9), was generated by inserting two point mutations in 
the HNH (H840A) and ruvC (D10A) domains and used for targeted 
!Ph.D. Thesis, 31/08/2015                                                                                                                       19 
silencing of transcription in bacteria and eukaryote cells135–138 (Fig.2C). This 
system known as CRISPR interference (CRISPRi) is based on dCas9 co-
expressed with a guide RNA to generate a DNA recognition complex that 
can specifically interfere with transcriptional elongation (Fig. 2C). When 
targeted to a promoter or ORF of a gene of interest, dCas9 can block 
progression of RNA polymerase and hence silence expression of the targeted 
gene. This technology has been proven to match perfectly the concept of 
synthetic cells, where the metabolic network can be redesigned using 
Boolean language and terminology known from electric components. As 
proof of concept Nielsen et al. have recently used CRISPRi system to 
construct genetic logic states in E. coli. Using a layered Boolean-logic of 
series of NOT and NOR gates, they were able to invert transcriptional inputs 
with >50-fold dynamic range thus demonstrating that CRISPRi can also be 
configured into transcriptional cascades that propagate signals as sgRNAs139 
(Fig.2C).  
Due to its programmable DNA binding proprieties, dCas9 is amenable to 
creating fusions with effector domains (KRAB repressor and VP64 activator 
domains) and RNA modules to turn transcription on and off in a dynamic 
and quantitative manner, enabling the investigation of gene functions as well 
as rewiring regulatory networks138,140,141 (Fig. 2E). CRISPR-TFs (CRISPR-
based Transcription Factors) enable the construction of complex large-scale 
synthetic circuits and transcriptional cascades in order to redirect natural 
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regulatory networks and to create multi-component genetic circuits whose 
feedback loops, interconnections, and behaviors could be revwired142. In this 
prospective Zalatan et al.143 have recently demonstrated the potential of 
CRISPR-TFs technology as scaffold to engineer complex synthetic 
transcriptional programs by attaching multiple protein-binding aptamers 
(MCP, PCP and com) to the sgRNAs linked to different aptamer structures 
(MS2, PP7 and com), for genomic localization of multi-protein complexes 
(CRISPR-TFs containing activator or repressor domains linked to MCP, 
PCP and com aptamers binding domain) functioning as genetic switches 
(Fig. 2F). Therefore, modified gRNA scaffolds can be used to generate 
synthetic multi-gene transcriptional programs in which is it possible to 
differentially switch on or off different genes at the same time (Fig. 2F). In 
conclusion, CRISPR based technologies have thrived in an efficient high-
throughput screening system, especially for complex organism like 
eukaryotic cells, to interrogate genes functions and map pathway complexity 
by the perturbation of their expression. This system was successfully applied 
to screen for cancer drug resistance, tumor suppressors, genes related to 
growth defect, regulators of differentiation and genes involved in bacterial 
induced toxicity such as for anthrax, diphtheria and cholera 73,123–125,144,145.  
Especially CRISPRi and the derived CRISPR-TFs technologies can be 
utilized as a powerful tool for interrogating, perturbing, and engineering 
cellular systems. In order to expand the range of possibilities and create even 
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more architectural complex and articulated synthetic circuits, they could also 
be combined with orthogonal Cas9 146 (Fig. 2C).  
It has also been possible to modulate transcriptional activation by 
manipulating the chromatin architecture. Indeed Hilton et al.147 have shown 
that by modifying the epigenome using a programmable dCas9-
acetyltransferase fusion, it was possible to activate specific promoters via 
their enhancers (Fig. 2H).  
Recently, also optogenetics has been integrated with CRISPR/Cas9 system 
to create a spatial and temporal transcriptional control148 and genome 
editing149 (Fig. 2G). 
Besides the use of dCas9 as regulatory player in complex systems, it has also 
been employed as an imaging tool. Indeed its fusion to a fluorescent 
proteins150–152 has created a novel in situ imaging platform that allows to 
better understand intracellular distance between loci on different 
chromosome and the spatiotemporal organization and dynamics of 
chromatin which plays a crucial role in regulating genome function (Fig. 2I). 
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Figure 2: CRISPR/Cas9 applications overview. A: Cas9 nuclease applications. DSB 
mediated modifications (indels, Knock-in/out) and toxic activity used for specific 
negative selection. B: mutated Cas9 with only nickase activity to increase the target 
stringency. C: CRISPRi applications. The ability of dead Cas9 (double mutant) to bind 
any sequence in the genome with lack of nuclease activity is used to control gene 
expression. dCas9 is directed to the promoter region or the at the transcriptional start site 
to interfere with the polymerase and thus with the elongations of the transcript. It can be 
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D: dCas9 can be associated with the nuclease domain Fok1 in order to increase the 
specificity. E: dCas9 can be fused with activator (PV64) or repressor (KREB) domains 
in order to control the gene expression. F: complex transcriptional circuits can be design 
by using dCas9, gRNA scaffold and aptamer binding proteins fused to activator or 
repressor domains. G: optogenetics can be integrated with CRISPR/Cas9 system to 
create a spatial and temporal transcriptional control and genome editing. H: it’s possible 
to modulate transcriptional activation by manipulating the chromatin architecture using 
dCas9 fused to an acetyltransferase domain. I: dCas9 can be fused to GFP and directed 
to specific sites along the chromosomes. In this way dCas9 offers an in situ imaging 
platform that allows to better understand intracellular distance between loci and the 
spatiotemporal organization and dynamics of chromatin. 
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Even though the potential of CRISPR type II (Cas9) seems endless and even 
though it has already opened up complete new branches of genome 
engineering research, other CRISPR types or subtypes have shown to be 
amenable for engineering purpose. For example Qui et al., have 
demonstrated the programmability of csy4 ribonuclease of CRISPR type III 
from P. aeruginosa153 to create a synthetic RNA-processing platform for 
predictable gene expression by cleaving precursor mRNAs. Using this 
approach, it is possible to minimize the polar effects stemming from gene 
localization and thus achieve predictable regulation of multi gene operons154. 
This “synthetic splicing” has also been combined with CRISPR-Cas9 for 
gRNA multiplex processing122, and for the construction of more complex 
circuit systems142. Furthermore the ability of Csy4 to bind RNA has been 
exploited to study specific RNA-binding proteins, and it has been suggested 
to improve the sensitivity of transcriptome studies by fishing multiple 
specific transcript using Csy4155.   
Also another type of CRISPR/Cas system has been engineered; indeed Luo 
et al., have programmed the E. coli endogenous CRISPR/Cas system type I-
E to modulate gene expression.  By deleting the nuclease Cas3, which is the 
subunit of the cascade complex accustomed for the DNA degradation, it was 
possible to control gene repression and thus create an alternative, species-
specific CRISPR/Cas regulator156.  
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Chapter 3: E. coli improved recombineering 
 
3.1 E. coli state of art engineering techniques  
Over the decades E. coli has become one of the most widely used model 
organism for metabolic engineering. Thanks to the detailed knowledge about 
its metabolism it has been possible to reconstruct a fairly accurate metabolic 
network that has empowered constrain-based models able to simulate E. coli 
physiology by predicting the flux distribution and the possible products out 
come157–159. The genetic of this bacterium has been extensively studied and 
several methods to engineering it has been developed and optimized. E. coli 
is one of the most known model organism in metabolic engineering for 
production of a wide range of bio-base compounds160. The integrated use of 
systems biology, synthetic biology and evolutionary engineering has enabled 
an extensive development of genetic tools and protocols for efficient, fast 
and cheap manipulations in order to make E. coli suitable for industrial 
applications. Engineering methods have been evolved from simple allelic 
replacements and P1 trunsduction to the use of special enzymes as 
integrases, recombinases and special phage proteins for recombineering 
(Fig. 3). Moreover, repurposing of the retrohoming group II introns and the 
new breakthrough CRISPR technology have become a promising and 
successful methods to introduce modifications and rewire E. coli, and in 
general, bacterial genomes (Fig. 3).  
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Allelic replacement and P1 transduction: allelic replacement basic 
principle is the idea of creating genome modification by using the 
endogenous repair system to replace genomic sites with a new sequence by 
using long homology arms (Fig. 3A). This can cause gene disruption if the 
new sequence is incorporated within an ORF and usually it relies on a 
“suicide”, non-replicative Ori plasmid carrier. The P1 transduction process 
is based on the inaccuracy of P1 phage packaging, which during the 
encapsulation of its DNA occasionally also incorporates pieces of its 
bacterial host. In this way when a P1 lysate is made, some of the particles 
also contain the host bacterial DNA, and when a second host is infected, 
then those pieces of bacterial DNA can be transferred into the new host 
through homology recombination161 (Fig. 3A). This method can be useful 
only if the targeted alleles in the donor host genome are impaired or have 
antibiotic markers within them. Moreover the donor and the recipient host 
need to be closely phylogenetic related in order for the HR to occur.  
Group II introns: mobile group II introns have been retargeted for 
chromosomal gene disruption and modification in a broad range of 
bacteria162–164. These bacterial retrotransposons work in a ribozyme manner 
to mediate a site-specific DNA integration (“retrohoming”) through a 
retrotranscription step (Fig. 3B). Since most of the DNA target site is 
recognized by base pairing, the intron-insertion site can be programmed by 
simply modifying a specific motif in the intron RNA. The high efficiency 
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and easy programmability of the group II introns have enabled the 
construction of specific gene-targeting vectors, or “targetrons”, for fast an 
easy manipulation that combined with Cre/Lox system, broaden the range of 
possible modifications165,166. Targetrons are widely used for genetic 
engineering of bacteria with an efficiency that vary from 1 to 80% 
depending on the site and species167, and several efforts have been invested 
and still continue to adapt them for function in eukaryotes168. Moreover, the 
system is active in a wide variety of microbes, providing genetic 
manipulation of species that cannot be modified using other methods165 .   
Recombinase: recombinases are phage or yeast derived enzymes that can 
efficiently excise DNA between two target sites in direct orientation or an 
inversion of the sequence in between can occur if the target sequences are 
inverted as can co-integration of two separate plasmids that each carry a 
target site, albeit at lower efficiency169. There are three major recombinase 
enzyme: the λ phage recombinase using attP-attB sites target, the yeast 
derived Cre which recognize LoxP sites, and the yeast mitochondrial Sce-I 
which is specialized in scar-less excisions. In the context of genome 
engineering they are utilized to introduce large DNA constructs, to recycle 
the selective markers after recombineering in sequential allelic exchange,  
“Knock-out or knock-in of DNA170–172 and for DNA shuffling173 (Fig. 3C-
D). 
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Recombineering: it is defined as genetic engineering using phage-derived 
recombination proteins174, and it has become probably the most widely used 
system for mutagenesis in E. coli because it is fast, simple and cheap since it 
relies basically on PCR products (for dsDNA) and DNA oligonucleotides 
(for ssDNA). The recombination system uses either the λ Red system or the 
RecET genes of the Rac prophage to dramatically improve the frequency of 
homologous recombination (HR) since the endogenous system, which relies 
on RecA/Rad5, works at very low efficiency and requires 4.5 kb to function 
properly. The high recombination efficiencies can be exploited in a variety 
of ways including the construction of chromosomal gene knock-out, knock-
in, point mutations, genomic libraries, mutagenesis of bacterial artificial 
chromosomes and in vivo cloning175–185. One of the first methods developed 
that marked a turning point in recombineering technology it was the 
repurposing of rec ET proteins from the Rac prophage to manipulate E. coli 
genome and plasmid using sequential steps of homologous and site-specific 
modification. In their work Zhang et al.,186 proposed for the first time a new 
concept of DNA engineering that moved forward from the classic restriction 
and ligation based methods. This system was based on Rec ET system and it 
was transferable between different E. coli strains. Despite the relatively low 
efficiencies, λ Red system has been the most employed and further 
developed recombineering method compared to Rec ET. It consists on three 
phage-encoded proteins, Exo (α), Beta (β), Gamma (γ) and it works 
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similarly to Rec ET system. Exo is a 5′→3′ exonuclease that degrades the 
dsDNA ends exposing a 3′ single-stranded DNA (ssDNA) tail to which the β 
protein can bind176–178,187. Subsequently the β protein-DNA form a complex 
with the target sequence through base pairing complementarity and promote 
recombineering by strand exchange or strand invasion188–191, while the 
protein Gamma inhibits the degradation of dsDNA by binding the RecB 
protein of the RecBCD system192,193 (Fig. 3D). RecE and RecT are 
functionally equivalents to Exo and Beta respectively176.  λβ is a single-
stranded DNA annealing protein194 and it is the only component required for 
recombineering with ssDNA183, while α and γ are necessary when dsDNA is 
involved. Phage-based recombineering is proficient with as little as 30-50 bp 
of homology flanking sequence to the target site when using PCR products 
containing selective markers or heterologous genes (typically an antibiotic 
resistance or metabolic gene) and 70 bp are considered the optimal length 
for ssDNA recombineering177,178,183,195.  However, in order to select the 
recombinant clones, all these methods rely upon antibiotic marker selection 
which has to be removed in order to introduce further modifications. In 
order to recycle the antibiotic markers and allow sequential modification, 
Flp flippase (with FRT target) and Cre-LoxP mediated site specific 
recombination have been used for precise excision of selection 
markers175,186,196–198. Despite the great advantage of re-using the selective 
marker for the subsequent modifications, these site-specific recombination 
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systems leave at least a copy of the FRT site or the loxP site (scar) after 
excision of the markers, which limits the repeated use of this procedure 
since internal chromosomal rearrangements can occur. Therefore, new 
methods based on cam-sacB counter selection or Sce-I scar-less 
meganuclease have been developed in order to overcome the problem of 
genome instability associated to having multiple scars with the same 
sequence spread along the genome179,184,195,199–203. Notwithstanding the issues 
related to the recombinogenic scars, a simple PCR product with flanking 
homologous sequences to the target site or single stranded oligonucleotides, 
enable limited rewriting of any region of the genome.  
Despite the good efficiency of the counter-selection, the engineering process 
becomes laborious and time consuming with multiple steps involved for the 
introduction of just a single modification. Additionally, the methods do not 
allow multiplexing since only few selective markers are available for 
combinatorial use and recombination with linear DNA in E. coli is limited 
because the transformed linear DNA is rapidly degraded by the bacterial 
RecBCD nuclease204. It has been demonstrated that it is possible to 
increase the number of recombinants by using mismatch repair 
mutants such as mutS205 and by using phosphorothioate linkages to 
protect the lagging-targeting206 strand in order to increase the half-life 
of the oligos or PCR products and thus the probability of their 
incorporation during the replication. The short ssDNA/dsDNA 
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oligonucleotide-mediated recombineering is best suited for inserting 
single genome mutations, and it turns challenging for targeted 
multiple gene insertions over a certain length207. Additionally, it 
becomes very difficult to screen for the desired mutations/indels if 
these do not display a clear phenotype.  
CRISPR/Cas9: the type II CRISPR/Cas system from Streptococcus 
pyogenes or pneomonie has been recently proved to be a powerful tool for 
genome engineering in different Prokaryotes such as E. coli 65,106,107, 
Actinomycetal spp.105, Streptomyces spp. 108,109, lactic acid bacteria208. The 
programmability of Cas9 has been shown to be a promising tool to 
manipulate genomes that are difficult to engineer, especially those where a 
recombineering system is absent or inefficient (Fig. 3E). In E. coli, the 
CRISPR/Cas9 system has been recently coupled to λ-RED oligo 
recombineering in order to improve its efficiency65,106,107. The power of 
CRISPR/Cas9 system is the ability to create a selective pressure during the 
recombineering procedure. Indeed the nuclease activity is retained towards 
the loci that have not incorporated the mutation thus constantly inducing 
double strand break that, in turn, cause cell death or a fitness defect (Fig. 
3E). 
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Figure 3: E. coli engineering methods overview. A: homologous recombination 
mediatetd modifications (can be knock-out/in or allelic replacement). P1 transduction 
relies on the same principle to insert the donor in the host genome. B: group II 
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are often used for marker recycling  after the modification has been inserted and selected 
for. D: λ red oligo mediated recombination. ssDNA or dsDNA oligos are used to modify 
the genome at a specific site by incorporating them at the lagging strand of replicating 
DNA. After the replication and cell segregations the mutation is inherited and fixed in 
the genome. E: Programmable endonucleases mediated modification. The system relies 
on the programmability of the endonuclease to induce DSB at specific genomic sites, 
which are then resolved with homologous recombination and insertion of the donor 
DNA. If the donor DNA is not present, constant introduction of DSBs can cause cell 
death. This can be used as programmable negative selection system. 
3.2 Towards genome-scale engineering 
In recent years the attention has been moved towards genome-scale 
approaches, especially thanks to the continuously decreasing in price and the 
high-throughput scale of DNA sequencing and DNA synthesis209, recent 
breakthroughs in genomics and genome editing, new in silico systems for 
large data analysis and larger metabolic and signaling network models 
enable rational reconstruction of cellular behavior. Together with the 
growing field of synthetic biology, this promises a greater role for rational 
design by reverse engineering and synthetic cell circuits to reconstruct cell 
factories. Although the plethora of in silico metabolic and flux models 
promises reconstruction of virtual synthetic cells optimized for production, 
the metabolism and its intricate networks have not yet been fully elucidated, 
and we are still limited by our ability to construct the predicted genome. The 
absence of molecular tools for genomic sequence manipulations in a fast and 
cheap way is the major driving force that has led us to often rely on selective 
breeding and evolutionary optimization using ALE (Automated Laboratory 
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Evolution)210 rather than rational genome design211. The restrictions that 
come with ALE are that evolution is biased by the first mutations that 
appear, which is not always the optimal path for pushing the cells towards 
the boundaries as would happen in cell factories. Thus, it does not sample all 
the possible solutions and most of the time it is difficult to find the selective 
pressure necessary for rearranging the flux towards production. Moreover, 
the objective function for ALE is growth coupled to production, which is not 
always optimal since a faster growing cell may be wasting energy on growth 
rather than production. In the best scenario when ALE would be able to 
evolve a strain with the desired phenotype, we are still facing the challenge 
of reverse-engineering the strain by inserting all the target mutations since 
there are no easy tools for identifying the causative mutants unless they are 
linked to a specific phenotype. 
Recoding organisms at the genome-scale level requires methods that enable 
the manipulation of living cells at the whole-genome level. Such methods 
are increasingly becoming attainable through the advent of advanced 
technologies for manipulating, recombining and synthesizing DNA212. This 
has engendered to a serial of impressive genome-scale methods, which 
include genome merging213, and recoding214, whole-genome 
transplantation215,  refactoring phage genomes216, creation of a bacterial cell 
controlled by a chemically synthesized genome217, whole-genome synthesis 
218, Tn5 whole-genome mutagenesis and oligos screening170,219,220 and 
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removing transposable elements221.  MAGE (Multiplex Automated Genome 
Engineering (MAGE)222,223 was developed as a method that facilitates 
genome-scale engineering. Tractable Multiplex Recombineering uses 
barcoded primers derived from DNA microarrays to generate pools of 
dsDNA cassettes that can target different sites across the genome224, while 
the CAGE (Conjugative Assembly Genome Engineering) technology 
permits genome-scale assembly of large portions of the genome via 
conjugation. This technology combined with MAGE, makes it possible to 
re-write the whole genome from single changes of genomic sequences with 
MAGE, to their assembly into a new chimeric genome225. Engineering of 
biological systems can be unpredictable and challenging since it often 
requires simultaneous genome-wide changes that are difficult to screen for. 
MAGE is the only method so far that allows multiplexing in one step by 
direct electroporation of SS-Oligos or PCR products. The efficiency of 
MAGE is highest for short genome modifications, where around 6 to 20 % 
can be achieved after single or multiple cycles respectively183,222, while 
larger modifications occur with significantly lower frequency (< 1%)206,222. 
Several methods have been developed to improve the efficiency as the co-
operative oligonucleotide co-selection226 or the use of using 
phosphorothioate linkages to protect the lagging-targeting strand in order to 
increase the half-life of the oligos or PCR products and thus the probability 
of their incorporation during the replication206. However, the efficiencies 
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still remain relatively low, and when the desired mutations do not result in a 
clear phenotypic, then it is necessary to implement cumbersome screening 
such as by PCR183. To address this we have developed an approach that 
integrates MAGE recombineering method with CRISPR technology, 
CRMAGE, as described below. 
3.3 Impact of CRISPR on E. coli genome editing: CRMAGE 
 
The recent tendency in genome-scale engineering is to explore more 
complex network and cellular behavior at a whole genome level, which has 
an increased demand on high-throughput and multiplexing methods that can 
be easily reprogram and repurpose DNA to generate genome-wide 
modifications. For these features CRISPR technology represent a new 
turning point for genome recoding and biological network rewiring, and it 
offers almost unlimited potentials in this direction. It has been not fully 
explored in E. coli, potentially because relatively efficient engineering 
methods were already available. Different form Eukaryotic cells, the 
CRISPR/Cas9 technology has had a major breakthrough in E. coli field 
when used as CRISPRi or CRISPR-TF rather than with its original 
endonuclease function. At this stage it may be difficult to imagine that 
CRISPR will substitute λ Red recombineering, which, in its simplicity, relies 
basically on electroporation of oligos and PCR products. Instead in order to 
introduce modification with CRISPR/Cas9 it necessary to always rely on a 
plasmid expressing the gRNA and one used as a donor, thus making this 
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system laborious and complex to just introduce one single modification and 
almost unfeasible to achieve multiplexing. However, CRISPR has recently 
been shown to be a very promising system if coupled with λ Red65,106,107. 
In this work we developed a system, CRMAGE, which drastically improves 
MAGE efficiency from 5% to 98% (Chapter 7, Paper 1). CRMAGE is 
based on the combination of MAGE recombineering and CRISPR/Cas9, 
which is used to induce targeted DSB to create a negative selection against 
the wild type sequence, in order to increase the recombineering 
performance. CRMAGE comes as a full, automatable and potentially high-
throughput engineering platform that includes a web-based tool that 
facilitate the design of both the λ red oligo required for the specific 
mutation, as well as gRNA required for the negative selection. Since not all 
genomic targets are located in direct proximity to an PAM site, the software 
also enables the use of degenerated codons to broaden the range of sequence 
targets. CRMAGE is based on a user-cloning BioBrick system to speed up 
the design and cloning process. Using this two plasmids-based system we 
were able to achieve close to 98% efficiency for single point mutations 
versus 5 % using traditional MAGE, while 66% was reached for modulation 
of protein translation by replacing 6 bp RBS sequence compared to 6% 
using traditional MAGE. CRMAGE has furthermore been designed to 
enable efficient recycling of the plasmid used for negative selection and 
through the same approach it will also be possible to remove the entire 
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system in the last round of CRMAGE, where the CRISPR/Cas9 killing 
activity can target origin and antibiotics markers in both plasmids thus 
resulting in a clean recombinant strain. Moreover, the system enables 
simultaneous integration of multiple mutations with no apparent loss of 
efficiency. For multiplexing of CRMAGE targets, it is necessary to express 
multiple gRNAs. However, the standard design used for synthetic sgRNA 
have significant stretches of sequence homology (typically 136 nucleotides) 
that may result in homologous recombination21. For this reason, we have 
shown that the presence of a constitutively transcribed trascRNA that can be 
repurposed to generate multiple gRNAs from a CRISPR array. The synthesis 
and cloning of such an array of gRNAs (target-repeat-target-repeat etc.) is 
simple and it minimizes the risk of recombination in the vector. Thus, the 
expression of the pre-cRNA for multiplex CRMAGE may substitute the 
sgRNAs if put under control of the inducible pLtet promoter, making it easy 
to control the timing of the expression.  
In conclusion, CRMAGE enables the generation of multiple mutations in a 
single cycle and multiple cycles within one working day, it has the potential 
to significantly increase the daily strain engineering capacity. The increased 
efficiency furthermore opens up the possibility of automating genome-scale 
engineering.  
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Chapter 4: Yeast engineering optimization 
 
4.1 State of the art of S. cerevisiae engineering !
Genetic manipulation in S. cerevisiae has always been quite easy due to the 
natural ability of this organism to recombine linear DNA in a very efficient 
way, as well as its efficient transformation capability. The use of Cre 
recombinase and FLP flippase227–232 or other recombination based 
approaches, like the 50:50 method233 enable marker recycling after each 
manipulations with knock-out or knock-in of exogenous DNA. The 
relatively high recombination efficiency of yeast has been also employed for 
combinatorial gene/pathway integration in δ sites with in vivo assembly of 
PCR product by using concatenated homologous arms 234,235. 
Despite the amenability of these methods, they are relatively time 
consuming and therefore not suitable for the introduction of large 
heterologous metabolic pathways or deletion of several genes in a 
reasonably short time. In recent years new methods relying on the ability of 
double strand break to boost the repair system have been used to improve 
the efficiency of gene knock-out/in. These approaches typically use the 
customizable Zinc finger127 and TAL activator-like effector coupled to 
nuclease domains236 to induce a targeted DSB in order to promoter the 
recombination with the donor DNA at the defined cutting site. Although 
these nuclease-based systems are every effective, they are not suitable for 
multiplex simultaneous editing and they are not optimized for genome-scale 
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level approaches. For this reason DiCarlo et al. developed a mirrored system 
of the E. coli MAGE, the Yeast Oligo-Mediated Genome Engineering 
(YOGE)237. In their work they were able to achieve appreciable 
oligonucleotide insertion efficiencies frequencies of 0.2–2.0% without 
phenotypic selection, thus making it suitable for moderate screening efforts 
with an estimated library size of 102–105 recombinants per locus for each 
cycle.  
Approaches like directed evolution with non-natural selective pressure 
combined with libraries of DNA parts derived by error-prone PCR or 
targeted mutagenesis have been used to identify specific traits, evolve 
synthetic devices and systems in order to expand the genomic diversity238–
240. The advent of more high-throughput of DNA synthesis and assembly 
have brought yeast genetic to the level of a complete de novo synthesis of all 
16 chromosomes241, Sc2.0. In this effort, all nonessential genes will be 
flanked by loxP sites, allowing to SCRaMbLE the genome for random 
deletion of genes upon expression of Cre recombinase, combined with 
screening for viable strains with improved characteristics for a selectable 
trait242,243.  
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4.2 Impact of CRISPR on S. cerevisiae engineering  
 
CRISPR/Cas9 has been applied for targeted single and multiple gene 
deletions in S. cerevisiae by homology-directed repair of DSBs using short 
oligonucleotides as repair donors, in different strain backgrounds98,100,244. A 
pioneer work of CRISPR in yeast, carried out by DiCarlo et al.98, 
demonstrated almost 100% recombination frequency without the use of a 
selectable marker by transforming linear double strand oligonucleotides as 
donor. This is a remarkably difference compared to YOGE where the 
integration is not mediated by DSB. The main advantages of endonuclease 
DSB mediated modifications over traditional techniques lay in their 
efficiency and accuracy since the inductions of DSB have been shown to 
increase the integration of heterologous DNA, as well as the accuracy of 
integration of heterologous linear DNA fragments with ends homologous to 
the DSB site245,246. Cas9 in particular appears as the most promising tool for 
rapid editing a genome at multiple loci. 
Several approaches have demonstrated the efficiency of Cas9 by multiple 
integrations, knock-outs and in vivo assembly for in vivo pathway 
reconstruction and to generate quantitative gene assembly and DNA library 
insertion99,101,102,244,247. It has also been proven successful in the manipulation 
of strains that are difficult to engineer, including industrial strains103. 
Jakociunas et al. have demonstrated the powerful application of the 
CRISPR/Cas9 system as a tool for metabolic engineering utilizing user-
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friendly and easy to use USER-technology-based gRNA constructs247. In 
order to further expand this existing platform with new engineering tools, we 
investigated whether CRISPR/Cas9 together with the DNA brick based 
EasyClone approach could be employed for targeted one-step selection-free 
integration of multiple genes into the S. cerevisiae genome (Chapter 7, 
paper 2)104. The basic idea of the work presented here was to use 
CRISPR/Cas9 for improving an already existing system, EasyClone, 
developed by Jensen et al.248. This EasyClone system consist of a set of 
vectors that enable fast and simultaneous multiple integrations of genes into 
specific “safe sites of insertion” with the possibility of recycling the 
selective markers248. The integration sites are located between essential 
elements, which limits the occurrence of chromosomal rearrangements due 
to the lethal effect this would cause232. Based on homologous recombination 
using 500 bp long homology arms, this method results in efficient 
integration into a single site. However, the efficiency of integration 
decreases when native genes or promoters are present on the fragment to be 
integrated, or in the case of multiple simultaneous integrations. Moreover, 
the method still relies on selective markers, and even though they are 
subsequently excided and recycled, this process requires more time and 
work. It additionally leaves scars scattered around the genome that can 
recombine and cause chromosomal aberrations. Increasing the efficiency of 
targeted integration without selection is therefore important for accelerating 
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and potentially automating the strain engineering process. For this reason we 
developed a marker-free multi gene and pathway integration platform, 
CrEdit (CRISPR/Cas9 mediated genome Editing) (Chapter 7, paper 2)104. 
In this system we combined the high specificity of CRISPR/Cas9 DSB 
mediated editing with the genome engineering tool EasyClone for achieving 
highly efficient and accurate marker-free simultaneous genomic integration 
of multiple pathway gene expression cassettes in different loci in the 
genome of S. cerevisiae.  Using CrEdit we were able to achieve up to 100% 
correct selection-free target integrations at the desired locus and a very high 
efficient simultaneous integrations of three pathway genes involved in the 
production of β-carotene at three different integration sites located on three 
different chromosomes without applying any selection pressure. CrEdit 
therefore enables efficient genome editing without the inclusion of selection 
markers, thereby saving time and eliminating the generation of scars 
associated with their removal.  
This system has proven to be a powerful tool for yeast engineering by 
eliminating the need of sequential introduction of gene modifications and 
marker recycle thus enabling marker-free and simultaneous multiple editing. 
Moreover, it offers the possibility to generate strains with combinatorial 
genetic modifications in just one transformation experiment.  
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Chapter 5: Revolution of CHO engineering !
5.1 Unraveling Chinese Hamster Ovary (CHO) cells  
Chinese hamster ovary (CHO) cells are the primary factories for 
biopharmaceuticals because of their capacity to correctly fold and post-
translationally modify recombinant proteins compatible with humans249. 
CHO studies have been hindered by the inaccessibility to modification of the 
genome and thus to access the genetic information necessary for the 
optimization of production, until recently when the genome sequence of 
CHO-K1 and Chinese Hamster was revealed250,251. The significant number 
of technological advances focusing on phenotypic screening and growth 
media optimization249,252 were achieved before the whole genome was 
sequenced. This has rendered CHO cells the workhorse of 
biopharmaceuticals, accounting for 35,5% of the total approved products in 
the market since 1987, when tissue plasminogen activator was first 
issued249,252. The unraveling of CHO-K1 genome sequence initiated a new -
omics era for CHO biology. Studies on proteomics, genome-scale modeling, 
genomics, metabolomics, transcriptomics, glycomics and fluxomics have 
emerged in the past few years 253. The availability of these huge datasets and 
the genome-scale models will enable a more rational design of CHO as cell 
factories like other organism have been already for decades such as E. coli 
or yeast. However the growing plethora of potential targets for increasing 
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cellular production capabilities and for improving product quality requires 
the development of new engineering technologies. The field of mammalian 
cell engineering technology has been developing quite slowly due to the 
difficulties in obtaining engineered cells with stable genome modifications. 
Antisense RNA254–256, PNA (Peptide Nucelic Acid) 257 and other interference 
mechanisms have been extensively used as tools for modulation of gene 
expression by targeting translation or transcription processes thus they were 
especially engaged for high-throughput screening and for the 
characterization of gene function and regulation. However, these systems do 
not cause permanent genetic modifications but just transient phenotypes 
associated to gene knock down. Historically the allelic replacement and gene 
knock-outs were achieved by homologous recombination followed by 
selection although with very low efficiency 258. Only in recent years break-
through technologies such as meganulease259,260, Zinc-Finger-phusion 
nuclease (ZFN)127,261–264 and TALENs128,265 have allowed researchers to 
modify and tailor specific DNA sequences creating stable genome 
modifications with very high efficiency266. The principles of  CHO genome 
editing rely on the induction of cellular DNA repair systems upon DNA 
damage267,268. The dsDNA breaks introduced by programmable nucleases are 
repaired by either non-homologous end-joining (NHEJ) or homology-
directed repair (HDR). The NHEJ is an error-prone mechanism, so enable to 
generate gene knock-outs due to the indels introduced at the target site 
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within the ORFs resulting in frameshift. HDR system instead allows specific 
allelic exchange and knock-ins but it does not occur frequently unless 
stimulated by the induced DSB of the nucleases269–271. However, the cost and 
amount of work required to produce tailored proteins is very high and 
therefore impacts on the speed and economy of large-scale projects. 
Additionally, it makes infeasible to perform high-throughput and genome-
scale studies. 
5.2 CHO engineering revolution with CRISPR technology  
In the course of the past two years the introduction of CRISPR/Cas9 (Cluster 
Regularly Interspaced Short Palindromic Repeats) genome editing 
technology in mammalian cells such as human and other cells lines69–
71,74,77,80,121,125,272 has circumvented these problems by decreasing the cost and 
time of cell line construction and allowing studies at genome-scale level68. 
Indeed, besides introducing single of few simultaneous mutations at the time 
with high efficiency 69,70,74,75,77,78,273, several studies have shown the effective 
application of this system for multiplexing at the whole genome-scale level 
by exploring phenotypic variation associated to desired phenotypes or in 
more ambitious cases to study cancer genesis and cancer markers 
genotyping73,123–126,274. Moreover, by introducing multiple simultaneous DSB 
it is possible to cause large kilo-base or mega-base deletions or even entire 
chromosomal rearrangements77,275–277, which makes it possible to investigate 
the effect of whole gene cluster deletions or the characterization of 
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phenotypes associated to structural changes of the chromosome and 
aneuploidy state of human cells276,277.  
The ability of Cas9 to create targeted DSBs has also been used to boost the 
HR efficiency resulting in high efficiency of DNA insertions by co-
transfecting either plasmid DNA or single stranded donor oligonucleotides 
(ssODNs) with 40–50 bp of short flanking homologous!sequences!76,121,270,278. 
Additionally, high efficiency of insertion could be achieved also via non 
HDR-mechanism as microhomology-mediated end joining (MMEJ) and 
NHEJ repairs119,279. The use of the nickase, as already mentioned in Chapter 
2, have been used to increase the stringency70,119–121. The use of CRISPRi 
and CRISPR-TFs have also improved the understanding of cell physiology 
and they have been applied for the investigation of gene functions as well as 
rewiring regulatory networks as previously discussed in Chapter 2.  
Our study (Chapter 7, paper 3) has been one of the pioneers in the field, 
being the first demonstrating the application of a CHO codon-optimized 
Cas9 for CHO genome editing by disrupting COSMC and FUT8, genes 
coding for proteins involved in O- and N- glycosylation, respectively 280,281. 
Additionally, we developed a web-based bioinformatics tool “CRISPy” to 
assist in the design of sgRNAs and to predict possible off-targets based on 
the annotated CHO-K1 genome in order to facilitate high-throughput 
automated gene disruptions in CHO. Therefore we demonstrated the high 
efficiency (we were able to achieve up to 47,3% of indels efficiency without 
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selection), robustness, ease of use, and low costs of CRISPR/Cas9 system in 
CHO, thus showing the potential of this system as a genome-editing tool for 
both the academic and industrial community. Moreover, the introduction of 
the CRISPR/Cas9 system in CHO cells combined with the CRISPy design 
tool will contribute to improve the genome editing tool box and cell 
network-interactions understanding in CHO cells and enhance will 
contribute to improve the platform of biopharmaceuticals production in 
terms of yields and quality. This technology in mammalian cells has been 
mainly used with the intention of screening for gene function rather than 
applied to engineer cells for cell factories.   We instead have been among the 
first to foresee its industrial potential by filling a patent (Chapter 7, EPO 
Patent Application WO2015052231) on the development of a multiplex 
editing system, especially suitable for mammalian cells, where a cell line 
with stable integrated and inducible Cas9 is used as engineering cell line for 
screening and fast development of new cell lines optimized for production. 
We have integrated the cell line with a system that enables virtually infinite 
integrations of the desire genes or pathways in safe “landing harbors” by 
regenerating the target sites (Fig. 4), beside the possibility of multiplexing 
knocks out and knock- ins in correlation with the amount of induction (Figs. 
5-6). 
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Fig. 4: The CRESC insert strategy using homologous recombination. Figure adapted 
from C.Ronda, L.E. Pedersen, H.F. Kildegaard, J.S. Lee. “Multiplex editing system”. 
EPO Patent Application (WO2015052231). 
 
 
  
Fig. 5: Percentage of indels generated in 2AGFP_Cas9 cell line. Figure adapted from 
C.Ronda, L.E. Pedersen, H.F. Kildegaard, J.S. Lee. “Multiplex editing system”. EPO 
Patent Application (WO2015052231). Preliminary data from polyclonal FACS enriched 
population and not single clone population with optimized Cas9 expression. The 
percentage of indels created at FUT8, BAK and BAX loci upon induction was analyzed 
by MiSeq sequencing of target loci. 
0%!5%!
10%!15%!
20%!25%!
FUT8_681494! BAK1_1544257! BAX_1345650!
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Fig. 6: Percentage of indels generated from permanently integrated Cas9 sorted for 
medium of high GFP expression. The percentage of indels created at FUT8 loci upon 
treatment of CHO cells with permanently integrated Cas9 and transiently transfected 
guideRNA was analyzed by MiSeq sequencing of target loci after FACS sorting for 
GFP. 
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Chapter 6: Conclusions and future prospective 
 
CRISRP based technology has opened a completely new branch of research 
due to its incredible pliability to any type of organism and to its very diverse 
applications. The incredible ability to reprogram a protein towards any 
genetic sequence has made Cas9 the Holy Grail for synthetic biologists since 
it can be fused to any catalytic domain, and thereby reassigning a new 
function, while still maintaining the sequence specific and programmable 
nature. The accuracy, efficiency, and cost of CRISPR/Cas9 makes it an 
attractive alternative to other methods of genome modification and to 
approach organisms that are difficult to engineer. This enables multiplexing 
and the creation of high-throughput libraries for screening, designing of 
complex circuit to reprogram cell behavior and redirecting cell fluxes or to 
be used as scaffold for imaging platforms. Even split Cas9 has emerged for 
new applications which are still to be developed282. Despite the great 
achievements, there are still caveats that must be addressed in order to 
improve and optimize its function and for expanding the engineering 
toolbox. Indeed the possible off-target effects still raise concern and need to 
be addressed once and for all before considering to use the technology 
therapeutically. This is also important to avoid unforeseen pleiotropic effects 
during genome-scale experiments. Additionally, the PAM sequence, albeit 
very frequent, is a considerable constrain for the target range. Moreover, in 
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other organisms like S. cerevisiae and bacteria such as E. coli, the ability of 
generating huge screening library is not an option since the NHEJ system is 
lacking or is not preferentially used and therefore DSB are usually repaired 
by HDR that requires a donor DNA and no indels are created. Besides that, 
gRNAs need to be expressed through plasmids, and in this way the system 
reaches a bottleneck when multiple gRNAs have to be expressed by one 
plasmid. For E. coli it is even more challenging since the multiple donors 
DNA required have to be transformed as plasmids since linearized DNA is 
degraded immediately.  
In conclusion even though CRISPR technology offers great prospective for 
next generation of cell factories, basic research and pharmaceutical industry 
(and there is still a lot to come with the discovery of new CRISPR systems 
or the optimization of CRISPR/Cas9), a moratorium on human germline 
modification has been called for. A huge ethical debate has begun focusing 
on the possibility of giving to the humankind the power to control its own 
evolution at the genome level283.  Is eugenics and uncontrolled generation of 
GMO organisms lurking behind CRISPR technology?  
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Abstract 
Metabolic engineering is currently pushing 
forward new frontiers by using combinations 
of metabolic network reconstructions, 
efficient laboratory evolution, and genome 
sequencing methods. One of the current 
bottlenecks is efficient genome engineering 
technologies required for creating the desired 
genotypes. Here, we combine CRISPR and 
MAGE technology (CRMAGE) to create a 
highly efficient and fast method for genome 
engineering of E. coli. This two plasmids 
based system combines   red 
recombineering and CRISPR/Cas9. Using 
CRMAGE we were able to increase MAGE 
performance from 5% to 97.6% efficiency for 
gene recoding that leads to a truncated protein 
and from 6% to between 62% to 70% 
efficiency for modulation of protein synthesis 
(small insertion/RBS substitution). The 
system also enables introduction of at least 
two mutations in a single round of 
recombineering with similar high efficiencies. 
Degenerate codon usage can be used to 
expand the range of CRISPR targets, thus 
creating a powerful tool for targeting any site 
in the genome. The CRMAGE system is 
based two plasmids that use a USER-cloning-
assembly-based system enabling quick and 
cost efficient gRNA target replacement. The 
system furthermore utilizes a CRISPR system 
targeting the plasmids, thereby enabling fast 
recycling of the vectors. A web-based tool 
was furthermore developed to predict a 
customized   red oligo required for the 
mutation of the desired nucleotides in the 
genome, as well as the possible gRNAs that 
can be used in combination with it. In 
conclusion, CRMAGE platform enables 
highly efficient and fast genome editing by 
combining MAGE with recombineering with 
CRISPR-based counter selection. The tool can 
be used for generation of multiple mutations 
in a single day and may open up promising 
prospective for automation of genome-scale 
engineering. 
 
Keywords: CRISPR/Cas9, E. Coli, Lambda 
Red, Recombineering, Negative Selection, 
Web-Tool, Modulation of Protein synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
E. coli is one of the most widely used model 
organisms for metabolic engineering for 
production of a wide range of biochemicals1. 
The integrated use of systems biology, 
synthetic biology and evolutionary 
engineering has enabled an extensive portfolio 
of genetic tools and protocols for efficient, 
fast and cheap manipulation in order to make 
E. coli suitable for industrial applications. 
Homologous recombination (RecET)2, group 
II intron retrohoming3–5 and phage-derived 
recombinases (-RED)6–8 have been applied 
to introduce modifications in the genome such 
as single point mutations or Knock-In/Out of 
genes. However in order to select for the 
recombinant clones, these methods rely upon 
antibiotic marker selection, which has to be 
removed in order to introduce further 
modifications. Recycling of the selective 
marker can be achieved by using Cre-Lox 
recombinase5 or FLP flippase4 but both these 
enzymes leave scars in the genome. This 
limits the application for sequential allelic 
exchange since the scars will increase the risk 
of internal chromosomal rearrangements. In 
order to overcome the problem of selecting 
the recombinant strains and recycling of 
antibiotic markers, different methods of 
scarless counter-selection have been 
developed, including a sacB-based method9 
and the use of the meganucleases such as Sce-
I10,11. Despite the high efficiency of the 
counter-selection, the repeated engineering 
process becomes laborious and time 
consuming with multiple steps involved for 
the introduction of just a single modification. 
Additionally, the methods do not enable 
multiplexing since only few selective markers 
are available for combinatorial use. 
The  -RED single/double-stranded DNA 
(ssDNA/dsDNA)-based mediated engineering 
is currently the only method that allows 
multiplexing in one step by direct 
electroporation of single stranded oligos or 
PCR products. For this reason it has been 
extensively used as editing tool and it has 
been employed for Multiplex Automated 
Genome Engineering (MAGE)12–14, a method 
that facilitates genome-scale engineering and 
barcoded genome profiling. It has recently 
been improved by co-operative 
oligonucleotide co-selection by leveraging 
selectable markers within 500 kb of multiple 
targets15. Moreover it has been demonstrated 
that it is possible to increase the number of 
recombinants by using mismatch repair 
mutants such as mutS16 and by using 
phosphorothioate linkages to protect the 
lagging-targeting strand in order to increase 
the half-life of the Oligos or PCR products 
and thus the probability of their incorporation 
during the replication17. The efficiency of 
short ssDNA/dsDNA oligonucleotide-
mediated recombineering (including MAGE) 
is highest for short genome modifications, 
where around 6 to 20 % can be achieved after 
single or multiple cycles respectively13,18, 
while larger modifications occur with 
significantly lower frequency (< 1%)13,17. 
Therefore, PCR screening is always required18 
making it challenging to identify the desired 
mutations that do not result in a clear 
phenotypic change.  
CRISPR/Cas9 (clustered regularly interspaced 
short palindromic repeats and its associated 
protein, Cas9) system has recently proven to 
be a powerful tool for genome engineering in 
different organism, both Eukaryotes and 
Prokaryotes such as E. coli19–21 Actinomycetal 
spp22. Streptomyces spp.23,24, lactic acid 
bacteria25, S.cerevisiae26–31, higher plants32,33 
Bombyx mori34, Drosophila35, Zebrafish36, 
human cell lines37,38 and CHO39–41 cells. The 
type II CRISPR-Cas system from 
Streptococcus pyogenes consists of the 
CRISPR- associated (Cas) protein, Cas9, a 
trans-activating CRISPR RNA (trascrRNA), 
and a programmable CRISPR targeting RNA 
(crRNA) that can be fused together to the 
tracrRNA in a synthetic sgRNA. Cas9 is a 
programmable nuclease that mediates blunt 
double-stranded break (DSB) at almost any 
target DNA locus were a PAM motif 
(protospacer-adjacent motif) is present at 3’ 
end42,43. In the case of S. pyogenes nuclease, 
the sgRNA scaffold can be programmed for a 
specific site by including 20 bp of the target 
locus at the 5’ position of the double guanine 
PAM motif (NGG) (20N-NGG). It is also 
possible to reprogram Cas9 by using 
tracrRNA and a synthetic array containing 30 
bp of the target (5’ of NGG) embedded 
between two repeat regions that will be 
subsequently be processed in the mature 
crRNA42. In both cases the PAM motif is not 
included in the target sequence used for the 
sgRNA or crRNA array. CRISPR/Cas9 can be 
used to create a selective pressure during the 
recombineering procedure. The nuclease 
activity targets the loci that have not 
incorporated the desired mutation, where it 
induces double strand breaks (DSB) that have 
a significant fitness cost and may even result 
in cell death. In E. coli, the CRISPR-Cas9 
system has been recently coupled to λ-RED 
oligos recombineering in order to improve its 
efficiency19–21. Recently, Jiang et al.19 were 
able to reach high efficiency of 
recombineering using dsDNA oligos by 
expressing in succession the two systems. 
Pyne et al. have recently demonstrated that 
the CRISPR/Cas9 system combined with λ-
RED is a promising strategy to facilitate scar-
less large chromosomal gene replacement20 
and multiple knock-outs and knock-ins of  
both small and large fragments21. However 
both of these methods rely mainly on dsDNA 
oligos, which always require all the λ RED 
proteins (exo, β and γ) and it is not suitable 
for a high-through put genome scale approach 
based on chip-based synthetized oligos44,45. 
Here we aimed at generating a simple and 
highly effective tool, CRMAGE, which 
enables fast genome editing. CRMAGE 
exploits intrinsic negative selection against 
the wild type of CRISPR/Cas9 in order to 
increase the MAGE performance for small 
genome modifications as codon substitution 
or translation control elements. The system is 
based on two curable plasmids that encode 
optimized versions of both systems λ RED 
recombineering and CRISPR/Cas9. Since 
both MAGE and gRNA oligos are critical for 
the protocol, we additionally created a web 
based tool for automating and optimizing the 
oligo design. We furthermore demonstrated 
that degenerate codon usage can be used to 
expand the range of CRISPR targets, thus 
creating a powerful tool to modify any site in 
the genome by introducing different types of 
modifications such as standard knock-Out/In, 
point mutations and modulate protein 
translation in one single step.  
 
 
 
 
 
 
Results 
Construction of the CRMAGE system 
CRMAGE technology exploits the ability of 
Cas9 to create DSB and thus kill cells that 
have not had the PAM sequence removed by 
the recombineering reaction in order to 
increase the overall MAGE performance. This 
method has been conceived to compact and 
optimize at the same time   RED 
recombineering and CRISPR/Cas9 in one 
system ready-to-use and to be applied for 
automation (Fig. 1). Therefore CRMAGE 
consist of only two plasmids, which are 
completely curable (Fig. 1). One plasmid 
(pMA7CR_2.0) expresses the  /RED  -
protein and the CRISPR/Cas9 protein, which 
are inducible by L-arabinose and 
anhydrotetracyline (aTetracycline) 
respectively. The second vector is a recycling 
plasmid (pMAZ-SK) that contains an 
aTetracyline inducible sgRNA used for the 
negative selection, as well as a “self-
destruction” gRNA cassette that targets the 
vectors own backbone in order to enable 
plasmid recycling and sequential 
recombineering steps (Fig. 1). The self-killing 
system consists on a trascrRNA that combines 
with two crRNAs, arranged in a natural 
CRISPR array (30bp repeat – 30bp target - 
30bp repeat – 30bp target etc.), to target the 
pCOLA plasmid origin (Ori) and the 
kanamycin antibiotic marker upon induction 
with L-rhamnose and aTetracycline.  The λ 
RED has been coupled to a transient mutS 
phenotype as detailed below, in order to 
optimize the recombineering step by having a 
transient deficient repair system. We have 
also attempted to increase the negative 
selection of CRISPR/Cas9 by coupling it with 
a transient recA- phenotype in order to 
promote cell death due to the inability to 
repair DSB as described below.  
  
Figure 1. Schematic cartoon of CRMAGE system: CRMAGE consist of two plasmids, pMA7CR_2.0 expresses λ/RED β-
protein and CRISPR/Cas9 protein that are inducible by L-Arabinose and aTetracyline respectively. The β-proteins are co-
expressed with dam, which gives a mutS mutator phenotype, and cas9 is expressed in a operon with recX, which blocks the repair 
of double strand breaks. The second plasmid (pMAZ-SK) contains an aTetracyline inducible sgRNA used for selection against 
the wild type sequence, as well as a self-eliminating circuit that targets its own backbone to enable plasmid recycling and 
sequential recombineering. Upon L-rhamnose induction (and aTetracycline for cas9 induction), a trascrRNA that combines with 
two crRNAs, arranged in a natural CRISPR in order to target the origin (Ori) and the antibiotic marker (Kanamycin).  !
CRISPR/Cas9 Killing efficiency and 
estimation of fitness advantage for protocol 
optimization 
In order to investigate the efficacy of the 
CRISPR/Cas9 negative selection and to 
estimate the selection time required for the 
CRMAGE protocol we first determined the 
CRISPR/Cas9 killing rate and the chance of 
recombinants take-over using a gRNA 
targeting the metabolic gene encoding the 
galactokinase (galK). The galK gene was used 
as a target because loss of function of this 
gene is easy to screen for using McConkey 
plates, where colonies capable of utilizing for 
example galactose will turn purple. The 
CRMAGE system (pMA7CR_2.0 and pMAZ-
SK::galK2) was transformed into the WT 
strain without introducing oligos for 
recombineering, and we then monitored the 
number of viable cells over time. An almost 
complete killing of all cells was achieved only 
two hours after induction (Fig. 2). Few 
colonies survived, likely because this CRISPR 
system may be susceptible to escapers. Indeed 
only a single point mutation in the PAM motif 
or in the seed region (8 nucleotides upstream 
the PAM) can create resistance and thereby 
eliminating the killing/selection activity. For 
this reason we tested the optimal time of 
induction of the CRMAGE system, in order to 
identify the best window of action where the 
recombinant population has the most 
significant fitness advantage over the WT 
strain. We therefore created a galK mutant 
that carries a stop codon in position 38 (TAC 
>TAG) that causes truncation and loss of 
function of the galactokinase (Tab.1). By 
inducing the CRMAGE system targeting the 
wild type galK sequence in both a WT 
background and in a galK* mutant, it was 
possible to track the survival of each strain 
over time. The strain carrying the galK* 
mutation took over the population, and more 
than 90% of the population displayed the 
mutant phenotype only two hours after 
induction and no WT colonies were detected 
after 3 hours. 
 
Fig. 2. Wild type killing efficiency: The graph represents the 
wild type killing efficiency monitored over time. For each time 
point the cells were plated and the ratio between WT/ galk* 
was calculated. 
 
RecA and mutS transient mutants contribution 
in CRMAGE optimization 
In order to increase the efficiency of 
CRMAGE, we aimed at improving the 
efficiency of both the  RED recombineering 
and the CRISPR/Cas9 killing. Costantino et 
al. has proven that defects in the mismatch 
repair system can enhance the efficiency of 
recombineering ore than 100-fold16. We 
therefore created a transient mutS- phenotype 
by overexpressing the Dam methyltransferase, 
since this has been documented to result in a 
mutator (mutS-) phenotype46–48. The Dam gene 
was expressed in an L-arabinose inducible 
synthetic operon together with the -protein 
in order to obtain a transient mutator strain 
that can be induced only during the 
recombineering stage, thereby minimizing the 
creation of unwanted mutations. To optimize 
the negative selection of the CRISPR/Cas9 
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system, both Cas9 and recX were expressed in 
a synthetic operon under control of the pLTet 
promoter. It has been previously been shown 
that overexpression of RecX inhibits RecA 
activity49,50, one of the major components of 
the DNA repair system. Since RecA mutants 
are not able to repair DSBs (Double Strand 
Break), we wished to investigate if 
overexpression of the inhibitor (RecX) would 
enhance the CRMAGE negative selection. 
After one CRMAGE cycle using a galK 
MAGE oligo we observed that recX 
overexpression most likely has a smaller 
positive impact on CRMAGE efficiency (p-
value <0.1) (Fig. 3), and we therefore decided 
to keep overexpression of recX in the 
CRMAGE system.  
 
 
Fig. 3. Contribution of RecX in CRMAGE efficiency: The 
graph shows the effect of recX expression on the CRISPR/Cas9 
killing activity after λ-RED recombineering. In pMA7CR_2.0 
(represented by the dark grey bar on the right) cas9 was 
expressed in a synthetic operon together with recX. In 
pMA7CR2, cas9 was expressed alone (represented by light 
grey bar on the left). The presence of recX positively 
contributes to the negative selection (dark grey bar on the right) 
with p-value < 0.1 according to a T-test analysis. 
 
 
Use of CRMAGE to target PAM-independent 
loci 
After estimating the optimal killing window 
for CRMAGE, we wanted to test if the system 
could be used to target loci in the genome that 
are not directly linked to a PAM sequence. As 
proof of concept we decided to create a galK 
knockout by changing one of the initial 
codons of the gene, which is not directly 
linked to a PAM site, into a stop codon (TAC 
>TAG) (Tab.1). To do this, we looked for a 
PAM in the closest proximity (within the 70 
bp coverage of the MAGE oligo) and we 
introduced a secondary silent mutation that 
disrupts the nearby PAM sequence while 
coding for the same amino acid (ACC > 
ACA) (Tab.1). After a single round of 
CRMAGE, we found that about 98% (Fig. 4a) 
of the population had incorporated the desired 
mutation in galK. Using traditional MAGE 
only 5 % of the population had the specific 
mutation incorporated (Fig. 4a), which is 
consistent with previous studies18 This makes 
it theoretically possible to utilize the 
CRMAGE system to target any site in the 
genome with a very high efficiency thus 
further expanding the ability to investigate 
codon usage and re-coding of the essential 
genes, as it has been previously attempted 
using MAGE alone51  
 
Use of CRMAGE for small insertions and 
modulation of protein synthesis  
The high efficiency of the CRMAGE system 
for achieving single point mutations prompted 
us to test if CRMAGE would enable larger 
genome modifications, which typically result 
in very low frequencies when relying on 
MAGE alone13,17. Since it is often desirable to 
modulate expression level of certain proteins, 
we tested if CRMAGE could be used to 
modify regulatory elements such as RBS 
sequences. We initially integrated GFP with a 
weak RBS on the genome. We then attempted 
to introduce an RBS variant (TCCTCC > 
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AGGAAG) (Tab.1) predicted to have 
significantly higher expression levels, thus 
resulting in higher fluorescence levels (GFP+). 
Using the CRMAGE system, an efficiency of 
almost 70% was achieved (Fig. 4b), while 
only 6% of the population had introduced the 
RBS modification when relying on MAGE 
alone (Fig. 4b). This demonstrates that it is 
feasible to generate libraries of different 
regulatory elements with high efficiency using 
CRMAGE 
 
Use of CRMAGE for multiplexing  
Given the high efficiency of introducing both 
single point mutations as well as a larger RBS 
modification, we decided to test if 
introduction of multiple mutations could be 
achieved in a single round of CRMAGE. In a 
wild type background, we therefore co-
selected for the introduction of both the 
replacement of the RBS sequence in front of 
GFP and the introduction of a stop-codon in 
galK. The two different MAGE oligos were 
co-transformed together with two different 
gRNAs for CRISPR/Cas9 negative selection. 
The final population was plated on both 
McConkey and LB plates and the efficiency 
was determined for each individual mutation 
(Fig 4c). In randomly picked colonies, 98% 
were found to carry the galK* mutation and 
70% carried the RBS modification (Fig 4c). 
Subsequently, recombinants clones for each 
mutation (GFP+ and galk*) were tested if they 
also carried the second mutation. All the 
tested colonies (40 out of 40) showing strong 
GFP fluorescence after CRMAGE also 
resulted in white colonies when plated on 
McConkey plates, thus proving that they also 
incorporated the galK* mutation. Similarly, 
all the colonies tested (15 out of 15) carrying 
the galK* mutations also showed strong GFP 
expression, thus resulting in a 100% 
efficiency of simultaneously introducing the 
double mutations (Fig. 4d). Using MAGE 
alone, only 5-6% of the colonies carried the 
galK* mutation, and of these only 10% 
carried showed strong GFP fluorescence  (Fig. 
4d).  
Table 1: Oligos used for the CRMAGE experiments. Taget sites are marked with red. Synonymous mutations are in blue. 
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Figure 4: Efficiency of CRMAGE. Panel A and B show the efficiency of CRMAGE for gene recoding using pMA7CR_2.0 
compared to the pMA7 control using only λ-RED. (a) The efficiency of CRMAGE for introducing codon substitution (galk* TAC 
>TAG) linked to a secondary silent codon substitution used by CRMAGE as counter selection (ACC > ACA). (b) The efficiency 
of substituting a weak RBS in front of GFP with a strong one (TCCTCC > AGGAAG) while disrupting the PAM sequence used 
for negative selection. Panel C-D shows the efficiency of multiplex CRMAGE. (c) The efficiency of a single round of CRMAGE 
for simultaneously introducing the two mutations mentioned above (the RBS exchange on the left and stop codon substitution on 
the right). (d) CRMAGE multiplexing efficiency (pMA7CR_2.0) of the two mutations compared to the control (pMA7) using 
only λ-RED. The data result from the analysis of 15 to 40 positive clones per each mutation that were re-streaked and tested if 
they were carrying also the second modification.
Elimination of gRNA plasmid for subsequent 
rounds of CRMAGE 
In order to enable sequential recombineering 
cycles, it is beneficial if the plasmid required 
for the negative selection can be quickly 
cured, so that a new vector can be introduced 
for the next round of CRMAGE. For this 
reason we designed the plasmid carrying the 
gRNAs as a self-killing plasmid (pMAZ-SK) 
by exploiting CRISPR/Cas9 ability to cut the 
plasmid DNA. An L-rhamnose inducible 
CRISPR natural array encoding two pre-
crRNAs that target the origin of the plasmid 
and the kanamycin antibiotic marker was 
therefore included in the vector. In order to 
create mature active crRNA, the trascrRNA 
was included on the plasmid under the control 
of a strong synthetic constitutive promoter. 
This way it should possible to induce plasmid 
digestion in order to cure the plasmid before 
starting a new round of CRMAGE. We 
initially determined the minimum amount of 
time required for successful curing of the 
plasmid by following the number of cells that 
retained the plasmid after L-rhamnose 
induction (Fig. 5). After just 2-3 hours of 
induction, 92-96% of the cells had lost the 
plasmid. Interestingly, a complete removal of 
the plasmid could not be achieved even after 
overnight incubation, where 0.2% of the 
population still retained the plasmid (Fig. 5). 
However, for the practical use for CRMAGE, 
very efficient plasmid loss can be achieved 
even after a short incubation time, which will 
significantly speed up the engineering 
process. The effective plasmid loss induced 
by the expression of trascRNA and the 
CRISPR array that targets the plasmid origin 
and the kanamycin cassette demonstrates that 
the processing of the RNA is functional. 
Using the same principle, it will therefore also 
be possible to include gRNAs that target the 
pMA7CR_2.0 plasmid, thereby making it 
possible to remove both plasmids at the end of 
the final engineering cycle.  
 
Figure 5: Self-eliminating proprieties of pMAZ-SK plasmid 
used for negative selection. The graph shows the rate of 
plasmid curing over time. The population was induced with L-
rhamnose (to induce self-killing crRNA) and aTetracycline (to 
induce Cas9 expression) and was plated on Kanamycin 
selective plates and compared to the un-induced population. 
 
CRMAGE  gRNA design tool 
A number of tools are available online for 
identifying and designing gRNAs for various 
organisms. However, since CRMAGE enables 
the generation of specific mutations 
throughout the genome, it is necessary to both 
identify the optimal gRNA for counter 
selection, as well as the oligos required for 
MAGE. Furthermore, when the specific 
mutation is not located in close proximity of a 
PAM sequence, it is necessary to identify a 
nearby PAM sequence that can be included in 
the MAGE oligo design as described earlier. 
In order to automate the design of both sets of 
oligos, we have created a web based tool, 
CRMAGE – Web tool (available at 
http://staff.biosustain.dtu.dk/laeb/crmage/), 
which guides the user through the necessary 
steps to create a CRMAGE mutated oligos, 
considering also the option of using 
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degenerate codons if the desired mutation is 
not located near a PAM sequence. It consists 
of 3 major steps which include: input of a 
DNA sequence to mutate, user based selection 
of the base(s) to mutate, and the program 
finally presents the user with available 
gRNAs near the desired mutation spot as well 
as with options to mutate the PAM site of the 
gRNA to prevent it from selecting against the 
recombinants. The final output includes the 
gRNA as well as an SS-DNA oligo to use for 
recombineering that contains both the desired 
mutation and the one required for negative 
selection (Fig. 6). 
 
 
Final CRMAGE oligo 
!
Possible gRNAs to use for negative selection 
Figure 6: CRMAGE Web-Tool. The program guides the user through the necessary steps to create a CRMAGE mutated oligos, 
considering also the option of using a degenerate codon if the desired mutation does not contain a PAM itself. It consists of three 
major steps: (1) Enter (copy/paste) the wild type DNA sequence; (2) Select the base to mutate and which base to change to. Step 
3: Choose the Open Reading Frame and the size of the CRMAGE mutation oligo. A list of potential gRNA sites are shown, and 
the user can pick silent mutations to destroy the indicated gRNA PAM site (pointed by the red bracket). Finally the program 
outputs the CRMAGE oligo sequence (shown by the red arrow).!
DISCUSSION 
CRMAGE is based on the combination of 
MAGE recombineering with the negative 
selection against the wild type sequence, 
which can be achieved using CRISPR/Cas9 
targeted double strand breaks. In a single 
round of CRMAGE recombineering, we were 
able to achieve close to 98% efficiency for 
single point mutations versus 5% using 
traditional MAGE. For replacing a larger 6 bp 
RBS sequence, an average of 66% was 
achieved in two separate types of 
experiments, while only 6% efficiency was 
reached using traditional MAGE. Such high 
efficiency with ssDNA oligos and short 
homology arms (70 bp) has not been 
previously reported. Pyne at al.20 achieved 
only 39% for small insertions (8bp) using 
dsDNA and 80% for small modifications with 
ssDNA and Jiang et al.21, could reach 
efficiencies in the range of 72% to 92%  
relying mainly on long homology arms (300-
400pb), while focusing mainly on large 
modifications. Moreover CRMAGE system 
enables integration of multiple mutations with 
no apparent loss of efficiency, which is 
different from previous work where the 
multiplexing efficiency dropped considerably 
from 39-47% to 0.68-0.25% and from 72-92% 
to 48-78% in Pyne et al. and Jiang et all 
systems respectively20,21. In the case of 
CRMAGE, we speculate that the reason for 
incomplete killing of the WT or rescue of the 
selection plasmid (pMAZ-SK) is the leakiness 
of the tetracycline and rhamnose promoters 
that may result in a selective pressure during 
the 5 hours of the whole CRMAGE protocol, 
which may result in few escapers that will not 
succumb to the negative selection.  
It has previously been attempted to modulate 
chromosomal gene expression in one single 
step using PCR products52. However this 
work relied on phenotypic screening, and the 
method leaves FRT scars after the regulatory 
element is inserted. The presence of scars in 
the genome promotes genome rearrangement 
after several rounds of modifications thus 
making it difficult to further engineer the 
strain. With CRMAGE we have demonstrated 
that is possible to modulate the protein 
translation with relatively high efficiency 
within the population, which can be applied to 
any regulatory element that could be inserted 
to modulate either the gene expression or 
protein translation. 
The CRMAGE system was furthermore 
designed to enable efficient recycling of the 
plasmid used for negative selection by 
targeting the Cas9 towards the origin and 
kanamycin cassette in the vector backbone 
itself. Controlled by a L-rhamnose inducible 
promoter, an almost complete loss (96%) of 
the plasmid was achieved after 2-3 hours of 
induction. This means that it is possible to 
proceed with subsequent rounds of CRMAGE 
without an intermediate screening for 
kanamycin sensitive clones. Using the same 
approach it will also be possible to remove the 
entire CRMAGE system in the last CRMAGE 
round, where the CRISPR/Cas9 killing 
activity can target origin and antibiotics 
markers in both plasmids thus resulting in a 
clean recombinant strain. The idea of 
generating a clean background strain and the 
possibility to recycle the plasmid containing 
the gRNA at the end of the engineering 
process has been considered by Jiang et al.21. 
In their work they have aimed at rescuing the 
plasmid harboring the gRNA for negative 
selection by induction with IPTG, and the 
plasmid carrying   RED and Cas9 by 
growing the culture at 37 ̊C. However it was 
not possible to proceed with a subsequent 
round of recombineering before of 8 or 16 
hours of IPTG induction. The use of the 
temperature sensitive origin used for plasmid 
encoding Cas9 furthermore increases the time 
required for one single round of 
recombineering since the growth rate of E. 
coli is significantly reduced at 30 ̊C.  
For multiplexing of the CRMAGE targets, it 
is necessary to express multiple synthetic 
gRNAs that have significant stretches of 
sequence homology (typically 136 
nucleotides). As discussed by Jiang et al., the 
repeated sgRNAs may result in homologous 
recombination21. Here, we have shown that 
the presence of a constitutively transcribed 
trascRNA in the pMAZ-SK vector makes it 
possible to generate multiple gRNAs from a 
single short region carrying only 30 
nucleotides per gRNA followed by a 30 
nucleotide repeat between them. The 
synthesis and cloning of such an array of 
gRNAs (target-repeat-target-repeat etc.) is 
simple and it minimizes the risk of 
recombination in the vector. The expression 
of the pre-cRNA for multiplex CRMAGE 
may substitute the sgRNAs if put under 
control of the inducible pLtet promoter, 
making it easy to control the timing of the 
expression. The system will most optimally 
use aTetracycline induction for negative 
selection (when pLtet is used in front of the 
CRISPR array) and L-Rhamnose induction for 
curing the plasmid.  
We furthermore demonstrate that degenerate 
codon usage can be used to expand the range 
of CRISPR targets, thus creating a powerful 
tool for targeting virtually any site in the 
genome and enabling single step engineering 
to create single point mutations as well as 
larger mutations, as demonstrated by the 
efficient RBS replacement for modulating 
protein translation. The same design can be 
applied for creating knock-ins or complete 
knock-outs, depending on the donor oligos. 
The web based CRMAGE web - tool has been 
engineered to facilitate the design of both the 
 red oligo required for the specific mutation 
as well as gRNA required for the negative 
selection and together with the convenient 
USER-cloning-assembly-based system we 
have developed, speed up the design and 
cloning process. Since CRMAGE enables the 
generation of multiple mutations in a single 
cycle and multiple cycles within a working 
day, it has the potential to significantly 
increase the daily strain engineering capacity. 
The increased efficiency furthermore opens 
up the possibility of automating genome-scale 
engineering.  
 
MATERIALS AND METHODS 
Strains, Media and Reagents 
E.coli K-12, MG1655 strain with genome 
integrated repressor from pZS4Int-tetR, was 
used to perform CRMAGE experiments and 
Dh5α strain instead was used for cloning 
purposes. CRMAGE was performed using 
LB-Lennox (10 g/L tryptone (“Enzymatic 
digest from caseine”- Fluka Analytical), 5 g/L 
yeast extract (Fluka Analytical), 5 g/L NaCl) 
supplemented with 0.5 mM of MgSO4 
(Sigma). All cultures were grown at 37 ̊C, 
250rpm shaking. For cloning Q5 high fidelity 
Polymerase (NebLab), Fasta Digestion 
enzymes and Buffer from Fermantas/Thermo 
Scientific and USER enzymes from NebLab 
was used. All oligonucleotides and gblocks 
were synthesized by Integrated DNA 
Technologies (IDT; Coralville, IA) at the 25 
nm scale using standard desalting. 
 
Plasmids constructions and CRMAGE plug-in 
and play BioBrick 
The pMA7CR_2.0 (AmpR) has been 
constructed by cloning Cas9 and RecX in 
pMA7 plasmid 53. RecX was first amplified 
from purified MG1655 genome using the 
primers 1 and 2 (Table S1) and cloned in 
pZ21MCS50 downstream of pLTet promoter 
using the restriction enzymes KpnI and 
BamHI. Then the expression cassette, gene + 
promoter (pLtet_recX), was amplified and 
cloned in pMA753 with USER using primers 
3, 4 and 5, 6 (Table S1) for the pMA7 
backbone and RecX respectively. Eventually 
a synthetic operon was created by cloning 
Cas9 with a strong RBS (AAGGAGA) 
downstream pLTet_recX using primers 7, 8 
(Table S1) to amplify the backbone with 
recX, and 9, 10 (Table S1) to amplify Cas9 
directly from S.pyogen genome (ATCC 
collection) (Fig. S1). The plasmid 
pMACR_2.0 comes in combo with plasmid 
pZS4Int-tetR (CAMR)54 that is a single copy 
plasmid harboring TetR repressor necessary 
for the control of Cas9 and sgRNA 
expression. This plasmid can also be 
integrated in the genome in one single step 
using the helper plasmid pLDR8 [WM2269] 
(ATCC® 77357) expressing the integrase. The 
self-killing gRNA plasmid (pMAZ-Self-
Killing: pMAZ-SK) was designed using 
pCOLA-duet (Millipore) as backbone vector 
and it consists on two main parts. The first 
one contains the aTetracycline inducible 
synthetic gRNA use for negative selection and 
the second one constituted of two subparts for 
the self-killing (Fig. 1), the pre-crRNA array 
and the trascrRNA. The pre-crRNA array and 
the trascrRNA were ordered as synthetic 
oligos and gBlock from Life Technology and 
IDT respectively. The first one, named 
part1_selfkilling (Table S1) was designed to 
have the pre-crRNA array coding for two 
crRNA targeting the Origin (Ori) and the 
antibiotic marker (Kanamycin) of the pCOLA 
backbone, and it was cloned using the 
restriction enzymes NcoI and PacI after the 
part containing the trascrRNA 
(part2_selfkilling) was cloned with USER 
using primers 11 to 14 (Table S1). In the 
part2_selfkilling component, there is the 
trascrRNA under a constitutive synthetic 
promoter and a synthetic terminator, both 
derived from igem.part.org (Table S1). Once 
the two major components of the self-killing 
plasmid were assembled in the pCOLA 
backbone, the synthetic gRNA for the 
negative selection was added using primers 17 
to 20 (Table S1) with USER cloning55. Only 
the gRNA GFP4 (Table S1) was ordered as a 
gBlock (from IDT) to have it as a unit 
organized in: the aTetracycline inducible 
promoter (pLtet), 20pb target sequence and 
the general scaffold that fuses part of the 
repeat region of the crRNA and the 
trascrRNA.   
In order to change the target sequence in the 
synthetic gRNA we have designed a USER-
cloning-assembly-based plug-and-play 
system, where it is only necessary to order 
two oligos to change the synthetic gRNA for 
the negative selection. This system relies on 
USER cloning55: the self-killing backbone 
was amplified using the universal primers 21, 
22 (Table S1) containing the uracil, the target 
sequence can be replaced by changing only 20 
internal nucleotides of two universal 
complementary oligo scaffolds (oligo 
scaffolds 23, 24 shown in Table S1). These 
oligos were designed to be complementary 
and when annealed will leave 10pb overhangs 
that match the overhangs left on the backbone 
after USER treatment. Therefore it is 
necessary replace only the 20 bp sequence 
with the new target in a way that the two 
oligos sequences will be complementary 
(20pb sequence on the forward oligo has to be 
complementary to the 20bp sequence on the 
reverse oligo). The oligos were ordered 
without uracil making the method very cost 
efficient, and 10 µL of each oligo (100µM 
concentrated) was then mixed with 10 µL of 
Neb Buffer4 and 70 µL of MilliQ Water (100 
µL reaction in total). The reaction mix was 
incubated at 95 °C for 5 minutes and let it 
cool down slowly overnight. Once the two 
oligos were annealed, they were mixed with 
the amplified backbone, treated with USER 
enzymes and directly transformed into 
chemically competent cells. The self-killing 
plasmid containing the galk2.2 gRNA was 
obtained with this method using primers 24, 
25 (Table S1) in just a single day of work. 
The second gRNA for multiplexing was 
inserted in pMAZ-SK::galK2 using primers 
27 to 30 (Table S1). pMA7CR_2.0 and 
pMAZ-SK sequences are shown in Table S1. 
 
CRMAGE protocol 
An overnight culture of 
MG1655::pMA7RCR_2.0 in LB with 100 
µg/mL ampicillin (to maintain 
pMA7CR_2.0), 35 µg/mL chloramphenicol 
(to maintain pZS4Int-tetR if not integrated in 
the genome) was shaken at 37°C. The 
following day 15 mL of LB with 100 µg/mL 
ampicillin, 35 µg/mL chloramphenicol was 
inoculated with 0.15 mL of the overnight 
culture in a 250 mL flask (starting OD 
between 0.02-0.03), incubated at 37°C 
shaking and grown until an OD of 0.5-0.6 
(about 1.5-2 hours). -RED was induced by 
adding L-arabinose to a final concentration of 
0.2%, followed by continued shaking at 37°C 
for 10-15 minutes. The culture was 
immediately put in a ice-water bath and left to 
cool for at least 15-20 minutes. The culture 
was then pelleted by centrifugation at 6500 x 
g for 5 minutes at 4°C, the supernatant was 
discarded and the pellet resuspended in 35 mL 
of ice-cold MilliQ water. This procedure was 
repeated two times more, where the pellet was 
first re-suspended in 15 mL and then in 1 mL 
of ice-cold MilliQ water. The 1 mL of cells 
were finally centrifuged at 6500-7000 x g for 
5 minutes at 4°C and the supernatant removed 
completely. Subsequently, cells were prepared 
for electroporation and re-suspended in 400-
800 µL of ice-cold MilliQ water. The MAGE 
oligonucleotides together with the plasmid for 
negative selection were prepared in advance 
in an Eppendorf tube containing 0.5 µL of 
equimolar amounts of each oligo (100 
pmol/µL of each) and 250 ng of the plasmid 
in MilliQ water. 50 µL of cells were added to 
the oligos/plasmid mix and electroporated at 
1.8 kV in a 1 mm gap cuvette, and 950 µL of 
LB with 100 µg/mL ampicillin, 35 µg/mL 
chloramphenicol was added immediately after 
and the cells were transferred to a new tube 
(15 mL) and left to recover for 1h at 37°C 
with shaking. Kanamycin was added to reach 
a concentration of 50 µg/mL and the culture 
was incubated for additional 2 hours. 
After 3 hours of incubation, tetracycline 
(200ng/mL) was added and the cells were 
grown for another 2 hours at 37°C shaking. 
After this point the cells can either be plated 
on selective media or the plasmid for the 
negative selection can be rescued to start 
another round of MAGE. For the plasmid 
cure, the cells were washed twice with fresh 
LB and resuspended in LB with 100 µg/mL 
ampicillin, 35 µg/mL chloramphenicol, 
aTetracycline 200ng/mL and 0.2% (w/v) of L-
rhamnose. If the cell were left to grow ON, a 
smaller inoculum (103 - 104 dilution) was 
used. If the culture was prepared for an 
immediate subsequent round of CRMAGE, 
the it was diluted to an OD that allows at least 
2-3h of growth before reaching OD:0.5-0.6, 
which is necessary to start the following 
round. 
 
CRMAGE  Web-Tool 
The CRMAGE web-based design tool is 
available at 
http://staff.biosustain.dtu.dk/laeb/crmage/ and 
follows three individual steps as described 
here: Step 1: Enter the wild type DNA 
sequence. Simply copy/paste or manually 
enter the sequence. Step 2: Select the base to 
mutate. Here the user is presented with a 
numbered and spaced version of the sequence 
entered in step 1 and the user can then click 
the exact base that should be mutated and can 
select into which base it should be mutated. 
Step 3: CRMAGE mutation oligo and gRNA. 
In this step the user can select a desired 
CRMAGE mutation oligo size. The size of the 
MAGE oligo determines which gRNA sites 
can be used since the program sets that as 
constraint region from which it samples the 
possible gRNAs to use as “negative selection 
marker”. The user should then select the 
correct reading frame. Then a list of potential 
gRNA sites are shown and the user can pick 
silent mutations with the intent to destroy the 
indicated gRNA PAM site. Be aware that all 
silent mutations are shown even if they do not 
destroy the gRNA PAM site. It is up to the 
user to ensure that the PAM site is destroyed. 
One or two mutation boxes may be shown 
next to a gRNA target. This is dependent on 
whether one or two codons cover the PAM 
site. At the very end of step 3, the mutation 
oligo sequence is presented and can be 
copy/pasted for synthesis. 
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Supplementary Figures, Tables and Sequences  
 
Primer Source
1 recX_fwd_kpnI ATCGAGGTACCATGACAGAATCAACATCCCGTC This study 
2 recX_rev_BamHI TCGTAGGATCCATCAGTCGGCAAAATTTCGCCA This study 
3 pMA7_fwd AAGCGGGUTTTTTTATGACAAACTCTTTTGTTTATT This study 
4 pMA7_rev ATAGGGAATAGGGAGUAGAAACGCAA This study 
5 fwd_insert_recX ACTCCCTATTCCCTAUCAGTGATAGAGATTGACAT This study 
6 rev_insert_recX ACCCGCTUGCGCGGGCTTTTTCACATTGATGCCTCTAG
CACGC 
This study 
7 pMA7CR_2.0_fw
d 
ACTGAGA/ideoxyU/CCCATGGTACGCGTG This study 
8 pMA7CR_2.0_rev ATCTCCTTC/ideoxyU/caGTCGGCAAAATTTCG This study 
9 c9_PMA7CR_2.0 
fwd 
AGAAGGAGA/ideoxyU/ATACATGGATAAGAAATACT This study 
10 c9_PMA7CR_2.0 
rev 
ATCTCAG/ideoxyU /CACCTCCTAGCTGACTCA This study 
11 trancrRNA_Coli_f
wd 
ACACCGAC/ideoxyU/AGCGAAAAAACC This study 
12 trancrRNA_Coli_r
ev 
ACGCTGCT/ideoxyU/TTGACGGCTA This study 
13 pCOLAtran_rev AGTCGGTG/ideoxyU/GCGCAACGCAATTAATGTA This study 
14 pCOLAtran_fwd AAGCAGCG/IDEOXYU/ATATACCATGGGCAGCAGC This study 
15 Part2_selfkilling TTAATTAACACCGACTAGCGAAAAAACCCCGCCGAAG
CGGGGTTTTTTGCGAAAAAAAGCACCGACTCGGTGCCA
CTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTT
GCTATGCTGTTTTGAATGGTTCCGCTAGCACTGTACCTA
GGACTGAGCTAGCCGTCAAAAGCAGCGTCCTCAGG 
This study 
16 Part1_selfkilling CCATGGCCACAATTCAGCAAATTGTGAACATCATCACG This study 
Table. 1
TTCATCTTTCCCTGGTTGCCAATGGCCCATTTTCCTGTC
AGTAACGAGAAGGTCGCGAATTCAGGCGCTTTTTAGAC
TGGTCGTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCA
AAACCCGTTCCGTGTAGACAGTTCGCTCCAAGCTGTTT
TAGAGCTATGCTGTTTTGAATGGTCCCAAAACGCCATG
TTTCAGAAACAACTCTGGCGCATCGTTTTAGAGCTATG
CTGTTTTGAATGGTCCCAAAACAAAAAAAAACCCCGCC
CCTGACAGGGCGGGGTTTTTTTTTTAATTAA 
17 pCOLAforgrna_f
wd 
ACCGGTA/ideoxyU/CCTAGGCTGCTGCCACCG This study 
18 pCOLAforgrna_re
v 
ACCAGAC/IDEOXY 
U/TTAATTAAAAAAAAAACCCCGCCCTGTCA 
This study 
19 pCOLA_gRNA_f
wd 
AGTCTGG/ideoxyU/TATAACCTGAGGTCCCTATCAGTGA
TAGAGA 
This study 
20 pCOLA_gRNA_r
ev 
ATACCGG/ideoxyU/TTCGACTTAAGCATTATGCGG This study 
21 new universal 
backbone fwd 
primer 
AGCTAGAAA/ideoxyU/AGCAAGTTAAAATAAGGC This study 
22 New rev back 
bone primer 
AGTATCTC/ideoxyU/ATCACTGATAGGGATGTCA This study 
23 variable region 
fwd 
GAGCAC (20N) GTTTTAGAGCTAGAAAT 
  
This study 
24 Variable region 
rev 
CTAAAAC(20N)GTGCTCAGTATCTCT 
 
 
This study 
25 Variable region 
galk2 fwd 
GAGCACAACGAAACCGTCGTTGTAGTGTTTTAGAGCT
AGAAAT 
This study 
26 Variable region 
galk2 rev 
CTAAAACACTACAACGACGGTTTCGTTGTGCTCAGTA
TCTCT 
This study 
27 2_sgRNA_fwd ACCGGTATTCCCTATCAGTGATAGAGAT This study 
28 2_sgRNA_rv AGCAGCCTAGGAAAAAAGCACCGACTCGG This Study 
29 2_sgRNAbb_fwd AGGCTGCTGCCACCGCTGA This Study 
30 2_sgRNAbb_rev ATACCGGTAAAAAAGCACCGACTCGGTGCCA This Study 
 CRMAGE oligos   
 GFP_RBS 
CHANGE 
GACAACTCCAGTGAAAAGTTCTTCTCCTTTGCTCATCTA
GTATTGTTCCTCTTTAATCTCTAGTAGCTAGCACTGTAC
CTAGGACTGAGC 
This study 
 Galk2.2_STOP_s
ynonymous codon 
GGCCGCGTGAATTTGATTGGTGAACACACAGACTAGA
ACGACGGTTTCGTTCTGCCCTGCGCGATTGATT 
This study 
 Synthetic gRNA   
 Promoter (pLtet) TCCCTATCAGTGATAGAGATTGACATCCCTATCAGTGA
TAGAGATACTGAGCAC 
This study 
54 
 Scaffold GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTA
GTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTG
CTTTTTT 
 
 37,38 
 GFP4  target CTCCTTTGCTCATCTAGTAT This study 
 Galk 2 target AACGAAACCGTCGTTGTAGT This study 
 crRNA Array   
 pRham CCACAATTCAGCAAATTGTGAACATCATCACGTTCATC
TTTCCCTGGTTGCCAATGGCCCATTTTCCTGTCAGTAAC
GAGAAGGTCGCGAATTCAGGCGCTTTTTAGACTGGTCG
T 
This study 
 Repeat GTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAAC This study 
 Target Ori CCGTTCCGTGTAGACAGTTCGCTCCAAGCT This study 
 Target Kanamycin GCCATGTTTCAGAAACAACTCTGGCGCATC This study 
 Synthetic 
Terminator  for 
crRNA 
array(BBa_b1006) 
AAAAAAAAACCCCGCCCCTGACAGGGCGGGGTTTTTTT
T 
 This study 
 
  
 
pMA7CR_2.0 sequence: 
CCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAA
ACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGA
CCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGG
TAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGC
ATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTC
GTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGAC
AAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCC
CGGAGGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGC
ATCAAATTAAGCAGAAGGCCATCCTGACGGATGGCCTTTTTG
CGTTTCTACTCCCTATTCCCTAUCAGTGATAGAGATTGACATC
CCTATCAGTGATAGAGATACTGAGCACATCAGCAGGACGCAC
 trascrRNA   
 trascrRNA 
sequence 
GGAACCATTCAAAACAGCATAGCAAGTTAAAATAAGG
CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCG
GTGCTTTTTTT 
This 
study,42 
 Promoter for 
trascrRNA 
(BBa_J23100pr) 
TTGACGGCTAGCTCAGTCCTAGGTACAGTGCTAGC This study 
 Terminator for 
trascrRNA 
(BBab_1002) 
CGCAAAAAACCCCGCTTCGGCGGGGTTTTTTCGC This study  
TGACCGAATTCATTAAAGAGGAGAAAGGTACCatgACAGAATC
AACATCCCGTCGCCCGGCATATGCTCGCCTGTTGGATCGTGC
GGTACGCATTCTGGCGGTGCGCGATCACAGTGAGCAAGAACT
GCGACGTAAACTCGCGGCACCGATTATGGGCAAAAATGGCCC
AGAAGAGATTGATGCTACGGCAGAAGATTACGAGCGCGTTAT
TGCCTGGTGCCATGAACATGGCTATCTCGATGACAGCCGATT
TGTTGCGCGCTTTATCGCCAGCCGTAGCCGCAAAGGTTATGG
ACCTGCGCGTATTCGCCAGGAACTGAATCAGAAAGGTATTTC
CCGCGAAGCGACAGAAAAAGCGATGCGTGAATGTGACATCGA
CTGGTGCGCACTGGCGCGCGATCAGGCGACGCGAAAATATG
GCGAACCTTTGCCAACTGTCTTTTCAGAAAAAGTTAAGATCCA
GCGTTTTCTGCTCTATCGTGGCTATCTGATGGAAGATATCCAG
GAGATTTGGCGAAATTTTGCCGACtgAGAAGGAGATATACATG
GATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGC
GTCGGATGGGCGGTGATCACTGATGAATATAAGGTTCCGTCT
AAAAAGTTCAAGGTTCTGGGAAATACAGACCGCCACAGTATC
AAAAAAAATCTTATAGGGGCTCTTTTATTTGACAGTGGAGAG
ACAGCGGAAGCGACTCGTCTCAAACGGACAGCTCGTAGAAGG
TATACACGTCGGAAGAATCGTATTTGTTATCTACAGGAGATTT
TTTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTTCATCG
ACTTGAAGAGTCTTTTTTGGTGGAAGAAGACAAGAAGCATGA
ACGTCATCCTATTTTTGGAAATATAGTAGATGAAGTTGCTTAT
CATGAGAAATATCCAACTATCTATCATCTGCGAAAAAAATTGG
TAGATTCTACTGATAAAGCGGATTTGCGCTTAATCTATTTGGC
CTTAGCGCATATGATTAAGTTTCGTGGTCATTTTTTGATTGAG
GGAGATTTAAATCCTGATAATAGTGATGTGGACAAACTATTTA
TCCAGTTGGTACAAACCTACAATCAATTATTTGAAGAAAACCC
TATTAACGCAAGTGGAGTAGATGCTAAAGCGATTCTTTCTGC
ACGATTGAGTAAATCAAGACGATTAGAAAATCTCATTGCTCA
GCTCCCCGGTGAGAAGAAAAATGGCTTATTTGGGAATCTCAT
TGCTTTGTCATTGGGTTTGACCCCTAATTTTAAATCAAATTTT
GATTTGGCAGAAGATGCTAAATTACAGCTTTCAAAAGATACTT
ACGATGATGATTTAGATAATTTATTGGCGCAAATTGGAGATCA
ATATGCTGATTTGTTTTTGGCAGCTAAGAATTTATCAGATGCT
ATTTTACTTTCAGATATCCTAAGAGTAAATACTGAAATAACTA
AGGCTCCCCTATCAGCTTCAATGATTAAACGCTACGATGAAC
ATCATCAAGACTTGACTCTTTTAAAAGCTTTAGTTCGACAACA
ACTTCCAGAAAAGTATAAAGAAATCTTTTTTGATCAATCAAAA
AACGGATATGCAGGTTATATTGATGGGGGAGCTAGCCAAGAA
GAATTTTATAAATTTATCAAACCAATTTTAGAAAAAATGGATG
GTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTGC
TGCGCAAGCAACGGACCTTTGACAACGGCTCTATTCCCCATC
AAATTCACTTGGGTGAGCTGCATGCTATTTTGAGAAGACAAG
AAGACTTTTATCCATTTTTAAAAGACAATCGTGAGAAGATTGA
AAAAATCTTGACTTTTCGAATTCCTTATTATGTTGGTCCATTG
GCGCGTGGCAATAGTCGTTTTGCATGGATGACTCGGAAGTCT
GAAGAAACAATTACCCCATGGAATTTTGAAGAAGTTGTCGAT
AAAGGTGCTTCAGCTCAATCATTTATTGAACGCATGACAAACT
TTGATAAAAATCTTCCAAATGAAAAAGTACTACCAAAACATAG
TTTGCTTTATGAGTATTTTACGGTTTATAACGAATTGACAAAG
GTCAAATATGTTACTGAAGGAATGCGAAAACCAGCATTTCTTT
CAGGTGAACAGAAGAAAGCCATTGTTGATTTACTCTTCAAAA
CAAATCGAAAAGTAACCGTTAAGCAATTAAAAGAAGATTATTT
CAAAAAAATAGAATGTTTTGATAGTGTTGAAATTTCAGGAGTT
GAAGATAGATTTAATGCTTCATTAGGTACCTACCATGATTTGC
TAAAAATTATTAAAGATAAAGATTTTTTGGATAATGAAGAAAA
TGAAGATATCTTAGAGGATATTGTTTTAACATTGACCTTATTT
GAAGATAGGGAGATGATTGAGGAAAGACTTAAAACATATGCT
CACCTCTTTGATGATAAGGTGATGAAACAGCTTAAACGTCGC
CGTTATACTGGTTGGGGACGTTTGTCTCGAAAATTGATTAATG
GTATTAGGGATAAGCAATCTGGCAAAACAATATTAGATTTTTT
GAAATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATC
CATGATGATAGTTTGACATTTAAAGAAGACATTCAAAAAGCAC
AAGTGTCTGGACAAGGCGATAGTTTACATGAACATATTGCAA
ATTTAGCTGGTAGCCCTGCTATTAAAAAAGGTATTTTACAGAC
TGTAAAAGTTGTTGATGAATTGGTCAAAGTAATGGGGCGGCA
TAAGCCAGAAAATATCGTTATTGAAATGGCACGTGAAAATCA
GACAACTCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAA
ACGAATCGAAGAAGGTATCAAAGAATTAGGAAGTCAGATTCT
TAAAGAGCATCCTGTTGAAAATACTCAATTGCAAAATGAAAA
GCTCTATCTCTATTATCTCCAAAATGGAAGAGACATGTATGTG
GACCAAGAATTAGATATTAATCGTTTAAGTGATTATGATGTCG
ATCACATTGTTCCACAAAGTTTCCTTAAAGACGATTCAATAGA
CAATAAGGTCTTAACGCGTTCTGATAAAAATCGTGGTAAATC
GGATAACGTTCCAAGTGAAGAAGTAGTCAAAAAGATGAAAAA
CTATTGGAGACAACTTCTAAACGCCAAGTTAATCACTCAACGT
AAGTTTGATAATTTAACGAAAGCTGAACGTGGAGGTTTGAGT
GAACTTGATAAAGCTGGTTTTATCAAACGCCAATTGGTTGAAA
CTCGCCAAATCACTAAGCATGTGGCACAAATTTTGGATAGTC
GCATGAATACTAAATACGATGAAAATGATAAACTTATTCGAGA
GGTTAAAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTC
CGAAAAGATTTCCAATTCTATAAAGTACGTGAGATTAACAATT
ACCATCATGCCCATGATGCGTATCTAAATGCCGTCGTTGGAA
CTGCTTTGATTAAGAAATATCCAAAACTTGAATCGGAGTTTGT
CTATGGTGATTATAAAGTTTATGATGTTCGTAAAATGATTGCT
AAGTCTGAGCAAGAAATAGGCAAAGCAACCGCAAAATATTTC
TTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATTACAC
TTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTA
ATGGGGAAACTGGAGAAATTGTCTGGGATAAAGGGCGAGATT
TTGCCACAGTGCGCAAAGTATTGTCCATGCCCCAAGTCAATA
TTGTCAAGAAAACAGAAGTACAGACAGGCGGATTCTCCAAGG
AGTCAATTTTACCAAAAAGAAATTCGGACAAGCTTATTGCTCG
TAAAAAAGACTGGGATCCAAAAAAATATGGTGGTTTTGATAG
TCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGA
AAAAGGGAAATCGAAGAAGTTAAAATCCGTTAAAGAGTTACT
AGGGATCACAATTATGGAAAGAAGTTCCTTTGAAAAAAATCC
GATTGACTTTTTAGAAGCTAAAGGATATAAGGAAGTTAAAAA
AGACTTAATCATTAAACTACCTAAATATAGTCTTTTTGAGTTA
GAAAACGGTCGTAAACGGATGCTGGCTAGTGCCGGAGAATTA
CAAAAAGGAAATGAGCTGGCTCTGCCAAGCAAATATGTGAAT
TTTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTC
CAGAAGATAACGAACAAAAACAATTGTTTGTGGAGCAGCATA
AGCATTATTTAGATGAGATTATTGAGCAAATCAGTGAATTTTC
TAAGCGTGTTATTTTAGCAGATGCCAATTTAGATAAAGTTCTT
AGTGCATATAACAAACATAGAGACAAACCAATACGTGAACAA
GCAGAAAATATTATTCATTTATTTACGTTGACGAATCTTGGAG
CTCCCGCTGCTTTTAAATATTTTGATACAACAATTGATCGTAA
ACGATATACGTCTACAAAAGAAGTTTTAGATGCCACTCTTATC
CATCAATCCATCACTGGTCTTTATGAAACACGCATTGATTTGA
GTCAGCTAGGAGGTGACTGAGATCCCATGGTACGCGTGCTAG
AGGCATCAATGTGAAAAAGCCCGCGCAAGCGGGUTTTTTTAT
GACAAACTCTTTTGTTTATTTTTCTAAATACATTCAAATATGTA
TCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATAT
TGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCC
CTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCA
CCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTT
GGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGG
TAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATG
ATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCC
GTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACT
ATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAA
AGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTG
CTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCT
GACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCA
CAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACC
GGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCAC
GATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAAC
TGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGAC
TGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCG
GCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCC
GGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCA
GATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGG
AGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAG
ATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAA
GTTTACTCATATATACTTTAGATTGATTTACGCGCCCTGTAGC
GGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGT
GACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC
TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGT
CAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGT
GCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGGGTGAT
GGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGC
CCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGT
TCCAAACTTGAACAACACTCAACCCTATCTCGGGCTATTCTTT
TGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAA
AATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAA
TATTAACGTTTACAATTTAAAAGGATCTAGGTGAAGATCCTTT
TTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTT
CCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTC
TTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACA
AAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAA
GAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGA
GCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTA
GGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTC
GCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGAT
AAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCG
GATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCAC
ACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATA
CCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGG
GAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAA
CAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGG
TATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGC
GTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGA
AAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTT
GCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGA
TTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACC
GCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAG
CGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTAC
GCATCTGTGCGGTATTTCACACCGCATAGGGTCATGGCTGCG
CCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCT
TGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTC
TCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCG
AAACGCGCGAGGCAGCAAGGAGATGGCGCCCAACAGTCCCC
CGGCCACGGGGCCTGCCACCATACCCACGCCGAAACAAGCGC
TCATGAGCCCGAAGTGGCGAGCCCGATCTTCCCCATCGGTGA
TGTCGGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGG
TGATGCCGGCCACGATGCGTCCGGCGTAGAGGATCTGCTCAT
GTTTGACAGCTTATCATCGATGCATAATGTGCCTGTCAAATGG
ACGAAGCAGGGATTCTGCAAACCCTATGCTACTCCGTCAAGC
CGTCAATTGTCTGATTCGTTACCAATTATGACAACTTGACGGC
TACATCATTCACTTTTTCTTCACAACCGGCACGGAACTCGCTC
GGGCTGGCCCCGGTGCATTTTTTAAATACCCGCGAGAAATAG
AGTTGATCGTCAAAACCAACATTGCGACCGACGGTGGCGATA
GGCATCCGGGTGGTGCTCAAAAGCAGCTTCGCCTGGCTGATA
CGTTGGTCCTCGCGCCAGCTTAAGACGCTAATCCCTAACTGC
TGGCGGAAAAGATGTGACAGACGCGACGGCGACAAGCAAAC
ATGCTGTGCGACGCTGGCGATATCAAAATTGCTGTCTGCCAG
GTGATCGCTGATGTACTGACAAGCCTCGCGTACCCGATTATC
CATCGGTGGATGGAGCGACTCGTTAATCGCTTCCATGCGCCG
CAGTAACAATTGCTCAAGCAGATTTATCGCCAGCAGCTCCGA
ATAGCGCCCTTCCCCTTGCCCGGCGTTAATGATTTGCCCAAA
CAGGTCGCTGAAATGCGGCTGGTGCGCTTCATCCGGGCGAAA
GAACCCCGTATTGGCAAATATTGACGGCCAGTTAAGCCATTC
ATGCCAGTAGGCGCGCGGACGAAAGTAAACCCACTGGTGATA
CCATTCGCGAGCCTCCGGATGACGACCGTAGTGATGAATCTC
TCCTGGCGGGAACAGCAAAATATCACCCGGTCGGCAAACAAA
TTCTCGTCCCTGATTTTTCACCACCCCCTGACCGCGAATGGTG
AGATTGAGAATATAACCTTTCATTCCCAGCGGTCGGTCGATA
AAAAAATCGAGATAACCGTTGGCCTCAATCGGCGTTAAACCC
GCCACCAGATGGGCATTAAACGAGTATCCCGGCAGCAGGGGA
TCATTTTGCGCTTCAGCCATACTTTTCATACTCCCGCCATTCA
GAGAAGAAACCAATTGTCCATATTGCATCAGACATTGCCGTC
ACTGCGTCTTTTACTGGCTCTTCTCGCTAACCAAACCGGTAAC
CCCGCTTATTAAAAGCATTCTGTAACAAAGCGGGACCAAAGC
CATGACAAAAACGCGTAACAAAAGTGTCTATAATCACGGCAG
AAAAGTCCACATTGATTATTTGCACGGCGTCACACTTTGCTAT
GCCATAGCATTTTTATCCATAAGATTAGCGGATCCTACCTGAC
GCTTTTTATCGCAACTCTCTACTGTTTCTCCATACCCGTTTTTT
TGGGCTAGCAGGAGGAATTCACCATGGGTACTGCACTCGCAA
CGCTGGCTGGGAAGCTGGCTGAACGTGTCGGCATGGATTCTG
TCGACCCACAGGAACTGATCACCACTCTTCGCCAGACGGCAT
TTAAAGGTGATGCCAGCGATGCGCAGTTCATCGCATTACTGA
TCGTTGCCAACCAGTACGGCCTTAATCCGTGGACGAAAGAAA
TTTACGCCTTTCCTGATAAGCAGAATGGCATCGTTCCGGTGG
TGGGCGTTGATGGCTGGTCCCGCATCATCAATGAAAACCAGC
AGTTTGATGGCATGGACTTTGAGCAGGACAATGAATCCTGTA
CATGCCGGATTTACCGCAAGGACCGTAATCATCCGATCTGCG
TTACCGAATGGATGGATGAATGCCGCCGCGAACCATTCAAAA
CTCGCGAAGGCAGAGAAATCACGGGGCCGTGGCAGTCGCAT
CCCAAACGGATGTTACGTCATAAAGCCATGATTCAGTGTGCC
CGTCTGGCCTTCGGATTTGCTGGTATCTATGACAAGGATGAA
GCCGAGCGCATTGTCGAAAATACTGCATACACTGCAGAACGT
CAGCCGGAACGCGACATCACTCCGGTTAACGATGAAACCATG
CAGGAGATTAACACTCTGCTGATCGCCCTGGATAAAACATGG
GATGACGACTTATTGCCGCTCTGTTCCCAGATATTTCGCCGC
GACATTCGTGCATCGTCAGAACTGACACAGGCCGAAGCAGTA
AAAGCTCTTGGATTCCTGAAACAGAAAGCCGCAGAGCAGAAG
GTGGCAGCATGAAGTCGGTGTGGAGTGAAACGATGAAGAAAA
ATCGCGCTTTTTTGAAGTGGGCAGGGGGCAAGTATCCCCTGC
TTGATGATATTAAACGGCATTTGCCCAAGGGCGAATGTCTGG
TTGAGCCTTTTGTAGGTGCCGGGTCGGTGTTTCTCAACACCG
ACTTTTCTCGTTATATCCTTGCCGATATCAATAGCGACCTGAT
CAGTCTCTATAACATTGTGAAGATGCGTACTGATGAGTACGT
ACAGGCCGCACGCGAGCTGTTTGTTCCCGAAACAAATTGCGC
CGAGGTTTACTATCAGTTCCGCGAAGAGTTCAACAAAAGCCA
GGATCCGTTCCGTCGGGCGGTACTGTTTTTATATTTGAACCG
CTACGGTTACAACGGCCTGTGTCGTTACAATCTGCGCGGTGA
GTTTAACGTGCCGTTCGGCCGCTACAAAAAACCCTATTTCCC
GGAAGCAGAGTTGTATCACTTCGCTGAAAAAGCGCAGAATGC
CTTTTTCTATTGTGAGTCTTACGCCGATAGCATGGCGCGCGC
AGATGATGCATCCGTCGTCTATTGCGATCCGCCTTATGCACC
GCTGTCTGCGACCGCCAACTTTACGGCGTATCACACAAACAG
TTTTACGCTTGAACAACAAGCGCATCTGGCGGAGATCGCCGA
AGGTCTGGTTGAGCGCCATATTCCAGTGCTGATCTCCAATCA
CGATACGATGTTAACGCGTGAGTGGTATCAGCGCGCAAAATT
GCATGTCGTCAAAGTTCGACGCAGTATAAGCAGCAACGGCGG
CACACGTAAAAAGGTGGACGAACTGCTGGCTTTGTACAAACC
AGGAGTCGTTTCACCCGCGAAAAAATAATAAGCTTGGCTGTT
TTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAAT
C 
 
pMAZ-Selfkilling (pMAZ-SK) sequence (20N is the location of the 
target sequence for the negative selection): 
ATATACCATGGCCACAATTCAGCAAATTGTGAACATCATCACG
TTCATCTTTCCCTGGTTGCCAATGGCCCATTTTCCTGTCAGTA
ACGAGAAGGTCGCGAATTCAGGCGCTTTTTAGACTGGTCGTG
TTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACCCGTTCCG
TGTAGACAGTTCGCTCCAAGCTGTTTTAGAGCTATGCTGTTTT
GAATGGTCCCAAAACGCCATGTTTCAGAAACAACTCTGGCGC
ATCGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAAAA
AAAAACCCCGCCCCTGACAGGGCGGGGTTTTTTTTTTAATTAA
AGTCTGGTCCTCGAGTCTGGTTATAATCCCTATCAGTGATAGA
GATTGACATCCCTATCAGTGATAGAGATACTGAGCACNNNNN
NNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAA
AATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAG
TCGGTGCTTTTTTATGCAGCCTACCGGTATCCTAGGCTGCTGC
CACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAA
ACGGGTCTTGAGGGGTTTTTTGCTGAAACCTCAGGCATTTGA
GAAGCACACGGTCACACTGCTTCCGGTAGTCAATAAACCGGT
AAACCAGCAATAGACATAAGCGGCTATTTAACGACCCTGCCC
TGAACCGACGACAAGCTGACGACCGGGTCTCCGCAAGTGGCA
CTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTT
CTAAATACATTCAAATATGTATCCGCTCATGAATTAATTCTTA
GAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATA
TCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTA
ATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAA
GATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAA
TACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAG
TGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGG
CAAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAG
CCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGT
TATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGGT
CGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACC
GGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTG
AATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGG
GATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGAT
AAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCA
GTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTA
CCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTC
CCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTAT
CGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGA
ATTTAATCGCGGCCTAGAGCAAGACGTTTCCCGTTGAATATG
GCTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAG
GGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGA
AAAATAAACAAATAGGCATGCTAGCGCAGAAACGTCCTAGAA
GATGCCAGGAGGATACTTAGCAGAGAGACAATAAGGCCGGA
GCGAAGCCGTTTTTCCATAGGCTCCGCCCCCCTGACGAACAT
CACGAAATCTGACGCTCAAATCAGTGGTGGCGAAACCCGACA
GGACTATAAAGATACCAGGCGTTTCCCCCTGATGGCTCCCTC
TTGCGCTCTCCTGTTCCCGTCCTGCGGCGTCCGTGTTGTGGT
GGAGGCTTTACCCAAATCACCACGTCCCGTTCCGTGTAGACA
GTTCGCTCCAAGCTGGGCTGTGTGCAAGAACCCCCCGTTCAG
CCCGACTGCTGCGCCTTATCCGGTAACTATCATCTTGAGTCCA
ACCCGGAAAGACACGACAAAACGCCACTGGCAGCAGCCATTG
GTAACTGAGAATTAGTGGATTTAGATATCGAGAGTCTTGAAG
TGGTGGCCTAACAGAGGCTACACTGAAAGGACAGTATTTGGT
ATCTGCGCTCCACTAAAGCCAGTTACCAGGTTAAGCAGTTCC
CCAACTGACTTAACCTTCGATCAAACCGCCTCCCCAGGCGGT
TTTTTCGTTTACAGAGCAGGAGATTACGACGATCGTAAAAGG
ATCTCAAGAAGATCCTTTACGGATTCCCGACACCATCACTCTA
GATTTCAGTGCAATTTATCTCTTCAAATGTAGCACCTGAAGTC
AGCCCCATACGATATAAGTTGTAATTCTCATGTTAGTCATGCC
CCGCGCCCACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAA
GGGCATCGGTCGAGATCCCGGTGCCTAATGAGTGAGCTAACT
TACATTAATTGCGTTGCGCACACCGACTAGCGAAAAAACCCC
GCCGAAGCGGGGTTTTTTGCGAAAAAAAGCACCGACTCGGTG
CCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTG
CTATGCTGTTTTGAATGGTTCCGCTAGCACTGTACCTAGGACT
GAGCTAGCCGTCAAAAGCAGCGT 
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Abstract 
Background: One of the bottlenecks in production of biochemicals and pharmaceuticals in Saccharomyces cerevisiae 
is stable and homogeneous expression of pathway genes. Integration of genes into the genome of the production 
organism is often a preferred option when compared to expression from episomal vectors. Existing approaches for 
achieving stable simultaneous genome integrations of multiple DNA fragments often result in relatively low integra-
tion eﬃciencies and furthermore rely on the use of selection markers.
Results: Here, we have developed a novel method, CrEdit (CRISPR/Cas9 mediated genome Editing), which utilizes 
targeted double strand breaks caused by CRISPR/Cas9 to significantly increase the eﬃciency of homologous inte-
gration in order to edit and manipulate genomic DNA. Using CrEdit, the eﬃciency and locus specificity of targeted 
genome integrations reach close to 100% for single gene integration using short homology arms down to 60 base 
pairs both with and without selection. This enables direct and cost eﬃcient inclusion of homology arms in PCR 
primers. As a proof of concept, a non-native β-carotene pathway was reconstructed in S. cerevisiae by simultaneous 
integration of three pathway genes into individual intergenic genomic sites. Using longer homology arms, we dem-
onstrate highly eﬃcient and locus-specific genome integration even without selection with up to 84% correct clones 
for simultaneous integration of three gene expression cassettes.
Conclusions: The CrEdit approach enables fast and cost eﬀective genome integration for engineering of S. cer-
evisiae. Since the choice of the targeting sites is flexible, CrEdit is a powerful tool for diverse genome engineering 
applications.
Keywords: Metabolic engineering, CRISPR/Cas9, Genome editing, Saccharomyces cerevisiae, Carotenoid production, 
Genome integrations
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Background
The production of bio-based chemicals, fuels, pharma-
ceuticals and food additives by microbial fermentation 
is a rapidly growing field. There is an increasing demand 
for eﬃcient cell factories that enable the production of 
biofuels and biochemicals from renewable resources at 
low and competitive cost. The knowledge of genetics, 
physiology, biochemistry and large-scale fermentation of 
baker’s yeast Saccharomyces cerevisiae, combined with 
the advent of genome engineering and recombinant DNA 
technology makes it a preferred host for many industrial 
bio-based applications, ranging from biofuels and bulk 
chemicals to nutraceuticals and pharmaceuticals [1–8]. 
Furthermore, S. cerevisiae has the advantage of being 
easy to manipulate genetically with a range of established 
cloning and vector systems [6, 9].
Production organisms with multi-enzyme pathways 
often require precise control of the expression level of the 
associated genes [2, 5, 10]. Besides regulating promoter 
strength, the copy number of genes is a critical control 
point. Both plasmid and genomic integration systems are 
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widely used for heterologous expression of genes in S. cere-
visiae. Plasmid-based systems typically oﬀer limited control 
of copy number, and significant segregational instability of 
plasmids is often observed even during growth in selective 
medium [10]. It has for example been demonstrated that 
plasmid-based gene expression is highly heterogeneous, 
and that both 2µ and CEN/ARS vectors can be diﬃcult to 
maintain at a stable level within the same cell population 
[11, 12]. Genomic integration is therefore the preferred 
alternative to ensure long-term stability and homogeneous 
expression of genes within a population.
Methods that enable fast, sequential or combinato-
rial integrations are valuable for metabolic engineering. 
Several powerful approaches, either plasmid- or PCR-
based, have been demonstrated for genome integra-
tions using selection markers. Such methods typically 
use active recombination systems, such as Cre/LoxP 
and FLP/FRT, to excise the marker without the need of 
counter selection [13, 14]. Recently, Jensen et  al. devel-
oped an eﬃcient set of vectors, the EasyClone vector 
set, that enables fast and simultaneous multiple integra-
tions of genes into specific “safe sites of insertion” with 
the possibility of recycling the selective markers [12]. The 
insertion sites are located between essential elements, 
which limits the occurrence of chromosomal aberrations 
due to the lethal eﬀect this would cause [15]. Based on 
homologous recombination using 500 bp long homology 
arms, this method results in successful integration into 
a single site [12]. However, the eﬃciency of integration 
decreases when native genes or promoters are present on 
the fragment to be integrated, or in the case of multiple 
simultaneous integrations (unpublished results). Jensen 
et al. reported 44% integration eﬃciency for simultane-
ous integration of three heterologous genes at three dif-
ferent loci using selection [12]. Increasing the eﬃciency 
of targeted integration without selection is therefore 
important for accelerating and potentially automating the 
strain engineering process.
The recent advent of CRISPR/Cas9 for genome engi-
neering has enabled eﬃcient genome editing in diﬀerent 
organisms such as bacteria [16], mice [17], plants [18], 
fruit flies [19], fish [20] and mammalian cells [21–23]. 
CRISPR/Cas9 has also been applied for targeted single 
and multiple gene deletions in S. cerevisiae by homology-
directed repair of double-strand breaks (DSBs) using 
short oligonucleotides as repair donors, in diﬀerent strain 
backgrounds [24–29]. The prevalent DSB repair mecha-
nism in S. cerevisiae is native homologous recombina-
tion (HR), and the introduction of a DSB has been shown 
to increase integration of heterologous linear DNA 
fragments with ends homologous to the DSB site [30, 
31]. Harnessing HR for DSB repair, Ryan et  al. recently 
reported the successful integration of a three-part DNA 
assembly into a single chromosomal locus [26], and Mans 
et al. performed a complete deletion of the ACS2 locus in 
combination with a six-part DNA assembly that resulted 
in the deletion of the ACS1 locus [26, 28]. This impressive 
approach, however, most likely requires additional intrin-
sic selection pressure, with the simultaneous deletion of 
these two loci being essential for viability. Furthermore 
both Horwitz et  al. and Jakociunas et  al. have recently 
shown multiplex assembly and integration of multiple 
parts in three loci, albeit with relatively low eﬃciencies 
[27, 29, 32]. Jakociunas et al. have demonstrated the pow-
erful application of the CRISPR/Cas9 system as a tool for 
metabolic engineering utilizing user-friendly and easy-
to-use USER-technology-based gRNA constructs [27]. In 
order to further expand this existing platform for knock 
out constructions, we wished to investigate whether 
CRISPR/Cas9 together with the DNA brick based Easy-
Clone approach could be employed for targeted one-step 
selection-free integration of multiple genes into the S. 
cerevisiae genome.
Here, we have developed a system, CrEdit (CRISPR/
Cas9 mediated genome Editing), which combines the 
high specificity of CRISPR/Cas9 with the convenient 
genome engineering tool EasyClone for achieving highly 
eﬃcient and accurate simultaneous genomic integration 
of multiple pathway gene expression cassettes in diﬀer-
ent loci in the genome of S. cerevisiae. The gRNA-guided 
Cas9 endonuclease was used to target gene integration 
at selected insertion sites, which resulted in up to 100% 
correct selection-free target integration at the desired 
locus for the donor DNA. CrEdit also enabled simulta-
neous and highly eﬃcient integration of three pathway 
genes involved in the production of β-carotene at three 
diﬀerent integration sites located on three diﬀerent 
chromosomes.
Results and discussion
Construction of the CrEdit system
In order to increase the eﬃciency of targeted integration 
into the S. cerevisiae genome, we decided to combine the 
well-characterized genomic integration sites used in the 
EasyClone system with the RNA-guided endonuclease 
activity of Cas9. Initially, we tested two diﬀerent designs 
for the system. In the first design, Cas9 was expressed 
from a constitutive promoter, PTEF1, on an ARS/CEN 
based vector, while the gRNA that targets Cas9 to the 
chosen EasyClone integration site was expressed from an 
episomal 2µ-based vector (Figure 1) [24]. In the second 
design, Cas9 was under the control of the inducible PCUP1 
promoter and integrated in the genome, and the gRNA 
supplied on a linearized integrative vector. The first 
design was chosen for its versatile and recyclable aspects, 
while the second design was chosen for the possibility of 
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controlling the expression of Cas9 and gRNAs at lower 
levels. Both types of gRNA carrier plasmids have been 
designed to enable a fast exchange of the gRNA expres-
sion cassettes via USER cloning. Thereby, it is possible 
to conveniently target a new locus by quick and easy 
single-step cloning of the gRNA plasmids [27]. Also, the 
USER-overhang system enables multiplexing of up to five 
gRNAs on one single plasmid [27].
In this study, we show the use of both genomic and 
plasmid versions in combination with the donor DNA 
being provided via EasyClone integration plasmids. The 
donor DNA can contain up to two promoter-gene-ter-
minator sequences, a selection marker flanked with loxP 
sites, and homology arms for homologous recombination 
at the defined insertion sites of the EasyClone system 
[12]. Importantly, for targeting integration site X-3, the 
sequence of the donor integration plasmid was modified 
by eliminating the PAM site (protospacer-adjacent motif, 
i.e. three nucleotides necessary for Cas9 recognition), 
since the PAM is located on a donor homology arm. This 
Figure 1 Schematic overview of the CrEdit system. a Replicative vectors expressing gRNAs and cas9. b Targeted DSBs mediated by Cas9 endonu-
clease activity facilitate the integration of linearized donor plasmids by homologous recombination. Donor plasmids harbor the desired integration 
sequences flanked by homology arms. Selected intergenic safe harbor sites can be used for simultaneous integration of multiple genomic  
expression cassettes for pathway engineering.
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design prevents Cas9 from cutting the target sequence 
once successful integration has occurred. In the other 
sites used, the PAM site is located within a section of the 
genome that is deleted by the successful integration event 
of the two interspaced homology arms. Since the PAM 
sequence is removed in case of completed integration, 
this might have an additional positive eﬀect on obtaining 
correct transformants, since Cas9 keeps cutting in cells 
where integration was not successful. Thereby the DSB 
fails to be repaired, which is lethal for the cells [24].
Targeted single genomic integration of tHMG1
As a proof of concept for the applicability of CrEdit for 
metabolic engineering, we used the well-established 
carotenoid biosynthetic pathway as a model. Carotenoids 
are part of the diverse group of natural compounds called 
isoprenoids, and are synthesized from precursors derived 
from the native mevalonic acid (MVA) pathway (Fig-
ure 2). The tHMG1 gene encodes a truncated HMG-CoA 
reductase, which has been shown to increase carbon flux 
through the pathway, leading to increased isoprenoid and 
carotenoid production [33, 34]. Therefore, we initially 
focused on introducing one copy of the tHMG1 overex-
pression cassette into the S. cerevisiae genome.
In order to test the eﬃciency of the two diﬀerent CrEdit 
designs, we decided to test single integration of donor 
DNA with diﬀerently sized homology arms. As donor we 
used an EasyClone integrative plasmid containing tHMG1 
with homology arms specific for intergenic site X-2 (Fig-
ure 3a) [15]. The integration eﬃciencies of all experiments 
are shown in Additional file 1: Table S1. We first tested the 
integration eﬃciency of using integrative gRNA in combi-
nation with a S. cerevisiae strain harboring genomic Cas9 
under the control of the PCUP1 promoter. Cas9 expres-
sion was induced by addition of Cu2+ 2 h before trans-
formation. We then co-transformed this Cas9-expressing 
strain with the specific donor DNA carrying tHMG1 with 
homology arms of 500, 110 or 60 bp length for site X-2, 
and the integrative gRNA targeting site X-2. An empty 
vector backbone without gRNA was used as a control. The 
resulting transformants were plated onto medium select-
ing for Cas9, the gRNA and the donor selection marker. 
We then analyzed the genotype of at least 16 colonies per 
condition to check for correct insertion at site X-2. When 
relying solely on intrinsic homologous recombination, the 
measured eﬃciency of correct integration at site X-2 was 
70% with homology arms of approximately 500 bp (Fig-
ure  3b, left panel, −gRNA). As expected, the eﬃciency 
of correct integration was found to decrease significantly 
when using shorter arms with lengths of either 110 or 
60  bp (Figure  3b, left panel, −gRNA). However, when 
the gRNA targeting X-2 was expressed, close to 100% 
successful integration was obtained at site X-2, regardless 
of the length of the homology arms (Figure 3b, left panel, 
+gRNA). Interestingly, when using the plasmid-based 
gRNA/Cas9 system and in the absence of gRNA, 100% 
correct integrants could only be obtained using 500  bp 
homology arms. Furthermore, and only in that condition, 
a low number of transformants was obtained on plates, 
which points towards a negative eﬀect of cas9 expres-
sion on cells when expressed from the constitutive strong 
TEF1 promoter and in the absence of gRNA. Ryan et al. 
Figure 2 Overview of the biosynthetic pathway for β-carotene 
production. The carotenoid biosynthetic pathway can be recon-
structed in S. cerevisiae by overexpression of the native GGPP 
synthase encoded by BTS1, and co-overexpression of the non-native 
bifunctional phytoene synthase/lycopene cyclase encoded by crtYB, 
and phytoene desaturase encoded by crtI of X. dendrorhous. HMG1 
encodes the major HMG-CoA reductase activity in S. cerevisiae. 
ERG9 encodes a farnesyl-diphosphate farnesyl transferase (squalene 
synthase) that acts in the sterol biosynthesis pathway. IPP isopentenyl 
diphosphate, DMAP dimethylallyl diphosphate, GPP geranyl diphos-
phate, FPP farnesyl diphosphate, GGPP geranylgeranyl diphosphate.
Page 5 of 11Ronda et al. Microb Cell Fact  (2015) 14:97 
reported a decreased fitness of yeast strains expressing 
cas9 from the strong TDH3 promoter [26], while Mans 
et  al. reported that the constitutive expression of cas9 
from the genome and the TEF1 promoter does not aﬀect 
the maximal specific growth rate on glucose based syn-
thetic media [28]. In light of these results, a more detailed 
study of the impact of cas9 expression levels on yeast cell 
physiology and especially the HR machinery is of interest. 
Still, 100% correct integrants were obtained in the pres-
ence of gRNA for all sizes of homology arms (Figure 3c, 
left panel), suggesting that the plasmid-based gRNA/Cas9 
system also is very eﬃcient.
In conclusion, we show that the DSB created by the 
guide RNA-targeted Cas9 endonuclease is instrumental 
for correct integration at a significantly higher eﬃciency 
than what can be achieved solely by endogenous homolo-
gous recombination. The lower eﬃciency observed in 
absence of CRISPR/Cas9 is possibly due to the fact that 
native genes tend to recombine at the native locus due 
to the large homology region. Also, expression cassettes 
a
b
c
Figure 3 Integration eﬃciency of tHMG1 at locus X-2 using diﬀerent lengths of homology arms. a Overview of the donor DNA fragment bearing 
tHMG1 with diﬀerently sized homology arms. b Integration eﬃciency of the CrEdit system with genomic inducible Cas9 and integrative gRNA. S. 
cerevisiae strain ST1011 harboring PCUP1-cas9 was induced with Cu
2+ 2 h prior to transformation start, and then co-transformed with (left, –gRNA) 
linearized empty vector pCfB257 and linearized donor DNA encoding tHMG1 (for details of donor DNA see Additional file 1), or (right, +gRNA) the 
linearized integrative gRNA vector pCfB2831 targeting X-2 and linearized donor DNA encoding tHMG1. Left panel Eﬃciency of targeted integration 
at site X-2 when selecting for donor DNA after transformation. Middle panel Eﬃciency of marker gene integration when not selecting for donor DNA 
after transformation. Right panel Frequency of correct integration at site X-2 determined by genotyping of URA+ colonies. c Integration eﬃciency 
of the CrEdit system with plasmid-based Cas9 and gRNA. S. cerevisiae strain TC-3 harboring PTEF1-cas9 on the centromeric plasmid pCfB1767 was 
co-transformed with (left, −gRNA) empty vector pCfB2999 and linearized donor DNA encoding tHMG1, or (right, +gRNA) the episomal gRNA 
vector pCfB3020 targeting X-2 and linearized donor DNA encoding tHMG1. Left panel Eﬃciency of targeted integration at site X-2 when selecting 
for donor DNA after transformation. Middle panel Eﬃciency of marker gene integration when not selecting for donor DNA after transformation. 
Right panel Frequency of correct integration at site X-2 determined by genotyping of URA+ colonies. Only +gRNA colonies were analyzed since no 
URA+ clones were obtained in the absence of gRNA. The experiment was repeated twice and error bars represent 95% confidence intervals. NA not 
analyzed.
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might integrate elsewhere in the genome possibly via 
break-induced replication (BIR), thus creating strains 
where it becomes diﬃcult to localize the gene of interest. 
The targeted DSB created by Cas9 likely boosts HR at the 
desired integration site.
Targeted genomic integration without selective pressure
Because of the high eﬃciency observed for integration 
of tHMG1, we investigated if integration of this gene 
expression cassette could be performed even without 
applying selection pressure for the donor DNA marker 
Kl.URA3. We repeated the integration experiment 
described above, however this time plating the transfor-
mants on medium only selecting for gRNA and Cas9. 
When the plasmid-based gRNA/Cas9 CrEdit system 
was used, 99, 90, and 98% eﬃciency of integration of the 
marker gene was observed for 500, 110 and 60 bp homol-
ogy arms, respectively (Figure 3c, middle panel, +gRNA). 
The PCR analysis at locus X-2 for the resulting Kl.URA3-
positive clones showed 100% correct integration into 
site X-2 for all tested sizes of homology arms (Figure 3c, 
right panel, +gRNA). However, when using the genomic 
CrEdit system with induced PCUP1-cas9, only 19, 3 and 
9% integration eﬃciency were achieved for 500, 110 
and 60 bp homology arms, respectively (Figure 3b, mid-
dle panel, +gRNA). Despite the lower integration eﬃ-
ciency, PCR analysis of the resulting Kl.URA3-positive 
clones showed 100% correct integration into site X-2 for 
all tested sizes of homology arms (Figure 3b, right panel, 
+gRNA). When the empty vector (−gRNA) was included 
in the transformation, the eﬃciency of marker integra-
tion was close to zero in all cases, independent on the 
length of the homology arms (Figure 3b, c, middle panels, 
−gRNA). In the case of genomic cas9 and long 500 bp 
homology arms, the genotyping of 16 Kl.URA3-positive 
clones showed approximately 75% correct integration at 
site X-2 (Figure 3b, right panel, −gRNA). Diﬀerences in 
promoters between the systems, and the time-limited 
induction of cas9 by the CUP1 promoter in our experi-
mental set-up (2 h prior to transformation) may lead to 
lower levels of Cas9 at transformation start compared to 
the plasmid-based system where cas9 is under the con-
trol of the constitutive TEF1 promoter on a centromeric 
plasmid. In conclusion, the highest eﬃciency of both 
selection- and non-selection based genomic integration 
was achieved when both gRNA and cas9 were expressed 
from plasmids, and we therefore chose this to be the final 
configuration of the CrEdit system (Figure 1).
Targeted simultaneous multi-loci integration of three 
carotenogenic pathway genes
In order to speed up the strain construction process, 
it is often desirable to simultaneously insert multiple 
genes into the genome. After having achieved highly eﬃ-
cient insertion of tHMG1 into intergenic site X-2 using 
the CrEdit method, we tested simultaneous integration 
of multiple genes into the genome of S. cerevisiae. As a 
proof of concept, we attempted to introduce the non-
native production of carotenoids in S. cerevisiae via 
expression of the two heterologous genes crtYB and crtI 
of X. dendrorhous combined with overexpression of S. 
cerevisiae geranylgeranyl diphosphate (GGPP) synthase 
encoded by BTS1 [35]. The gene crtYB encodes a bi-
functional enzyme with phytoene synthase and lycopene 
cyclase activity, while crtI encodes a phytoene desaturase 
[36].
Using the plasmid-based CrEdit system, cells express-
ing Cas9 were simultaneously transformed with three 
diﬀerent large EasyClone donor DNAs for integration of 
PTDH3-crtI (6.6 kb), PTEF1-crtYB (5.8 kb), and PPGK1-BTS1 
(5.1 kb) into three intergenic sites X-3, XI-2, and XII-5 
situated on diﬀerent chromosomes, using 500 bp homol-
ogy arms. The cells were co-transformed with one episo-
mal vector expressing the three gRNAs targeting these 
three sites, or with the empty vector for the −gRNA con-
trol. Transformants were plated on media selecting only 
for Cas9 and gRNA expressing plasmids. We observed 
that 84% of the derived colonies presented orange pig-
ment formation when the gRNAs were present, indicat-
ing complete β-carotene pathway integration. In contrast, 
we only observed white colonies when the gRNAs were 
absent, indicating that no correct triple integration had 
been achieved (Figure 4a). All colonies were then repli-
cated on single drop-out plates in order to screen for the 
integration of the three independent selection marker 
genes. As expected, all orange colonies were positive 
for all the three marker genes (Figure 4b, left panel). We 
subsequently tested the genotype of 32 orange colonies 
at the three expected integration sites, and observed 
100% correct integration, thereby confirming complete 
pathway assembly (Figure  4b, right panel). In addition, 
we measured β-carotene levels by HPLC in three con-
firmed clones, and demonstrated that 12.7 ± 2.5 mg L−1 
β-carotene was produced (Figure  4c). This proves the 
ability of the CrEdit system to simultaneously integrate 
three large DNA fragments with surprisingly high eﬃ-
ciency (84%) at the correct loci even without selection 
pressure. As for comparison, simultaneous integration 
of three genes has previously been demonstrated with 
44% eﬃciency when relying on native HR alone and 
when applying selective pressure [12]. It was furthermore 
attempted to repeat the multi-loci pathway integration 
using short homology arms (60 bp) to investigate if we 
could simply use PCR products directly as donors for the 
multiplex integration. However, no viable colonies grew 
on the plates even after 1 week of incubation (data not 
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shown), indicating that longer homology arms are ben-
eficial for multiplex genome integrations. We assume this 
may due to the fact that multi-loci pathway integration 
is quite demanding with regards to coordinated repair 
activity, and long homology arms are easier to utilize for 
the native yeast HR machinery, thereby enabling correct 
simultaneous integration at multiple loci.
The results obtained for simultaneous integration of 
three genes (BTS1, crtYB and crtI) show the ability of 
the CrEdit system to insert very large fragments (up to 
Figure 4 Multiple simultaneous integration of three β-carotene pathway genes. a Picture of colonies after simultaneous integration of BTS1, crtYB 
and crtI on plates without selection. S. cerevisiae (TC-3) harboring a centromeric plasmid constitutively expressing cas9 was co-transformed with: left 
empty vector control and linearized donor DNAs encoding BTS1, crtYB and crtI. Right gRNA vector expressing three gRNAs targeting intergenic loci 
XII-5, XI-2 and X-3, and linearized donor DNAs encoding BTS1, crtYB and crtI. Colonies with successful pathway integration accumulate β-carotene, 
resulting in an orange pigmentation. b Percentage of complete pathway integration with and without the expression of targeting gRNAs.  
c Frequency of correct simultaneous integration of the three genes BTS1, crtYB, and crtI at the specific intergenic loci XII-5, XI-2 and X-3, respectively, 
determined by genotyping. d HPLC analysis of β-carotene production of three independent orange colonies and a non-producing strain as control 
(CEN.PK113-7D). The experiment was repeated twice and error bars in all panels represent 95% confidence intervals.
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17.5  kb in this study) without the need for a selection 
marker, which is very attractive for industrial metabolic 
engineering applications. Industrial strains are often pro-
totrophic, and/or diploid or even polyploid, thus making 
the use of auxotrophic markers challenging. Further-
more, even for haploid auxotrophic strains, the limited 
number of available selection markers typically neces-
sitates recycling of the markers. Several systems can 
be used for looping out genetic elements, including the 
Cre-LoxP and FRT/FLP systems [12–14]. Such methods 
are not only time consuming but can also leave scars, 
which can cause genome instability and rearrangements 
in recombinant strains [37]. Importantly, CrEdit enables 
selection-free and scarless integration of desired DNA 
sequences, thereby limiting the risk for strain instabil-
ity while significantly speeding up strain engineering. 
Moreover, CrEdit is a versatile genome engineering tool, 
since the design of novel gRNAs for alternative integra-
tion sites can be easily achieved using for example the 
recently developed in silico gRNA selection tool, CRISPy, 
which minimizes the potential risk of oﬀ-target eﬀects of 
Cas9 activity [23, 27].
Recently, high eﬃciencies using CRISPR/Cas9 system 
for genome integration have been reported, but most 
systems either still rely on selective pressure or, if selec-
tion was not applied, only short DNA sequences were 
inserted [25, 26]. In the recent work by Horwitz et  al., 
an 11 gene pathway was integrated via 6-part integra-
tion, however only very low eﬃciency was observed [32]. 
Stovicek et  al. also demonstrated successful multi-part 
assembly at three diﬀerent loci, yet with relatively low 
eﬃciencies [29]. In contrast, CrEdit is a versatile sys-
tem for achieving high eﬃciency of single and multiple 
simultaneous integrations without the need for selection 
(when long homology arms are used). The CrEdit system 
was designed in a way that the PAM sequence is elimi-
nated upon successful integration. The continued cutting 
of the wild-type DNA is thereby possibly contributing to 
the very high eﬃciency of integration [24].
Further engineering of carotenoid production
A significant amount of work is available on engineer-
ing organisms for production of carotenoids [38–41], 
and in recent years a biosustainable and economically 
attractive production of β-carotene has been achieved 
[34, 42]. In an attempt to further boost β-carotene pro-
duction, we integrated the β-carotene pathway in S. cer-
evisiae strains bearing genetic modifications previously 
reported as being beneficial for the flux to the meva-
lonate pathway. We therefore performed the multi-loci 
integration experiment in a CEN.PK strain carrying a 
down-regulated version of the squalene synthase ERG9 
gene (erg9::∆-220–176). In this strain, a deletion of an 
upstream section of the promoter causes lower ERG9 
transcript and protein levels, thereby reducing the flux 
towards the competing endogenous sterol biosynthetic 
pathway [27, 43]. We also transformed a CEN.PK strain 
that carried both the erg9::∆-220–176 modification and 
an overexpression of tHMG1. Orange colonies producing 
carotenoids were obtained with high eﬃciency in both 
genetic backgrounds (Additional file 1: Figure S1). It was 
also observed that these latter strains were clearly less 
orange compared to the unmodified CEN.PK strain only 
expressing the β-carotene pathway (compare Figure  4 
and Additional file 1: Figure S1). β-carotene concentra-
tions were measured and it was shown that the additional 
genetic modifications did not lead to an increase in the 
β-carotene levels. A significant decrease in β-carotene 
concentration was even observed for the strain bearing 
both erg9::∆-220–176 and the overexpression of tHMG1 
(Additional file 1: Figure S1). Indeed, Verwaal et al. have 
shown that the desaturation of phytoene, catalyzed by 
CrtI, is a rate-limiting step in carotenoid production, and 
that an increase of the total carotenoid accumulation is 
largely caused by a significant increase of this precur-
sor [35]. As phytoene is color-less, it is expected that its 
accumulation in the strains improved for precursor avail-
ability results in the less intense coloration of the yeast 
colonies. In order to avoid this precursor accumulation, it 
may be possible to further boost the expression of crtI by 
integrating this pathway gene in more copies [35].
Conclusion
In summary, we were able to demonstrate the ability of 
the CrEdit system to simultaneously integrate up to three 
large DNA fragments with high eﬃciency even without 
selective pressure into diﬀerent genetic backgrounds, 
supporting the strength and robustness of the method.
CrEdit combines the stability and versatility of the 
EasyClone vector system with the precision and eﬃ-
ciency of CRISPR/Cas9, thereby significantly increasing 
the eﬃciency of genome integrations in S. cerevisiae. We 
demonstrate how this system can be used for simultane-
ous integration of multiple genes with high eﬃciency, 
even without selection for donor DNA. CrEdit is also 
very eﬃcient in integrating large fragments at single loci 
using short homology arms of 60 bp that can be included 
in PCR primers. This facilitates quick and easy exchange 
from one integration site to another. A further advan-
tage of the primer-based preparation of donor DNA 
is that the PAM recognition site can easily be removed 
from the short homology arms. Provided that a suitable 
PAM sequence is present at the genomic site of inter-
est, the system can easily be developed for other genome 
engineering applications, such as combining integrations 
with gene deletions, defined site-specific mutagenesis, 
Page 9 of 11Ronda et al. Microb Cell Fact  (2015) 14:97 
gene replacements, promoter exchange, protein domain 
swapping, in a scarless and selection-free manner. We 
therefore believe that CrEdit will be a valuable genome 
engineering tool to facilitate fast and cost-eﬀective pro-
duction strain engineering.
Methods
Strains and media
Saccharomyces cerevisiae CEN.PK strains were obtained 
from Peter Kötter (Johann Wolfgang Goethe-University 
Frankfurt, Germany). All yeast strains used in this study 
were derivatives of CEN.PK (Additional file 1: Table S2). 
All standard cloning was carried out using E. coli strain 
DH5alpha. Media and standard genetic techniques used 
for manipulating yeast strains were performed as previ-
ously described [44]. Synthetic complete medium as well 
as drop-out media and agar plates were prepared using 
premixed drop-out powders (Sigma-Aldrich). All chemi-
cals were obtained from Sigma-Aldrich. Escherichia coli 
transformants were grown in standard Luria–Bertani 
(LB) medium containing 100 µg mL−1 ampicillin.
Construction of plasmids for single targeted integration
All plasmids are described in Additional file  1: Table 
S3, and all gRNA sequences are listed in the Additional 
file 1 as well. Construction of expression plasmids used 
as donor DNA for integration is explained in detail 
in the Additional file  1. For design of all gRNA tar-
get sequences, the overall design was based on DiCarlo 
et al. [24] (Additional file 1: Table S4), and for designing 
the target sequence the program CRISPy was used [23, 
27]. gRNA plasmid pCfB2831 used for integrating the 
gRNA X-2′ (targeting site X-2) into chromosomal site 
X-3 [15] was constructed by amplifying a gRNA expres-
sion cassette (ordered from Integrated DNA Technolo-
gies as gBlock), gRNA_X-2′ (Additional file 1: Table S5), 
with primers PR-10735/PR-10736 (Additional file  1: 
Table S6), and subsequent USER cloning into AsiSI/Nb.
BsmI-digested pCfB257 according to Jensen et al. [12]. To 
construct the episomal gRNA plasmid pTAJAK-76 (tar-
geting site X-2), a backbone-cloning vector was created 
for USER cloning of the gRNA expression cassettes by 
amplifying and re-ligating pESC-LEU with TJOS-97F and 
TJOS-97R. Secondly, the resulting vector was amplified 
using the primers TJOS-108 and TJOS-102R in order to 
remove the KlLEU2 marker. The NatMXsyn marker was 
then amplified from pCfB2180 (GeneArt) with the prim-
ers TJOS-106F and TJOS-106R, and USER-cloned into 
the vector lacking the KlLEU2 marker, resulting in plas-
mid pTAJAK-71. Finally, to target site X-2 [15] with Cas9, 
a gRNA expression cassette was ordered from Integrated 
DNA Technologies as gBlock, gRNA_X-2 (Additional 
file  1: Table S5), and amplified with following primers: 
TJOS-62, TJOS-65. Amplified gRNA was USER cloned 
into pTAJAK-71, which was previously digested with 
AsiSI/Nb.BsmI, resulting in the plasmid pTAJAK-76.
Construction of plasmids carrying multiple gRNAs
First, a backbone-cloning vector was created for USER 
cloning of the gRNA expression cassettes by ampli-
fying and re-ligating pESC-LEU with TJOS-97F and 
TJOS-97R. Secondly, the resulting vector was amplified 
using the primers TJOS-108 and TJOS-102R in order 
to remove the KlLEU2 marker. The KanMXsyn marker 
was then amplified from pCfB2179 (GeneArt) with the 
primers TJOS-106F and TJOS-106R, and cloned into 
the vector lacking the KlLEU2 marker, resulting in plas-
mid pTAJAK-72. Finally, to target the sites X-3, XI-2 and 
XII-5 [15] with Cas9, gRNA expression cassettes [24] 
were ordered from Integrated DNA Technologies as 
gBlocks (gRNA sequences are listed in Additional file 1: 
Table S4) and amplified with following primers: TJOS-
62/TJOS-66 (gRNA_X-3); TJOS-63/TJOS-67 (gRNA_
XI-2) and TJOS-64/TJOS-65 (gRNA_XII-5). Amplified 
gRNAs were USER cloned into pTAJAK-72, which was 
previously digested with AsiSI/Nb.BsmI, resulting in the 
plasmid pTAJAK-92 according to Ref. [27].
Transformation protocol for single integration
Plasmids were transformed into S. cerevisiae cells using 
the lithium acetate transformation protocol [45]. Ini-
tially, PCUP1-cas9 was integrated into EasyClone site X-4 
by transforming CEN.PK102-5B with the integrative 
vector pCFB1129 resulting in strain ST1011 (Additional 
file 1: Table S3). When transforming strain ST1011, Cas9 
transcription was induced by adding 200 µM CuSO4 2 h 
before harvesting the cells for transformation. Prior to 
transformation, donor DNA was prepared as follows. For 
500 bp homology arms, the integrative vector pCfB772 
was digested by NotI and column-purified (Nucelospin 
Gel and PCR cleanup kit, Macherey Nagel). For shorter 
homology arms, pCfB772 was amplified by PCR using 
primer sets PR-9706/PR-9707 (110  bp) or PR-9704/
PR-9705 (60 bp), DpnI-treated and resolved on 1% aga-
rose gel containing SYBR®-SAFE (Invitrogen) and purified 
using NucleoSpin® Gel and PCR Clean-up kit (Mach-
erey Nagel). For single integration, 1 µg donor DNA and 
1 µg NotI-linearized integrative gRNA plasmid or 500 ng 
undigested episomal gRNA plasmid was co-transformed 
into competent yeast cells. Cells were plated on media 
that selected for the presence of the gRNA (KlLEU2) and 
Cas9 (SpHIS5), and optionally donor marker (KlURA3) 
where stated. When colonies appeared, the transforma-
tion plates were replicated on selective plates (SC-LEU, 
SC-URA, SC-HIS) to screen for colonies with integrated 
selection markers. Correct integration at the specific 
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genomic locus was verified by colony PCR with following 
primers: PR-2221/PR-901 (X-2: PTEF1-tHMG1).
Transformation protocol for multiple integration 
of carotenoid pathway
To simultaneously integrate three genes required for 
carotene production, 3 µg of each carrier plasmid (pTA-
JAK-94, pTAJAK-95, pTAJAK-12) were linearized by NotI 
digestion. S. cerevisiae strain TC-3 [27] was co-trans-
formed with these linearized donor plasmids plus 1 µg 
of triple gRNA plasmid pTAJAK-92. Cells were plated 
on media that selected for the presence of the gRNA 
(kanMX) and Cas9 (TRP1) plasmids. When colonies 
appeared, the transformation plates were replicated on 
selective plates (SC-LEU, SC-URA, SC-HIS) to screen 
for colonies with integrated selection markers. To screen 
for correct integrations to the expected loci of carotene 
genes, colony PCR was performed with following prim-
ers: PR-2221/PR-903 (X-3: PTDH3-crtI); PR-2221/PR-909 
(XI-2: PTEF1-crtYB); PR-2221/PR-899 (XII-5: PPGK1-
BTS1). The experiment was carried out in triplicate, and 
statistical analysis (one-tailed Student’s t test) was per-
formed on the complete data set. Multiple integration 
of carotenoid pathway was further performed in strains 
TC-23 and ST3450, according to the protocol mentioned 
above. Strain TC-23 harbors a erg9::∆-220–176 genetic 
modification [30]. Strain ST3450 was obtained by trans-
forming S. cerevisiae strain TC-23 with a NotI linearized 
pCfB2996 and transformants were selected on medium 
containing nourseothricin. Strain ST3450 therefore har-
bors erg9::∆-220–176 and a copy of PTEF1-tHMG1 inte-
grated at chromosome locus X-2.
β-Carotene quantification
Three independent orange colonies from S. cerevisiae 
TC-3 containing the three expression cassettes for BTS1, 
crtYB and crtI were used to inoculate test tubes contain-
ing 4 mL of drop out medium per well. As a reference, a 
colony of S. cerevisiae CEN. PK 113-7D was inoculated 
in the same conditions, and all cells were cultivated at 
30°C with 300 r.p.m shaking. After approximately 48  h 
of cultivation, 3.5  mL of cultivation broth was centri-
fuged for 5 min at 4,000  rpm. Then supernatants were 
discarded and cell pellets resuspended in 0.2 mL of mil-
liQ water. Cell suspensions were transferred to screw-cap 
tubes, suitable for subsequent cell breakage in a Precellys 
homogenizer. Glass beads and 1 mL of hexane were added 
to the cell suspension and cells were mechanically lysed 
for four cycles, each of 20  s at 6,500  rpm. Tubes were 
placed on ice for 1 min in between each lysis cycle. Sub-
sequently, tubes were centrifuged for 5 min at 10,000 rpm 
to separate cell debris, aqueous and solvent fractions. The 
hexane fraction was collected in glass vials. Hexane was 
then evaporated in a rotary evaporator, under vacuum, 
and dry extracts were re-dissolved in 1 mL of ethanol 
99%. Extracts were then analysed by LC–MS. LC–MS 
data was collected on Orbitrap Fusion equipped with a 
Dionex brand Ultimate 3000 UHPLC pumping system 
(ThermoFisher Scientific, Waltham, MA, USA). Samples 
were held in the autosampler at a temperature of 10.0°C 
during the analysis. 2 µL injections of the sample were 
made onto a Supelco Discovery HS F5-3 HPLC column, 
with a 3 µm particle size, 2.1 mm i.d. and 150 mm long. 
The column was held at a temperature of 30.0°C. The sol-
vent system used was Solvent A “Water with 0.1% formic 
acid” and Solvent B “Acetonitrile with 0.1% formic acid”. 
The flow rate was 1.000 mL min−1 with an initial solvent 
composition of %A = 75, %B = 25.0 held until 3.0 min, 
the solvent composition was then changed following a 
linear gradient until it reached %A = 0.0 and %B = 100.0 
at 15.0 min. This was continued until 20 min, when the 
solvent was returned to the initial conditions and the col-
umn was re-equilibrated until 25 min. The column elu-
ent flowed directly into the Heated ESI probe of the MS 
which was held at 325°C and a voltage of 3,500 V. Profile 
data was collected in positive ion mode with resolution 
setting of 30K and scan range (m/z) = 50–600. The other 
MS settings were as follows, sheath gas flow rate of 60 
units, Aux gas flow rate of 20 units, sweep gas flow rate 
of 5 units, ion transfer tube temp was 380°C, maximum 
injection time of 100 ms, S-lens RF level = 60 V, using 1 
Microscans and AGC target = 200,000 counts.
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ABSTRACT: Chinese hamster ovary (CHO) cells are widely
used in the biopharmaceutical industry as a host for the
production of complex pharmaceutical proteins. Thus
genome engineering of CHO cells for improved product
quality and yield is of great interest. Here, we demonstrate for
the ﬁrst time the efﬁcacy of the CRISPR Cas9 technology in
CHO cells by generating site-speciﬁc gene disruptions in
COSMC and FUT8, both of which encode proteins involved
in glycosylation. The tested single guide RNAs (sgRNAs)
created an indel frequency up to 47.3% in COSMC, while an
indel frequency up to 99.7% in FUT8 was achieved by
applying lectin selection. All eight sgRNAs examined in this
study resulted in relatively high indel frequencies, demon-
strating that the Cas9 system is a robust and efﬁcient genome-
editing methodology in CHO cells. Deep sequencing revealed
that 85% of the indels created by Cas9 resulted in frameshift
mutations at the target sites, with a strong preference for
single base indels. Finally, we have developed a user-friendly
bioinformatics tool, named “CRISPy” for rapid identiﬁcation
of sgRNA target sequences in the CHO-K1 genome. The
CRISPy tool identiﬁed 1,970,449 CRISPR targets divided into
27,553 genes and lists the number of off-target sites in the
genome. In conclusion, the proven functionality of Cas9 to
edit CHO genomes combined with our CRISPy database have
the potential to accelerate genome editing and synthetic
biology efforts in CHO cells.
Biotechnol. Bioeng. 2014;111: 1604–1616.
! 2014 The Authors. Biotechnology and Bioengineering
Published by Wiley Periodicals, Inc.
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Introduction
Chinese hamster ovary (CHO) cells are the primary factories
for biopharmaceuticals, due to their capacity to correctly fold
and post-translationally modify recombinant proteins com-
patible with humans (Jayapal et al., 2007). Genome editing
and engineering are of increasing interest in this ﬁeld for the
purpose of increasing cellular production capabilities and
improving product quality. This is facilitated by the
expanding amount of data being generated for CHO cells
including genomic sequences (Lewis et al., 2013; Xu et al.,
2011) and other ’omics data such as transcriptomics,
proteomics, and metabolomics information (Kildegaard
et al., 2013). Early efforts to engineer CHO cells by gene
disruptions have been performed mainly by conventional
gene targeting strategies based on homologous recombina-
tion (HR) (Yamane-Ohnuki et al., 2004). However, HR-based
gene targeting is rare event in mammalian cells, since non-
homologous end-joining (NHEJ) occurs several orders of
magnitude more frequently than HR (Sedivy and Sharp,
1989). NHEJ is an imperfect repair process that often results
in insertions or deletions of DNA bases at the site of the
double strand break (DSB) during repair, making NHEJ
particularly applicable for generating gene disruptions. To
induce site speciﬁc gene disruptions, targeting endonucleases
like transcription activator-like effector nucleases (TALENs),
zinc-ﬁnger nucleases (ZFNs), and meganucleases have been
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successfully applied to mammalian cells such as human and
CHO cell lines (Galetto et al., 2009; Miller et al., 2011;
Santiago et al., 2008).
More recently the RNA-guided Cas9 nuclease has proven
to be a highly valuable tool for genome editing in
nematodes (Waaijers et al., 2013), fruitﬂies (Bassett
et al., 2013; Gratz et al., 2013), zebraﬁsh (Chang et al.,
2013; Hwang et al., 2013), plants (Jiang et al., 2013), mice
(Wang et al., 2013; Yang et al., 2013), and human cells
(Cho et al., 2013; Cong et al., 2013; Mali et al., 2013). Cas9
is the effector protein of the type II clustered regularly
interspaced short palindromic repeat (CRISPR) immune
system of Streptococcus pyogenes and functions as a RNA-
guided endonuclease (Carroll, 2012; Jinek et al., 2012).
Together with two noncoding RNAs called CRISPR-RNA
(crRNA) and trans-activating crRNA (tracrRNA), Cas9
binds to and cleaves DNA in a site-speciﬁc manner. The
speciﬁcity is brought about by the crRNA that basepairs to
the target DNA. The target site must be adjacent to a
protospacer adjacent motif (PAM) consisting of a random
nucleotide and two guanines (NGG) (Jinek et al., 2012;
Mali et al., 2013). The tracrRNA molecule together with
crRNA functions as a scaffold onto which Cas9 binds. In
recent studies, a chimeric RNA that combines the crRNA
and tracrRNA termed single guide RNA (sgRNA) has been
applied (Chang et al., 2013; Cong et al., 2013; DiCarlo
et al., 2013; Jinek et al., 2013; Mali et al., 2013).
In order to express the small chimeric sgRNA, an RNA
pol III promoter is required and in previous studies on
human cells, a U6 promoter was chosen for this purpose
(Cong et al., 2013; Jinek et al., 2013; Mali et al., 2013). Since
the U6 promoter initiates transcription at a guanine (G),
this base must be present in the 50 end of the genomic target
site sequence. The U6 promoter-dependent requirement
combined with the PAM motif gives rise to the following
general scheme of the genomic target site sequence: G
(N)19NGG. One potential advantage of CRISPR Cas9
technology, when compared to existing methods using
TALENs and ZNFs, is its relative low cost. Furthermore, in
contrast to ZNFs and TALENs, time-consuming protein
engineering is not required to obtain an effective endonu-
clease (Pennisi, 2013). Thus, the CRISPR technology is
attractive for the CHO cell line engineering ﬁeld and for the
genome engineering and synthetic biology community at
large.
In this study, we demonstrate for the ﬁrst time the
application of a CHO codon-optimized Cas9 for modifying
the genome of CHO cells by disrupting COSMC and FUT8,
which are genes encoding proteins involved in O- and N-
glycosylation, respectively (Miyoshi et al., 1999; Wang et al.,
2010). Deep sequencing analysis revealed a strong preference
toward single nucleotide indels. Since no CRISPR bioinfor-
matics tools are available for optimal sgRNA design in CHO
cells, the web-based bioinformatics tool “CRISPy” was
developed. This design tool facilitates easy and fast sgRNA
selection and also incorporates information on possible off-
target sites. Combining the CRISPR Cas9 technology and the
CRISPy bioinformatics tool, we demonstrate efﬁcient, fast
and low cost genetic manipulation of the CHO genome.
Materials and Methods
Plasmid Construction and sgRNA Target Design
The Cas9 sequence from the S. pyogenes strain M1 GAS
genome with a 30 nuclear localization signal was codon-
optimized for CHO cells, synthesized (for sequence, see
Supplementary Materials and Methods) and subcloned into
themammalian expression vector pJ607-03 (DNA 2.0,Menlo
Park, CA, Fig. 1A). The plasmid was then transformed into
DH5a subcloning cells (Life Technologies, Paisley, U.K.).
Transformant clones were selected on 100mg/mL Ampicillin
(Sigma–Aldrich, St. Louis, MO) LB plates. The chosen
sgRNA target sequences are listed in Supplementary Table SI.
The sgRNA expression constructs were designed by fusing
tracrRNA and crRNA into a chimeric sgRNA (Jinek et al.,
2012) and located immediately downstream of a U6
promoter (Chang et al., 2013). The sequences of the U6
promoter, scaffold and terminator are shown in Supplemen-
tary Materials and Methods. Initially, the sgRNA expression
cassette (Fig. 1A) was synthesized as a gBlock (Integrated
DNATechnologies, Leuven, Belgium) and subcloned into the
pRSFDuet-1 vector (Novagen, Merck, Damstadt, Germany)
using KpnI and HindIII restriction sites. This pRSFDuet-1/
sgRNA expression vector was used as backbone in a PCR-
based uracil-speciﬁc excision reagent (USER) cloning
method (Hansen et al., 2012; Nour-Eldin et al., 2006). This
method was designed to easily and rapidly change the 19 bp-
long variable region (N19) of the sgRNA in order to generate
our sgRNA constructs. From the pRSFDuet-1/sgRNA
expression vector, a 4,221 bp-long amplicon (expression
vector backbone) was generated by PCR (1": 98#C for 2min;
30": 98#C for 10 s, 57#C for 30 s, 72#C for 4min 12 s; 1":
72#C for 5min) using two uracil-containing primers (sgRNA
Backbone_fw and sgRNA Backbone_rv, Integrated DNA
Technologies, Supplementary Table SII) and the X7 DNA
polymerase (Nørholm, 2010). Subsequent to Fastdigest DpnI
(Thermo Fisher Scientiﬁc, Waltham, MA) treatment, the
amplicon was puriﬁed from a 2% agarose TBE gel using the
QIAEX II Gel Extraction Kit (Qiagen, Hilden, Germany). In
parallel, 54 bp-long and 53 bp-long single stranded oligos
(sense and antisense strand, respectively) comprising the
variable region of the sgRNA were synthesized (TAG
Copenhagen, Denmark, Supplementary Table SII). The sense
and antisense single stranded oligos (100mM) were annealed
in NEBuffer4 (New England Biolabs, Ipswich, MA) by
incubating the oligo mix at 95#C for 5min in a heating block
and the oligo mix was subsequently allowed to slowly cool to
RT by turning off the heating block. The annealed oligos were
then mixed with the gel puriﬁed expression vector backbone
and treated with USER enzyme (New England Biolabs)
according to manufacturer’s recommendations. After USER
enzyme treatment, the reaction mixture was transformed
into E. coli Mach1 competent cells (Life Technologies)
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according to standard procedures. Transformant clones were
selected on 50mg/mL Kanamycin (Sigma–Aldrich) LB plates.
All constructs were veriﬁed by sequencing and puriﬁed by
NucleoBond Xtra Midi EF (Macherey-Nagel, Düren,
Germany) according to manufacturer’s guidelines.
Cell Culture and Transfection
CHO-K1 adherent cells obtained from ATCC (#ATCC-CCL-
61) were grown in CHO-K1 F-12K medium (ATCC)
supplemented with 10% fetal calf serum (Life Technologies)
and 1% Penicillin–Streptomycin (Sigma–Aldrich). Cells were
expanded in T-75 cm2 vented cap tissue culture ﬂasks
(SARSTEDT, Nümbrecht, Germany) and experiments were
performed in Advanced TC Cell Culture Multiwell plates
(Greiner Bio-one, Frickenhausen, Germany). Cells were
released from plastic ware using trypsin-EDTA (Sigma–
Aldrich). Cells were transfected (Day 0) by the Nucleofector
2b device using the Amaxa Cell Line Nucleofector Kit V
(Lonza, Basel, Switzerland) according to manufacturer’s
guidelines (program U-023). A total of 1" 106 cells were
transfected with 1mg Cas9 plasmid and 1mg sgRNA plasmid.
Cells were incubated at 30#C, 5% CO2 from Day 1 to Day 2
(cold shock) and incubated at 37#C, 5% CO2 at all other
times. Two days after transfection (Day 2), cells transfected
with the pmaxGFP plasmid (Lonza) were used to estimate the
pJ607- CMV BGHCas9 CHO opt.
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Figure 1. Genome editing in CHO cells by CRISPR Cas9.A: Schematics of the Cas9 and sgRNA expression cassettes. The Cas9 expression cassette consists of a CMV promoter,
Cas9 ORF codon-optimized for CHO, SV40 nuclear localization sequence (NLS) and bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence.
The sgRNA expression cassette consists of a U6 polymerase III promoter, a target gRNA sequence, a gRNA scaffold sequence and a poly(T) termination sequence. B: Illustration of
the sgRNA genomic target sites in COSMC and FUT8. Red lines denote the position of the sgRNA target sites. Introns are depicted as broken lines (not drawn to scale) and exons as
arrowed boxes. C: Indel frequency in COSMC analyzed by T7 endonuclease assay. Genomic DNAwas extracted from CHO-K1 cells 5 days after transfection with plasmids encoding
Cas9 and sgRNA against COSMC. The PCR amplicon covering the sgRNA-target sites as shown in panel B was re-annealed to enable heteroduplex formation before treatment with
T7 endonuclease where indicated. Samples were subsequently analyzed by agarose gel electrophoresis. Approximate quantification of indels (%) was peformed with ImageJ
software analysis of the uncut (WT) DNA bands. For details see Supplementary Table SVII.
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transfection efﬁciency by analyzing GFP signal using a Celigo
Imaging Cell Cytometer (Brooks Automation, Chelmsford,
MA). The transfection efﬁciency was calculated as the
percentage of GFP positive cells. Five days after transfection
(Day 5), cells were trypsinized and pelleted (200 g, 5min,
RT). Genomic DNAwas extracted from the cell pellets using
QuickExtract DNA extraction solution (Epicentre, Illumina,
Madison, WI) according to manufacturer’s instructions and
stored at $20#C.
Selection and Phenotypic Analysis of FUT8 Knockout
Cells
Five days after transfection (Day 5), selection of FUT8
knockout cells was initiated by supplementing complete
medium with 50mg/mL Lens culinaris agglutinin (LCA; Vector
Laboratories, Peterborough, UK) from a 5mg/mL LCA
(10mM Hepes/NaOH, pH 8.5, 0.15mM NaCl, 0.1mM
CaCl2) stock solution. Bright ﬁeld images were taken with a
Celigo Imaging Cell Cytometer (Brooks Automation). After 7
days of selection (Day 12), genomic DNA was extracted as
described above. In parallel, cells were seeded in complete
medium without LCA. The day after (Day 13), cells were
incubated for 45min at RT in complete medium containing
20mg/mL ﬂuorescein-LCA (Vector Laboratories) and two
droplets NucBlue1 Live ReadyProbes (Life Technologies) per
mL media. Cells were washed three times with complete
medium and ﬂuorescence microscopy was performed on a
LEAP instrument (Intrexon,Germantown,MD)using the two
channel imaging applicationwith theNucBlue stain as target 1
using the blueﬂuorescence channel and theﬂuorescein labeled
LCA as target 2 using the green ﬂuorescence channel.
T7 Endonuclease Assay
Genomic regions ﬂanking the CRISPR target site for T7
endonuclease assay were ampliﬁed from the genomic DNA
extracts using DreamTaq DNA polymerase (Thermo Fisher
Scientiﬁc) by touchdown PCR for COSMC (95#C for 2min;
10": 95#C for 30 s, 69–59#C ($1#C/cycle) for 30 s, 72#C for
50 s; 20": 95#C for 30 s, 59#C for 30 s, 72#C for 50 s; 72#C for
5min), using PCR primers listed in Supplementary Table SII.
The PCR products were subjected to a re-annealing process to
enable heteroduplex formation which is sensitive to T7
digestion: 95#C for 10min; 95–85#C ramping at $2#C/s;
85#C to 25#C at $0.25#C/s; and 25#C hold for 1min. Re-
annealed PCR products were treated with T7 endonuclease
(New England Biolabs) for 30min at 37#C. T7 digested and
undigested samples were analyzed on a 3% TAE gel. The
percentage of indels was estimated from analysis of the uncut
(WT) gel bands with ImageJ software. For details see
Supplementary Table SVII.
TOPOTM TA Cloning and Sanger Sequencing
A genomic region of 318 bp covering the four COSMC
sgRNA target sites was PCR-ampliﬁed from the genomic
extracts as described in the T7 endonuclease assay. PCR
products were subjected to agarose gel electrophoresis and
subsequently gel puriﬁed from a 1% agarose TBE gel using
the QiaQuick Gel Extraction Kit (Qiagen). Puriﬁed PCR
products were TOPO-cloned into the pCR4-TOPO vector
using the TOPOTM TA cloning kit (Life Technologies) and
subsequently transformed into E. coli Mach1 chemically
competent cells (Life Technologies). Transformed Mach1
cells were then plated on LB-ampicillin agar plates and grown
at 37#C overnight. Plasmids from single colony 60mg/mL
carbenicillin (Novagen, Merck) 2X YT-cultures were ex-
tracted using the Nucleospin 8/96 Plasmid kit (Macherey-
Nagel). Each plasmid preparation was sequenced using the
M13 forward ($20) primer (Supplementary Table SII) on an
AB 3500xL Genetic Analyzer (Life Technologies) using the
BigDye Terminator v3.1 cycle sequencing kit (Life
Technologies).
MiSeq Library Construction and Deep Sequencing
PCR amplicons were designed to be between 150 and 200 bp
long and to span the sgRNA target sequence (See
Supplementary Table SII for primers and Supplementary
Table SIII for amplicon sizes). Amplicons were generated
from the genomic DNA extracts using Phusion Hot Start II
HF Pfu polymerase (Thermo Fisher Scientiﬁc) by touch-
down PCR (95#C for 7min; 20": 95#C for 45 s, 69#C$ 59#C
($0.5#C/cycle) for 30 s, 72#C for 30 s; 35": 95#C for 45 s,
59#C for 30 s, 72#C for 30 s; 72#C for 7min). Amplicons were
puriﬁed on 2% agarose TBE gels and bands with expected
fragment sizes were excised and puriﬁed using QIAEX II Gel
Extraction Kit (Qiagen). Amplicon concentration was
measured on Qubit1 using the dsDNA BR Assay Kit (Life
Technologies). Amplicons were pooled in four for multi-
plexing (25 ng each, 100 ng in total). Illumina multiplexing
adapters were ligated to the pooled amplicons using the
TruSeqTM LT DNA Sample Preparation LT kit (Illumina)
according to manufacturer’s instructions. DNA concentra-
tion of the multiplexed libraries was measured with the
Qubit1 dsDNA BR Assay Kit, and library quality was
determined with an Agilent DNA1000 Chip (Agilent
Bioanalyzer 2100). Finally, multiplexed libraries were pooled
and sequenced on a MiSeq Benchtop Sequencer (Illumina)
using the MiSeq Reagent Kit v2 (300 cycles) according to
manufacturer’s protocol for a 151 bp paired-end analysis.
Deep Sequencing Data Analysis
To minimize the number of required indexes, the same index
was used on different PCR products (multiplexing) and the
identities of the PCR products were found in the data analysis
step based on their individual PCR primer sequences. A
Python script was developed to process MiSeq data resulting
from the targeted re-sequencing of the Cas9 target site
regions. The script performs the following tasks: (1) join
paired-end reads; (2) check if resulting sequences contain
correct PCR primer at both beginning and end of the
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sequences and discard those sequences that fail to do so; (3)
compute output length of PCR product; and (4) compare
PCR product length to expected PCR product length. Paired-
end reads were joined using fastq-join (Aronesty 2011: http://
code.google.com/p/ea-utils). Ends were checked for correct
PCR primer using fastx_barcode_splitter (http://hannonlab.
cshl.edu/fastx_toolkit/index.html).
Cas9 Target Finding Database and Web Interface CRISPy
A python script, utilizing BioPython (Cock et al., 2009), was
created to search through the CHO-K1 genome obtained
from http://www.chogenome.org (Hammond et al., 2012).
Potential target sequences of the format G(N)19NGG were
searched for in annotated exons. Each of the identiﬁed
target sequences was then searched against the entire
genome for potential off-targets. Only genomic sequences
matching the 13 bp sequence immediately upstream of the
NGG were identiﬁed as potential off-targets, and one or two
mismatches were allowed. Additionally, it was tested if an
off-target/mismatch was located within an exon. The
database generated by the Python script was uploaded to
a MySQL database and an interface based on HTML, PHP,
and JavaScript was created to allow public access to the
database.
Results
RNA-Guided CRISPR Cas9 Shows Targeted Endonuclease
Activity in CHO
In order to test if the RNA-guided CRISPR Cas9 system
could be applied for gene disruptions in CHO cells, an
expression vector with a CHO codon-optimized version of
Cas9 with a C-terminal SV40 nuclear localization signal
under the control of a CMV promoter was constructed
(Fig. 1A). To direct Cas9 to disrupt genes of interest, sgRNA
expression constructs were generated using the human U6
polymerase III promoter as previously described (Mali et al.,
2013) (Fig. 1A). Four sgRNAs were designed for each of the
two genes; C1GALT1C1 (COSMC) encoding the C1GALT1-
speciﬁc chaperone 1 and FUT8 encoding fucosyltransferase
8 (alpha-(1,6)-fucosyltransferase). COSMC is a chaperone
essential for correct protein O-glycosylation (Wang et al.,
2010) and FUT8 catalyzes the transfer of fucose from GDP-
fucose to N-acetylglucosamine (Wilson et al., 1976). In
general, it may be desirable to choose a target early in the
gene in order to avoid a truncated yet partially functional
protein. However, knowledge regarding alternative splicing
or active sites may in some cases make a more downstream
position or exon a better choice. The four sgRNA constructs
for COSMC target the only exon present in the gene. This
exon has previously been targeted with a ZFN in human cells
(Steentoft et al., 2011). FUT8 consists of 11 exons and the
FUT8 sgRNA constructs target exon 5, exon 7, and exon 9
(Fig. 1B). Exon 9 was chosen based on previously published
work targeting FUT8 with a ZFN (Malphettes et al., 2010),
and exons 5 and 7 were chosen to target earlier exons in the
gene sequence. To compare the activity of the designed
sgRNAs, adherent CHO-K1 cells were transfected transient-
ly with the CHO codon-optimized Cas9 expression vector
and each of the eight sgRNAs to introduce DSBs in the two
test genes in two independent experiments (replicate 1 and
2). Initially, a T7 endonuclease assay was performed to
analyze the indel frequency at the COSMC loci resulting
from Cas9 guided by the four different COSMC-targeting
sgRNAs (sgRNA1_C, sgRNA2_C, sgRNA3_C, and
sgRNA4_C). When assayed 5 days after transfection,
genomic indel events were detected for all four sgRNAs
(Fig. 1C, replicate #1 is shown). Using ImageJ software
analysis of the uncut gel bands, the percentage of indels
generated at the COSMC loci was estimated to be between
21% and 49% (Supplementary Table SVII). The fragment
sizes of the digested amplicons correspond to the expected
sizes (Supplementary Table SIV).
High Indel Frequency Obtained by All Four
COSMC-Targeting sgRNAs
To further assess the indel frequency achieved with the
COSMC sgRNAs, TOPO cloning-based sequencing of gel-
puriﬁed amplicons from the COSMC genomic site was
performed (Fig. 2A, Supplementary Table SV). Consistent
with the T7 endonuclease assay, Cas9 activity was observed
for all four COSMC sgRNAs in two independent experiments
(replicate 1 and 2). sgRNA1_C gave rise to the highest indel
frequency of 48.0% and 66.7% and sgRNA4_C displayed the
lowest indel frequency of 10.3% and 17.9%, in replicate 1 and
2, respectively. Based on GFP ﬂuorescence of cells transfected
with GFP-encoding plasmids, transfection efﬁciency was
estimated to be approximately 60% and 65% for replicate
1 and 2, respectively. The indels created by the COSMC
sgRNAs predominantly involved a single-base insertion of a
thymine or deletions (Fig. 2B; only sgRNA1_C, replicate #1 is
shown). To analyze the Cas9 activity in greater detail, deep
sequencing was performed using the genomic DNA extracts
from the two independent experiments (Fig. 2C). Deep
sequencing data comprising between approximately
200,000–700,000 reads per sgRNA in each of the two
replicates correlated well with the sequencing data obtained
from TOPO cloning (between 21 and 32 sequences per
sgRNA). Both sequence-based methods detected relatively
high Cas9-activity for all four sgRNAs. Deep sequencing
reported indel frequencies of 47.3% and 44.3% for
sgRNA1_C, 45.6% and 40.2% for sgRNA2_C, 36.0% and
27.2% for sgRNA3_C and 15.2% and 13.6% for sgRNA4_C
in replicate 1 and 2, respectively. Deep sequencing of control
cells transfected only with Cas9-encoding plasmids showed
an indel frequency of 0.1–0.2% (Supplementary Fig. S1). To
examine the ﬁdelity of both sequence-based methods, indel-
containing sequences obtained from TOPO-cloning were
checked using the deep sequencing data. All indels detected in
the TOPO-cloning experiments were also retrieved in the
deep sequencing data (data not shown).
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Figure 2. Analysis of generated indels in COSMC. A: TOPOTM TA-based sequence analysis of COSMC. Genomic DNAwas extracted from CHO-K1 cells 5 days after transfection
with plasmids encoding Cas9 and sgRNA against COSMC. PCR amplicons covering the sgRNA-target sites in COSMC were TOPOTM TA-cloned and Sanger sequenced. Between 21
and 32 sequences were obtained for each sgRNA. The percentages of wt and indel sequences are illustrated in the bar plot and shown in the table. B: Alignment of TOPOTM
sequence traces. Genomic DNA from cells transfected with Cas9þ sgRNA1_C (replicate #1) were subjected to TOPOTM cloning as described in panel A. The sequence traces are
aligned to the CHO-K1 genomic sequence. The red arrow indicates the genomic target site of sgRNA1_C. The numbers denote the position (bp) in the open reading frame of COSMC.
Green, red and orange colors indicate insertions, deletions and substitutions, respectively. C: Targeted deep sequencing analysis of COSMC. The same extracted genomic DNA as
described for panel A was used as template for the MiSeq analysis. Between 200,000 and 700,000 sequences were obtained for each sgRNA. The percentages of wt and indel
sequences are illustrated in the bar plot and shown in the table.
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Homozygous Knockout of FUT8 in CHO Cells Generated
by CRISPR
The a1,6-fucosyltransferase FUT8 catalyzes the addition of
fucose on IgG1 antibodies produced by CHO cells which
can reduce antibody-dependent cell-mediated cytotoxicity
(Niwa et al., 2004; Shields et al., 2002; Shinkawa et al.,
2003). Disruption of the FUT8 gene in CHO cells is
therefore attractive in order to achieve highly active and
completely nonfucosylated therapeutic antibodies (Ya-
mane-Ohnuki et al., 2004). To expand our knowledge of
applying CRISPR Cas9 in CHO cells, the gene disruption
efﬁciency of four FUT8 sgRNAs was investigated by deep
sequencing. Genomic regions covering the target site of
sgRNA1_F, sgRNA2_F, sgRNA3_F, and sgRNA4_F were
PCR ampliﬁed and sequenced. This analysis revealed that
all four sgRNAs gave rise to signiﬁcant Cas9 activity with an
indel frequency of 17.6% and 15.1% for sgRNA1_F, 38.7%
and 31.2% for sgRNA2_F, 42.5% and 36.0% for sgRNA3_F,
and 18.9% and 11.1% for sgRNA4_F in replicate 1 and 2,
respectively (Fig. 3A). As previously mentioned, transfec-
tion efﬁciency was estimated to be approximately 60% and
65% for replicate 1 and 2, respectively. Lens culinaris
agglutinin (LCA)-based selection was further used to select
for FUT8-disrupted CHO cells. LCA binds fucosylated
plasma membrane proteins leading to endocytosis and cell
death. This enables selection for homozygous FUT8 gene
disruptions, since LCA can no longer bind to cells devoid of
FUT8 and these cells therefore survive (Malphettes et al.,
2010). LCA-treatment was initiated 5 days after transfec-
tion and resulted in non-adherent round-shaped mor-
phology of all control cells (Fig. 3B). However, many
adherent cells were detected in the pool of cells transfected
with Cas9 and the four FUT8 sgRNAs (Fig. 3B, only
sgRNA3_F is shown), indicating Cas9-mediated functional
knockout of FUT8 in these cells. To analyze the phenotypic
change of CRISPR Cas9 mediated disruption of FUT8 on
cell surface exposed a-1,6-linked fucose moieties, a lectin
stain was performed (Malphettes et al., 2010; Mori et al.,
2004; Yamane-Ohnuki et al., 2004). Eight days after
initiation of selection, LCA selected and non-LCA selected
cells transfected with and without Cas9 and sgRNAs were
stained with ﬂuorescein-labeled LCA (F-LCA) (Fig. 3C and
Supplementary Fig. S2). Cells transfected with Cas9þ
sgRNAs without LCA selection revealed a fraction of F-LCA
negative cells, demonstrating the presence of cells with
homozygous disruption of the FUT8 gene. For Cas9þ
sgRNA3_F, these F-LCA negative cells constituted 29.1% of
the entire population (Fig. 3D). Cells transfected with
Cas9þ sgRNA3_F, which subsequently had been exposed
to LCA treatment revealed that the majority of cells
(98.6%) stained LCA negative (Fig. 3D). This clearly
demonstrates that the LCA treatment efﬁciently selects for
cells devoid of functional FUT8 as previously observed
(Malphettes et al., 2010, Mori et al., 2004; Yamane-Ohnuki
et al., 2004). Indeed, this observation was conﬁrmed by
deep sequencing, since LCA selection signiﬁcantly enriched
cells with FUT8 disruption to an indel frequency between
98.2% and 99.7% for the four FUT8-targeting sgRNAs
(Fig. 3A).
The Majority of CRISPR-Generated Indels Is Single Base
Pair Insertions
The vast amount of information obtained from deep
sequencing led us to investigate further the indel sizes
created by the NHEJ repair mechanism resulting from the
COSMC and FUT8 sgRNAs. The frequency was calculated as
an average for both independent experiments and was based
on 11" 105 reads for COSMC sgRNAs and 8" 105 reads for
FUT8 sgRNAs (Supplementary Figs. S3 and S4 and Table
SVI). All targets were weighted equally with each target
contributing 12.5%. The data was compiled into a single plot,
displaying the frequency of speciﬁc indel sizes ranging from
37 bp deletions to 11 bp insertions within the individual
targets (Fig. 4A). Surprisingly, mainly single base pair
insertions were detected with a frequency of 32.8%. A high
frequency of single base pair insertions was also observed in
sequences obtained from TOPO cloning (Fig. 2B, only
sgRNA1_C, replicate #1 is shown). Two and one base pair
deletions were the second and third most frequent indel size
with a frequency of 10.3% and 8.7%, respectively. Together,
almost half of the identiﬁed indels (56.5%) were single or
double-base pair indels. Collectively, 85% of the indels
observed in this study resulted in frame shift mutations (%1
or %2 bp) in the reading frame (Fig. 4B), which most likely
leads to a loss-of-function of the target protein. This ﬁnding
further underlines CRISPR Cas9 as a powerful tool to disrupt
genes of interest in the CHO genome, and prompted us to
develop a target design tool that facilitates identiﬁcation of
Cas9 targets.
Cas9 Target Finding Tool CRISPy for CHO-K1
To our knowledge, there are currently three Cas9 target
design tools available to the public. The “ZiFiT Targeter”
(http://ziﬁt.partners.org/ZiFiT/ChoiceMenu.aspx) identiﬁes
Cas9 targets in a given sequence. The “CRISPR Design”
(http://crispr.mit.edu/) (Hsu et al., 2013), allows the user to
ﬁnd targets in a given sequence and then checks for off-
targets in the genome of either human, mouse, zebraﬁsh, or
C. elegans. The “Cas9 guide RNADesign” tool (Ma et al., 2013)
is highly similar to “CRISPR Design” with the addition of
reporting content of AT (adenine and thymine) and
predicting secondary RNA structure. However, neither can
currently be applied to ﬁnd sgRNA target sequences with off-
target information in CHO genomes, nor provide pre-
conﬁgured links to primer design tools.
In order to design the Cas9 system for gene knockouts, a
number of tasks must be performed. Once a gene of interest
has been selected, one or more targets must be identiﬁed in
the exons of the gene. These targets should then be evaluated
based on their position in the gene and sequence similarity to
the rest of the genome. Once suitable targets have been
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Figure 3. Functional and genomic knockout of FUT8 in CHO-K1. A: Targeted deep sequencing analysis of the FUT8 locus in CHO-K1 cells. Genomic DNA was extracted from
CHO-K1 cells transfected with Cas9 and FUT8 sgRNAs harvested on Day 5 (no LCA selection) or Day 12 (7 days with LCA selection). The percentages of wt and indel sequences are
illustrated in the bar plot and shown in the table.B: Selection of FUT8 knockout CHO-K1 cells by LCA. As indicated, cells were either transfectedwith only a Cas9-encoding plasmid or
in combination with an sgRNA3_F-encoding plasmid. Five days after transfection (Day 5), selection with LCA was initiated. The day after (Day 6), the shown bright field images were
acquired. The magnified view shows cells with normal (adherent-looking) morphology from pool of cells transfected with Cas9 and sgRNA3_F. C: Phenotypic staining of FUT8
knockout CHO-K1 cells by fluorescein-labeled LCA (F-LCA). CHO-K1 cells were treated as described for panel A. On Day 13, cells were treated with Hoechst and with F-LCA where
indicated. Fluorescence microscopy images were subsequently acquired. Hoechst and F-LCA signal is depicted as red and green color, respectively, in the merged images and as
grayscale in the individual images. D: Quantification of fluorescent-based phenotypic staining of FUT8 knockout CHO-K1 cells. Cells were gated based on signal intensity of Hoechst
and F-LCA as shown. The percentages of F-LCA positive (FUT8 WT) and negative (phenotypic knockout of FUT8) cells are shown. LCA: Lens culinaris agglutinin.
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identiﬁed, a method for monitoring creation of gene
disruptions must be established. This is commonly done
using PCR ampliﬁcation and sequencing of the targeted
genomic region. To facilitate this workﬂow (Fig. 5), we have
developed a bioinformatics tool “CRISPy” that is freely
accessible at “http://staff.biosustain.dtu.dk/laeb/crispy/.” The
web interface interacts with a precompiled database of all
possible Cas9 target sites in CHO-K1 genes based on the
annotated CHO-K1 genome (Hammond et al., 2012; Xu
et al., 2011). Every target sequence has the following format
GN19NGG. For every Cas9 target sequence, we have compiled
a list of off-targets of the format B13NGG (B is a nucleotide
identical to the genomic sequence and N is a random
nucleotide) with 0–2 mismatches. This list also shows the
genomic site of each off-target for the 0 and 1 bpmismatches.
Overall, this has resulted in a database with 1,970,449 targets
divided into 27,553 genes.
While improvements of the CHO-K1 genome annotation
are still underway, there are 21,610 coding sequences
annotated as of this publication. They contain 231,866
exons. 221,353 of these (95.5%) have at least one potential
Cas9 target site. Given CRISPy’s 1,970,449 potential Cas9
target sites in exons, this gives an average of nine target sites
per exon. If a researcher chooses one of these target sites at
random, there is a risk of choosing a target site with high
sequence similarity to other parts of the genome; thus
producing potential off-target effects. The median number of
exact DNA sequence matches elsewhere in the genome for a
target site is 6. For 1 bpmismatches the number is 377 and for
2 bp mismatches the number is 4558. Off-targets are here
based on the ﬁrst 13 bp upstream of the PAM sequence.
However, 248,777 of 1,970,449 target sites (12.6% unique
sites) have zero exact off-target matches. This highlights the
importance of using CRISPy to select the most speciﬁc
CRISPR target site.
The user can search for a gene of interest based on the
annotation available for the CHO-K1 genome at the time of
database generation; for example, GeneID, gene symbol and
name (Fig. 5). After clicking the gene of interest, the user
will be presented with a schematic overview of the gene and
targets. All exonic targets can either be listed together or on
an exon-by-exon basis. Targets are listed with number of
off-targets with 0, 1, or 2 bp mismatches as well as a list of
genes in which one or more of the perfectly matching off-
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targets occur. Once one or more suitable targets have been
selected, the user can click on a link to get to a target speciﬁc
page with direct pre-conﬁgured links to the NCBI Primer-
Blast tool (Ye et al., 2012) on which the user simply has to
click the “Get Primers” button. Once the Primer-Blast tool
returns results, the user can verify that the PCRs amplify the
desired region by copy/pasting the target sequence into the
“Find on Sequence” ﬁeld, which should return at least one
sequence hit (if more than one hit, then select the one at the
position indicated as your PCR region). It should be noted
Figure 5. Workflow of Cas9 target finding tool: CRISPy. Screenshots of the online CRISPy tool showing the process of (1) finding a target gene, (2) selecting an exon, (3)
evaluating the available targets, and (4) showing links to PCR primer designs for analysis of on- and off-target effects resulting from Cas9þ sgRNA activity. The tool is available at
http://staff.biosustain.dtu.dk/laeb/crispy/.
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that the pre-conﬁgured link to the Primer-Blast tool is set to
generate PCR amplicons of 100–200 bp for compatibility
with deep sequencing such as MiSeq. The user can alter the
size on the Primer-Blast tool page if necessary. In addition
there are links to the genomic sequence at either NCBI or
UDEL. On the target speciﬁc page the user will also ﬁnd a
list of 0 or 1 bp mismatch off-targets for which there are also
links to genome sequence and Primer-Blasts to facilitate
easy monitoring of potential off-targets. Since the database
is precompiled, there are no time-consuming computation-
al steps.
Discussion
In this study, we demonstrate the successful application of
RNA-guided CRISPRCas9 for generating gene disruptions in
CHO-K1 cells. The tested sgRNAs for COSMC created indels
with a frequency between 13.6% and 47.3% according to
MiSeq analysis in a pool of transfected cells with a
transfection efﬁciency of approximately 60%. In comparison,
genetic disruption frequency of 3.8% and 6.3% in CHO cells
for BAK and BAX, respectively, has been observed using pre-
screened ZFNs (Cost et al., 2010). With an indel frequency
between 11.1% and 42.5% created at the target sites, the
tested sgRNAs for FUT8 revealed an activity similar to the
high efﬁciencies observed for COSMC. Selection pressure
with LCA furthermore facilitated enrichment of cells
exhibiting functional disruptions in the FUT8 gene for
each of the four sgRNAs. Together, RNA-guided Cas9 activity
was able to generate indels with a relatively high frequency for
all eight sgRNAs examined, demonstrating that the Cas9
genome-editing methodology is robust and efﬁcient. With
these high efﬁciencies obtained with CRISPR Cas9 system in
CHO cells, it will be worthwhile to investigate the capacity of
Cas9-based multiplexing to generate multiple gene disrup-
tions in a single round of modiﬁcations. Since Cas9-based
multiplexing has successfully been performed in other
mammalian cells (Cong et al., 2013; Wang et al., 2013),
multiplexing using the Cas9 systemmay as well be a powerful
technique in CHO cells.
The mutations created by the eight sgRNAs were
predominantly very short indels (56.5% single or double
base pair indels) with a preference for single base pair
insertions. Analysis of indel sizes obtained with Cas9 in
human cells revealed mainly single base pair deletions (Mali
et al., 2013). The preference for small single base pair
deletions was also observed in another study involving Cas9
in human cells (Wang et al., 2014). Interestingly, the
preference for single base pair insertions or deletions
observed in our study resulted in a high frequency of indels
creating frameshifts (85%) within the open reading frame
further supporting Cas9 as a highly attractive endonuclease
for generating gene disruptions.
To enable high throughput automated gene disruptions in
CHO, the bioinformatics tool “CRISPy” was developed to
assist in identiﬁcation of sgRNA target sites. The sgRNA
design tool incorporates additional elements/properties not
currently available elsewhere including visualization of
sgRNA target sites, detailed off-target information and links
to primer design tools. Since off-target indel events have been
observed in previous reports on Cas9 in human cells (Fu
et al., 2013; Hsu et al., 2013; Wang et al., 2014), prescreening
sgRNAs for possible off-target effects represents a useful
addition to the target design tool box. The CRISPy tool
presented here provides upfront off-target analysis of the
designed sgRNAs, enabling selection of sgRNAs with the
minimal number of possible off-target sites. Furthermore,
CRISPy aids researchers in primer design for targeted analysis
of off-target effects. We envision incorporating new
knowledge on target sequence-dependent activity of sgRNAs
as it becomes available in the future.
In this study, we have been able to enrich the FUT8
knockout population by LCA selection. However, this type of
selection is often unavailable and so single cell cloning will be
required to obtain cells with the desired gene disruptions.
This is commonly achieved through either FACS sorting or
limited dilution. These clones must then be analyzed for
homozygous populations through screening by fragment
analysis and sequencing. However, this process can be time
consuming and includes a number of challenges. With the
high genome editing efﬁciency of the Cas9 system, the
number of analyzed single cell clones sufﬁcient for obtaining
homozygous mutations is expected to be lowered consider-
ably. Thus, the CRISPR Cas9 system holds the potential to
signiﬁcantly decrease the heavy workload involved in
generating knockout CHO cell lines.
Our study demonstrates that design and implementa-
tion of Cas9-sgRNA-based genome engineering is straight-
forward and fast. Additionally, the CRISPR Cas9 system is
relatively inexpensive as the Cas9 expression vector is
reused and only new sgRNA constructs need to be cloned
for every target sequence at the cost of a few oligonucleo-
tides. The high efﬁciency, robustness, ease of use, and low
costs make the CRISPR Cas9 system a highly attractive
genome-editing tool for both the academic and industrial
community. The introduction of the CRISPR Cas9 system
in CHO cells combined with the CRISPy design tool
will signiﬁcantly accelerate the pace of genome editing in
CHO cells and enhance the rate of CHO cell line
improvement for increasing yields and quality of
biopharmaceuticals.
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